#treatment
db_id	participant_id	categories	drug_treatment	drugs	drug_combinations	line_of_treatment	treatment_regimen	start_date_dfd	stop_date_dfd	stop_reason	pre_status	post_status	notes	primary_cohort
15757	MGHCC0001	Hormone/Endocrine Therapy, Other	true	Letrozole, Zoledronic Acid			letrozole/zometa	31	215	NA				true
15758	MGHCC0001	Hormone/Endocrine Therapy	true	Letrozole			LEE011/Letrozole, CDK4/6	264	318	NA				true
15759	MGHCC0001	Chemotherapy	true	Capecitabine			capecitabine	312	490	NA				true
15760	MGHCC0001	Chemotherapy	true	Eribulin Mesylate			eribulin	508	578	NA				true
15761	MGHCC0001	Precision/Targeted Therapy	true	Everolimus, Exemestane			LEE011/Exemestane/Everolimus, PIK3CA/mTOR	600	774	NA				true
15762	MGHCC0001	Chemotherapy	true	Doxorubicin Hydrochloride Liposome			doxil	614	914	NA			admitted & dc'ed to hospice	true
15763	MGHCC0001	Chemotherapy	true	Vinorelbine Tartrate			navelbine	775	826	NA				true
15764	MGHCC0002	Chemotherapy	true	Cyclophosphamide, Fluorouracil, Methotrexate			cyclophosphamide/methotrexate/fluorouracil	18	170	NA				true
15765	MGHCC0002	Hormone/Endocrine Therapy	true	Letrozole			letrozole	4744	5193	Progression and relapse				true
15766	MGHCC0002		true	Exemestane			exemestane	5193	5344	Progression and relapse			(worsening of liver mets & LNs)	true
15767	MGHCC0002	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			tamoxifen	5375	5648	Progression and relapse				true
15768	MGHCC0002	Hormone/Endocrine Therapy	true	Fulvestrant			fulvestrant	5648	5832	NA				true
15769	MGHCC0002	Chemotherapy	true	Capecitabine			capecitabine	5832	6320	Progression and relapse				true
15770	MGHCC0002	Chemotherapy	true	Paclitaxel			paclitaxel	6377	6670	Progression and relapse				true
15771	MGHCC0002	Precision/Targeted Therapy	true	Everolimus, Exemestane			exemestane/everolimus/LEE011	6694	7086	Progression and relapse				true
15772	MGHCC0002	Chemotherapy	true	Doxorubicin			doxorubicin	7201	7995	NA				true
15773	MGHCC0002	Chemotherapy	true	Vinorelbine Tartrate			vinorelbine	8024	8086	NA				true
15774	MGHCC0002	Chemotherapy	true	Gemcitabine Hydrochloride			gemcitabine	8087	8449	NA			stopped for unrelated acute thrombotic microangiopathy	true
15775	MGHCC0002	Chemotherapy	true	Eribulin Mesylate			eribulin	8108	8128	Progression and relapse				true
15776	MGHCC0002	Precision/Targeted Therapy	true	Abemaciclib			abemaciclib, CDK 4/6	8150	8163	NA				true
15777	MGHCC0002	Chemotherapy	true	Cyclophosphamide			cyclphosphamide	8253	8400	Progression and relapse			progression, planned to start new chemo but never did	true
15778	MGHCC0003		true		CMF		CMF	13	105	NA				true
15779	MGHCC0003	Chemotherapy	true	Cyclophosphamide, Doxorubicin			cytoxan/adriamycin	154	291	NA				true
15780	MGHCC0003	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			tamoxifen	348	2174	NA			5 years of adjuvant endocrine therapy	true
15781	MGHCC0003	Hormone/Endocrine Therapy	true	Letrozole			letrozole	4886	5492	Progression and relapse				true
15782	MGHCC0003	Hormone/Endocrine Therapy	true	Exemestane, Fulvestrant			exemestane/faslodex	5523	5676	NA				true
15783	MGHCC0003	Precision/Targeted Therapy	true	Everolimus, Exemestane			everolimus/exemestane	5676	5768	NA				true
15784	MGHCC0003	Chemotherapy	true	Capecitabine			capecitabine	5768	5857	NA			discontinued d/t toxicirty (severe nausea, vomiting and weight loss)	true
15785	MGHCC0003	Chemotherapy	true	Paclitaxel			paclitaxel	5888	6172	NA			clinical progression (rising tumor markers)	true
15786	MGHCC0003	Precision/Targeted Therapy	true	Everolimus, Exemestane			exemestane/everolimus/LEE011	6401	6551	Progression and relapse				true
15787	MGHCC0003	Chemotherapy	true	Eribulin Mesylate			eribulin	6577	6684	Progression and relapse			d/c'ed d/t neuropathy	true
15788	MGHCC0003	Chemotherapy, Precision/Targeted Therapy	true	Trastuzumab, Vinorelbine Tartrate			trastuzumab/navelbine	6738	6744	NA			transitioned to hospice	true
15789	MGHCC0004	Hormone/Endocrine Therapy	true	Letrozole			letrozole	8460	8825	NA				true
15790	MGHCC0004	Hormone/Endocrine Therapy	true	Fulvestrant			fulvestrant	8825	8978	NA			break from therapy d/t weakness/possible rxn	true
15791	MGHCC0004	Chemotherapy	true	Capecitabine			capecitabine	9070	9168	Progression and relapse			CNS progression	true
15792	MGHCC0004	Hormone/Endocrine Therapy	true	Letrozole			LEE011/Letrozole, CDK4/6	9221	9466	NA			Screened for another trial after, did not enroll	true
15793	MGHCC0005	Chemotherapy	true	Cyclophosphamide, Docetaxel, Doxorubicin			docetaxel/doxorubicin/cyclophosphamide	12	126	NA				true
15794	MGHCC0005	Hormone/Endocrine Therapy	true	Anastrozole			anastrozole	131	2019	NA				true
15795	MGHCC0005	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			tamoxifen	2019	2504	NA				true
15796	MGHCC0005	Chemotherapy	true	Vinorelbine Tartrate			toremifene	2546	3474	NA				true
15797	MGHCC0005	Chemotherapy	true	Capecitabine			capecitabine	3480	3786	Progression and relapse				true
15798	MGHCC0005	Precision/Targeted Therapy	true	Everolimus, Exemestane			exemestane/everolimus	3788	3864	NA				true
15799	MGHCC0005	Chemotherapy	true	Vinorelbine Tartrate			vinorelbine	3904	4143	NA				true
15800	MGHCC0005	Precision/Targeted Therapy	true	Everolimus, Exemestane			exemestane/everolimus/LEE011	4166	4542	NA				true
15801	MGHCC0006	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			tamoxifen	1504	1637	NA				true
15802	MGHCC0006	Hormone/Endocrine Therapy	true	Anastrozole			arimidex	1637	1762	NA				true
15803	MGHCC0006	Hormone/Endocrine Therapy	true	Fulvestrant			fulvestrant	1762	1823	NA				true
15804	MGHCC0006	Chemotherapy	true	Capecitabine, Exemestane			exemestane/xeloda	1839	2177	NA				true
15805	MGHCC0006	Chemotherapy	true	Paclitaxel			taxol	2232	2517	Progression and relapse				true
15806	MGHCC0006		true	Exemestane			Exemestane/LEE011	2541	2597	Progression and relapse				true
15807	MGHCC0006	Precision/Targeted Therapy	true	Everolimus, Exemestane			Exemestane/Everolimus/LEE011	2621	2665	Progression and relapse				true
15808	MGHCC0006	Chemotherapy	true	Eribulin Mesylate			eribulin	2709	2803	NA			d/c'ed on hospice	true
15809	MGHCC0007		true	Exemestane			exemestane	49	153	NA			d/c'ed for non-clinical reasons and switched to letrozole	true
15810	MGHCC0007	Hormone/Endocrine Therapy	true	Letrozole			letrozole	153	570	NA				true
15811	MGHCC0007	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			tamoxifen	573	644	Progression and relapse				true
15812	MGHCC0007		true	Exemestane			Exemestane + LEE011	716	884	NA				true
15813	MGHCC0007	Chemotherapy	true	Capecitabine			capecitabine	922	1129	Progression and relapse				true
15814	MGHCC0007	Chemotherapy	true	Vinorelbine Tartrate			navelbine	1176	1198	NA				true
15815	MGHCC1005	Chemotherapy	true	Cyclophosphamide, Doxorubicin, Paclitaxel			adriamycin/cytoxan/taxol	20	118	Completion of standard course			completed course	true
15816	MGHCC1005	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			tamoxifen	195	719	NA				true
15817	MGHCC1005	Hormone/Endocrine Therapy	true	Letrozole			AI (letrozole)	740	854	NA			progression	true
15818	MGHCC1005	Hormone/Endocrine Therapy	true	Letrozole			LEE011/BYL719/letrozole, PIK3CA/mTOR	888	1252	Progression and relapse				true
15819	MGHCC1005	Precision/Targeted Therapy	true	Everolimus, Exemestane			LEE011/everolimus/exemestane, CDK 4/6	1336	1378	Progression and relapse				true
15820	MGHCC1005	Chemotherapy	true	Capecitabine			capecitabine	1386	1526	Progression and relapse				true
15821	MGHCC1005	Chemotherapy	true	Eribulin Mesylate			eribulin	1529	1619	NA				true
15822	MGHCC1006	Hormone/Endocrine Therapy	true	Anastrozole			anastrozole	9	2688	NA				true
15823	MGHCC1006	Hormone/Endocrine Therapy	true	Letrozole			letrozole	4058	4117	NA				true
15824	MGHCC1006	Hormone/Endocrine Therapy	true	Letrozole			LEE011/Letrozole, CDK4/6	4117	4379	NA				true
15825	MGHCC1006	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Letrozole, Palbociclib			palbociclib/letrozole, CDK4/6	4423	4620	NA				true
15826	MGHCC1006	Hormone/Endocrine Therapy	true	Alpelisib, Fulvestrant			alpelisib/placebo + fulvestrant, PIK3CA/mTOR	4640	4747	NA				true
15827	MGHCC1006	Chemotherapy	true	Capecitabine			capecitabine	4760	5653	Progression and relapse			progression (new hepatic mets)	true
15828	MGHCC1006	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Abemaciclib, Fulvestrant			abemaciclib/fulvestrant, CDK4/6	5895	5929	NA			d/c'ed d/t LFT elevation	true
15829	MGHCC1006	Chemotherapy	true	Eribulin Mesylate			eribulin	5929	6010	Progression and relapse			progression, enrolled in hospice	true
15830	MGHCC1009	Chemotherapy	true	Gemcitabine Hydrochloride, Paclitaxel			taxol/gemcitabine	796	886	NA				true
15831	MGHCC1009	Hormone/Endocrine Therapy	true	Exemestane, Fulvestrant			fulvestrant/exemestane	886	900	NA				true
15832	MGHCC1009	Chemotherapy	true	Gemcitabine Hydrochloride, Paclitaxel			gemcitabine/paclitaxel	917	947	NA				true
15833	MGHCC1009	Hormone/Endocrine Therapy	true	Letrozole			letrozole	978	1107	Progression and relapse				true
15834	MGHCC1009	Precision/Targeted Therapy	true	Everolimus, Exemestane			exemestane/everolimus	1100	1330	NA				true
15835	MGHCC1009	Hormone/Endocrine Therapy	true	Letrozole			LEE011/BYL719/Letrozole, CDK4/6	1345	1596	NA				true
15836	MGHCC1009	Chemotherapy	true	Capecitabine			capecitabine	1632	1931	Progression and relapse				true
15837	MGHCC1009	Chemotherapy	true	Carboplatin, Paclitaxel Albumin-stabilized Nanoparticle Formulation			carboplatin/abraxane	2009	2195	Progression and relapse				true
15838	MGHCC1009	Chemotherapy	true	Carboplatin, Gemcitabine Hydrochloride			carboplatin/gemcitabine	2200		NA				true
15839	MGHCC1015	Chemotherapy	true	Cyclophosphamide, Doxorubicin, Paclitaxel			Doxorubucin/cyclophosphamide/paclitaxel	41	192	NA				true
15840	MGHCC1015	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			Tamoxifen	254	2110	NA				true
15841	MGHCC1015	Hormone/Endocrine Therapy	true	Letrozole			letrozole	3423	4362	NA				true
15842	MGHCC1015	Hormone/Endocrine Therapy	true	Fulvestrant			Fulvestrant	4362	4598	NA				true
15843	MGHCC1015	Hormone/Endocrine Therapy	true	Letrozole			LEE011/Letrozole, CDK 4/6	5104	5270	NA				true
15844	MGHCC1015	Hormone/Endocrine Therapy	true	Letrozole			LEE011/Letrozole/BYL719, PIK3CA/mTOR	5293	5351	NA				true
15845	MGHCC1015	Precision/Targeted Therapy	true	Everolimus, Exemestane			LEE011/Exemestane/Everolimus, PIK3CA/mTOR	5433	5741	NA				true
15846	MGHCC1030	Chemotherapy	true	Cyclophosphamide, Doxorubicin			doxorubicin/cyclophosphamide	63	155	Completion of standard course				true
15847	MGHCC1030	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			tamoxifen	186	807	NA				true
15848	MGHCC1030	Hormone/Endocrine Therapy	true	Anastrozole			anastrozole	927	4510	NA				true
15849	MGHCC1030		true	Raloxifene Hydrochloride			raloxifene	4510	5552	NA				true
15850	MGHCC1030	Hormone/Endocrine Therapy	true	Letrozole			LEE011/letrozole, CDK 4/6	5579	5831	Progression and relapse				true
15851	MGHCC1030	Hormone/Endocrine Therapy	true	Fulvestrant			GDC0032/fulvestrant	5858	5894	Progression and relapse				true
15852	MGHCC1030	Chemotherapy	true	Capecitabine			capecitabine	5907	5991	Progression and relapse				true
15853	MGHCC1030	Precision/Targeted Therapy	true	Everolimus, Exemestane			LEE011/everolimus/exemestane, PIK3CA/mTOR	6022	6049	Progression and relapse				true
15854	MGHCC1030	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			cisplatin/gemcitabine	6068	6124	NA			gemzar d/c'ed, cisplatin held and never resumed	true
15855	MGHCC1041	Chemotherapy	true	Cyclophosphamide, Doxorubicin, Paclitaxel			doxorubicin/cyclophosphamide/paclitaxel	35	136	Completion of standard course				true
15856	MGHCC1041	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			tamoxifen	227	558	NA			stopped due to tinnitus/cramps in legs__	true
15857	MGHCC1041	Hormone/Endocrine Therapy	true	Anastrozole			anastrozole	560	857	NA			d/c'ed d/t musculoskeletal symptoms & neuropathy	true
15858	MGHCC1041	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			tamoxifen	885	1169	Progression and relapse				true
15859	MGHCC1041	Hormone/Endocrine Therapy	true	Fulvestrant			BKM120/fulvestrant, PIK3CA/mTOR	1239	1519	Progression and relapse				true
15860	MGHCC1041	Precision/Targeted Therapy	true	Everolimus, Exemestane			LEE011/exemestane/everolimus	1532	1812	Progression and relapse				true
15861	MGHCC1041	Chemotherapy	true	Capecitabine, Exemestane			capecitabine/exemestane	1834	2061	Progression and relapse				true
15862	MGHCC1041	Chemotherapy	true	Eribulin Mesylate			eribulin	2349	2415	Progression and relapse				true
15863	MGHCC1041	Chemotherapy	true	Vinorelbine Tartrate			vinorelbine	2461	2479	Progression and relapse			progression (liver mets)	true
15864	MGHCC1041	Chemotherapy	true	Doxorubicin			doxorubicin	2495	2526	NA				true
15865	MGHCC1041	Hormone/Endocrine Therapy	true	Fulvestrant			fulvestrant	2546	2569	NA			d/c'ed on hospice	true
15866	MGHCC1099	Chemotherapy	true	Cyclophosphamide, Doxorubicin, Paclitaxel			doxorubicin/cyclophosphamide/paclitaxel	124	284	Completion of standard course				true
15867	MGHCC1099	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			tamoxifen	326	1371	NA				true
15868	MGHCC1099	Hormone/Endocrine Therapy	true	Fulvestrant			fulvestrant	1418	1649	NA			d/c'ed d/t rising tumor markers	true
15869	MGHCC1099	Chemotherapy	true	Capecitabine			capecitabine	1652	1793	NA				true
15870	MGHCC1099	Hormone/Endocrine Therapy	true	Letrozole			BYL719/LEE011/letrozole, PIK3CA/mTOR	1818	2337	Progression and relapse				true
15871	MGHCC1099	Chemotherapy	true	Vinorelbine Tartrate			vinorelbine	2357	2462	Progression and relapse			progression (new liver mets)	true
15872	MGHCC1099	Chemotherapy	true	Eribulin Mesylate			eribulin	2560	2560	NA			single dose, later admitted prior to next one	true
15873	MGHCC1101	Chemotherapy	true	Cyclophosphamide, Docetaxel, Doxorubicin			docetaxel/cyclophosphamide/doxorubicin	2418	2523	Completion of standard course				true
15874	MGHCC1101	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			tamoxifen	2549	3684	NA				true
15875	MGHCC1101	Hormone/Endocrine Therapy	true	Anastrozole			anastrozole	3711	3751	Progression and relapse				true
15876	MGHCC1101	Chemotherapy	true	Capecitabine			capecitabine	3751	3816	Progression and relapse				true
15877	MGHCC1101	Precision/Targeted Therapy	true	Everolimus, Exemestane			LEE011/exemestane/everolimus, CDK 4/6	3840	4005	Progression and relapse				true
15878	MGHCC1101	Chemotherapy	true	Eribulin Mesylate			eribulin	4019	4186	NA				true
15879	MGHCC1101	Chemotherapy	true	Methotrexate			high-dose methotrexate	4152	4194	NA				true
15880	MGHCC1101	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Everolimus, Fulvestrant			fulvestrant/everolimus, PIK3CA/mTOR	4200	4285	Progression and relapse				true
15881	MGHCC1108	Chemotherapy	true	Cyclophosphamide, Docetaxel, Doxorubicin			docetaxel/doxorubicin/cyclophosphamide	61	168	NA				true
15882	MGHCC1108	Hormone/Endocrine Therapy	true	Anastrozole			anastrozole	191	1064	NA				true
15883	MGHCC1108	Hormone/Endocrine Therapy	true	Fulvestrant			fulvestrant	1064	1723	Progression and relapse				true
15884	MGHCC1108	Hormone/Endocrine Therapy	true	Letrozole			BKM120/letrozole, PIK3CA/mTOR	1735	2015	NA			d/c'ed due to intolerable side effects	true
15885	MGHCC1108	Chemotherapy	true	Capecitabine			capecitabine	2157	2164	NA			had one week, d/c'ed due to GI effects	true
15886	MGHCC1108	Chemotherapy	true	Vinorelbine Tartrate			vinorelbine	2171	2486	Progression and relapse			slight progression	true
15887	MGHCC1108	Hormone/Endocrine Therapy	true	Letrozole			LEE011/letrozole, CDK 4/6	2521	2773	Progression and relapse				true
15888	MGHCC1108	Hormone/Endocrine Therapy	true	Letrozole			BYL719/LEE011/letrozole, PIK3CA/mTOR	2805	2843	NA				true
15889	MGHCC1108	Chemotherapy	true	Eribulin Mesylate			eribulin	2843	2892	Progression and relapse				true
15890	MGHCC1108	Chemotherapy	true	Capecitabine			capecitabine	2911	3564	Progression and relapse			slight progression	true
15891	MGHCC1108	Chemotherapy	true	Doxorubicin			doxorubicin	3564	3592	Progression and relapse				true
15892	MGHCC1112	Chemotherapy	true	Cyclophosphamide, Doxorubicin, Paclitaxel			doxorubicin/cyclophosphamide/taxol	85	204	NA				true
15893	MGHCC1112	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			tamoxifen	277	730	NA				true
15894	MGHCC1112	Hormone/Endocrine Therapy	true	Anastrozole			anastrozole	758	1877	NA				true
15895	MGHCC1112	Hormone/Endocrine Therapy	true	Fulvestrant			fulvestrant	1899	2045	Progression and relapse				true
15896	MGHCC1112	Chemotherapy	true	Capecitabine			capecitabine	2073	2107	NA				true
15897	MGHCC1112	Precision/Targeted Therapy	true	Everolimus, Exemestane			LEE011/exemestane/everolimus, CDK 4/6	2130	2270	Progression and relapse				true
15898	MGHCC1112	Chemotherapy	true	Eribulin Mesylate			eribulin	2307	2319	NA			d/c'ed d/t neutropenia & thrombocytopenia	true
15899	MGHCC1112	Chemotherapy	true	Paclitaxel Albumin-stabilized Nanoparticle Formulation			abraxane	2349		NA			lost to follow-up	true
15900	MGHCC1173	Hormone/Endocrine Therapy	true	Anastrozole			anastrozole	194	1156	NA				true
15901	MGHCC1173	Precision/Targeted Therapy	true	Everolimus, Exemestane			LEE011/everolimus/exemestane, CDK 4/6	1303	1583	Progression and relapse				true
15902	MGHCC1173	Chemotherapy	true	Capecitabine			capecitabine	1594	1712	Progression and relapse				true
15903	MGHCC1173	Hormone/Endocrine Therapy	true	Cabozantinib-S-Malate, Fulvestrant			cabozantinib/fulvestrant	1742	1843	NA			d/c'ed d/t rising markers, increased bone pain, and concern for progression (Scans w/ mixed response)	true
15904	MGHCC1173	Chemotherapy	true	Vinorelbine Tartrate			vinorelbine	1844	1948	NA				true
15905	MGHCC1173	Chemotherapy	true	Doxorubicin			doxorubicin	1949	1956	NA			d/c'ed d/t infusion reactions	true
15906	MGHCC1173	Chemotherapy	true	Eribulin Mesylate			eribulin	1963	2160	NA			held and never restarted	true
15907	MGHCC1328	Chemotherapy	true	Cyclophosphamide, Doxorubicin			doxorubicin/cyclophosphamide	178	241	NA				true
15908	MGHCC1328	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			tamoxifen	365	1581	NA				true
15909	MGHCC1328	Hormone/Endocrine Therapy	true	Anastrozole			anastrozole	3499	3592	NA				true
15910	MGHCC1328	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Letrozole, Palbociclib			palbociclib/letrozole, CDK4/6	6417	6613	Progression and relapse				true
15911	MGHCC1328	Hormone/Endocrine Therapy	true	Alpelisib, Fulvestrant			alpelisib (or placebo)/fulvestrant, PIK3CA/mTOR	6628	6739	Progression and relapse				true
15912	MGHCC1328	Chemotherapy	true	Capecitabine			capecitabine	6769	7273	Progression and relapse				true
15913	MGHCC1328	Chemotherapy	true	Eribulin Mesylate			eribulin	7547	7574	NA				true
15914	MGHCC1328	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Abemaciclib, Fulvestrant			abemaciclib/fulvestrant, CDK4/6	7615	7678	NA			d/c'ed d/t clical deterioration	true
15915	MGHCC1328	Chemotherapy	true	Doxorubicin			doxorubicin	7676	7767	Progression and relapse			transition to hospice	true
15916	MGHCC1573	Biological Therapy, Chemotherapy	true	Bevacizumab, Cyclophosphamide, Doxorubicin, Paclitaxel			dd Adriamycin/Cotoxan/Taxol + Avastin	13	146	NA				true
15917	MGHCC1573	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			tamoxifen	188	879	NA				true
15918	MGHCC1573	Hormone/Endocrine Therapy	true	Letrozole			letrozole	861	951	NA				true
15919	MGHCC1573	Precision/Targeted Therapy	true	Everolimus, Exemestane			Lee011/Exemestane/Everolimus, CDK4/6	1526	1638	Progression and relapse				true
15920	MGHCC1573	Chemotherapy	true	Vinorelbine Tartrate			vinorelbine	2071	2328	Progression and relapse				true
15921	MGHCC1573	Chemotherapy	true	Eribulin Mesylate			eribulin	2442	2505	Progression and relapse				true
15922	MGHCC1573	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Fulvestrant, Palbociclib			fulvestrant/palbociclib, CDK4/6	2505	2559	Progression and relapse				true
15923	MGHCC1573	Chemotherapy	true	Doxorubicin			doxorubicin	2591	2912	Progression and relapse				true
15924	MGHCC1573	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Fulvestrant, Palbociclib			fulvestrant/palbociclib, CDK4/6	2912	2953	NA			transitioned to hospice in setting of worsening respiratory symptoms	true
15925	RA_1002	Chemotherapy	true	Cyclophosphamide, Doxorubicin			adriamycin and Cytoxan (4 Cycles)	0	0	NA			Regimen: adriamycin and Cytoxan (4 Cycles)	true
15926	RA_1002		true		CMF		CMF (6 Cycles)	5478	5478	NA			Regimen: CMF (6 Cycles)	true
15927	RA_1002	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			Tamoxifen	5478	5844	NA			Regimen: Tamoxifen	true
15928	RA_1002	Hormone/Endocrine Therapy	true	Letrozole			Letrozole	5995	6574	NA			Regimen: Letrozole	true
15929	RA_1002		true	Exemestane			Exemestane	6574	7670	NA			Regimen: Exemestane	true
15930	RA_1002	Chemotherapy	true	Cyclophosphamide, Docetaxel			Taxotere + Cytoxan (X 4 Cycles)	8825	8886	NA			Regimen: Taxotere + Cytoxan (X 4 Cycles)	true
15931	RA_1002	Hormone/Endocrine Therapy	true	Anastrozole			Anastrozole	9009	9243	NA			Regimen: Anastrozole	true
15932	RA_1002	Chemotherapy	true	Carboplatin, Paclitaxel			Veliparib + Carbo/Paclitaxel (X17 Cycles)	9255	9668	NA	Recurrence		Clinical Trial - Best Response = PR (-37.3% from BL) // PD = disease progression, increase in number of skin lesions (-13.9% from BL , +37.4% from Nadir) ~ Regimen: Veliparib + Carbo/Paclitaxel (X17 Cycles)	true
15933	RA_1002	Hormone/Endocrine Therapy	true	Letrozole, Ribociclib			BYL719/LEE(Ribociclib)/letrozole (X 9 Cycles)	9700	9951	NA			Clinical Trial - Best Response = SD (-8.1% from BL) // PD = Interval increase in size of subcutaneous nodules in the left anterior chest wall and right lateral flank, concerning for worsening metastatic disease.Slight interval increase in size in soft tissue nodule within the musculature of the anterior chest wall ~ Regimen: BYL719/LEE(Ribociclib)/letrozole (X 9 Cycles)	true
15934	RA_1002	Precision/Targeted Therapy	true	Everolimus, Exemestane, Ribociclib			LEE011(Ribociclib)/examestane/everolimus (X 2 Cycles)	9990	10047	NA			Clinical Trial  - Best Response =  SD (+17.5% from BL) = Taken off, interval increase  in thickening throughout anterior chest wall, extending into left anterior and lateral abdominal wall ~ Regimen: LEE011(Ribociclib)/examestane/everolimus (X 2 Cycles)	true
15935	RA_1002	Chemotherapy	true	Capecitabine			Xeloda	10062	10201	NA			Regimen: Xeloda	true
15936	RA_1002	Chemotherapy	true	Vinorelbine Tartrate			Vinorelbine	10260	10316	NA			Regimen: Vinorelbine	true
15937	RA_1002	Hormone/Endocrine Therapy	true	Letrozole			GDC-0077 (PIK3CA Inhibitor) + letrozole (X3 Cycles)	10351	10435	NA			Clinical Trial  - Best Response = // Progression =  PD in chest wall lesions ~ Regimen: GDC-0077 (PIK3CA Inhibitor) + letrozole (X3 Cycles)	true
15938	RA_1011	Precision/Targeted Therapy	true	Everolimus			Everolimus	361	749	Progression and relapse			regression of chest wall lesions ~ Regimen: Everolimus	true
15939	RA_1011	Biological Therapy, Chemotherapy, Precision/Targeted Therapy	true	Bevacizumab, Doxorubicin Hydrochloride Liposome, Everolimus			Doxil/Everolimus/Bevacizumab (2 Cycles)	780	826	Progression and relapse			Regimen: Doxil/Everolimus/Bevacizumab (2 Cycles)	true
15940	RA_1011	Chemotherapy	true	Carboplatin, Temsirolimus			Carboplatin + Temsirolimus (2 Cycles)	827	915	Progression and relapse			progressive disease in the lungs ~ Regimen: Carboplatin + Temsirolimus (2 Cycles)	true
15941	RA_1011	Precision/Targeted Therapy	true	Everolimus			Everolimus	959	1038	Other			D/C to pursue clinical trial ~ Regimen: Everolimus	true
15942	RA_1011	Chemotherapy	true	Paclitaxel Albumin-stabilized Nanoparticle Formulation	FEC		FEC/Abraxane			Progression and relapse			Relapsed locally during adjuvant chemotherapy ~ Regimen: FEC/Abraxane	true
15943	RA_1035	Chemotherapy	true	Cyclophosphamide, Doxorubicin			Neoadjuvant ddAC (Adriamycin+ Cytoxan) - 4 Cycles	28	70	Completion of standard course			Regimen: Neoadjuvant ddAC (Adriamycin+ Cytoxan) - 4 Cycles	true
15944	RA_1035	Chemotherapy	true	Cyclophosphamide, Doxorubicin			Neoadjuvant ddAC (Adriamycin+ Cytoxan) - 4 Cycles	28	70	Completion of standard course			Regimen: Neoadjuvant ddAC (Adriamycin+ Cytoxan) - 4 Cycles	true
15945	RA_1035	Chemotherapy	true	Paclitaxel			Adjuvant Taxol - 4 Cycles	84	126	Completion of standard course			Regimen: Adjuvant Taxol - 4 Cycles	true
15946	RA_1035	Chemotherapy	true	Paclitaxel			Adjuvant Taxol - 4 Cycles	84	126	Completion of standard course			Regimen: Adjuvant Taxol - 4 Cycles	true
15947	RA_1035	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			Tamoxifen	212	2069	Completion of standard course			Regimen: Tamoxifen	true
15948	RA_1035	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			Tamoxifen	212	2069	Completion of standard course			Regimen: Tamoxifen	true
15949	RA_1035	Hormone/Endocrine Therapy	true	Letrozole			Femara	2082	2342	Other			D/C due to "Feeling Poorly" ~ Regimen: Femara	true
15950	RA_1035	Hormone/Endocrine Therapy	true	Letrozole			Femara	2082	2342	Other			D/C due to "Feeling Poorly" ~ Regimen: Femara	true
15951	RA_1035	Hormone/Endocrine Therapy, Other	true	Denosumab, Letrozole			Letrozole + Xgeva	2750	3224	Progression and relapse			Progressing metastatic disease.  New scalp lesions, hepatic, gastric, rectal metastases. ~ Regimen: Letrozole + Xgeva	true
15952	RA_1035	Hormone/Endocrine Therapy, Other	true	Denosumab, Letrozole			Letrozole + Xgeva	2750	3224	Progression and relapse			Progressing metastatic disease.  New scalp lesions, hepatic, gastric, rectal metastases. ~ Regimen: Letrozole + Xgeva	true
15953	RA_1035	Chemotherapy	true	Vinorelbine Tartrate			Navelbine (X 4 Cycles)	3226	3296	Toxicity			Neutropenia ~ Regimen: Navelbine (X 4 Cycles)	true
15954	RA_1035	Chemotherapy	true	Vinorelbine Tartrate			Navelbine (X 4 Cycles)	3226	3296	Toxicity			Neutropenia ~ Regimen: Navelbine (X 4 Cycles)	true
15955	RA_1035	Hormone/Endocrine Therapy	true	Letrozole			BYL-719 [PI3K? inhibitor]/Letrozole   (6 Cycles)	3325	3490	Progression and relapse			Slight increase in bilateral pleural effusions. Significant increase in size of muliple liver lesions. New liver lesions are also seen ~ Regimen: BYL-719 [PI3K? inhibitor]/Letrozole   (6 Cycles)	true
15956	RA_1035	Hormone/Endocrine Therapy	true	Letrozole			BYL-719 [PI3K? inhibitor]/Letrozole   (6 Cycles)	3325	3490	Progression and relapse			Slight increase in bilateral pleural effusions. Significant increase in size of muliple liver lesions. New liver lesions are also seen ~ Regimen: BYL-719 [PI3K? inhibitor]/Letrozole   (6 Cycles)	true
15957	RA_1035	Chemotherapy	true	Eribulin Mesylate			Eribulin (2 Cycles)	3498	3542	Progression and relapse			Diffuse osteoblastic metastases. Persistent lymphangitic carcinomatosis with bilateral pleural effusions. Scattered lung nodules, consistent with metastases. Prominent cervical lymph nodes ~ Regimen: Eribulin (2 Cycles)	true
15958	RA_1035	Chemotherapy	true	Eribulin Mesylate			Eribulin (2 Cycles)	3498	3542	Progression and relapse			Diffuse osteoblastic metastases. Persistent lymphangitic carcinomatosis with bilateral pleural effusions. Scattered lung nodules, consistent with metastases. Prominent cervical lymph nodes ~ Regimen: Eribulin (2 Cycles)	true
15959	RA_1045		true		AC-T		Dose dense AC+T +AVASTIN (neoadjuvant)	17	128	NA			Regimen: Dose dense AC+T +AVASTIN (neoadjuvant)	true
15960	RA_1045	Chemotherapy, Precision/Targeted Therapy	true	Capecitabine, Trastuzumab			Herceptin (Trastuzumab) + Xeloda (Capecitabine)	280	322	NA			Regimen: Herceptin (Trastuzumab) + Xeloda (Capecitabine)	true
15961	RA_1045	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Anastrozole, Trastuzumab			Herceptin (Trastuzumab) + Arimidex (Anastrazole)	323	560	NA			Regimen: Herceptin (Trastuzumab) + Arimidex (Anastrazole)	true
15962	RA_1045	Hormone/Endocrine Therapy	true	Anastrozole			Arimidex (Anastrazole)	561	1216	NA			Regimen: Arimidex (Anastrazole)	true
15963	RA_1045	Hormone/Endocrine Therapy	true	Fulvestrant			BYL719/fulvestrant	1542	2998	NA			Clinic Trial: Best Response = Partial Response -79.2% // Progression new liver lesions multiple sites/ throughout all lobes (-78.84% from BL) ~ Regimen: BYL719/fulvestrant	true
15964	RA_1045	Chemotherapy	true	Capecitabine			Xeloda	3017	3075	NA			Regimen: Xeloda	true
15965	RA_1045	Chemotherapy	true	Eribulin Mesylate			Eribulin	3076	3083	NA			Regimen: Eribulin	true
15966	RA_1078	Chemotherapy	true	Cyclophosphamide, Doxorubicin, Paclitaxel			Doxorubicin + Taxol + Cytoxan	98	237	NA			Regimen: Doxorubicin + Taxol + Cytoxan	true
15967	RA_1078	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			Tamoxifen	241	2063	NA			Regimen: Tamoxifen	true
15968	RA_1078	Hormone/Endocrine Therapy	true	Anastrozole			Arimidex (Anastrozole)	2063	2154	NA			Regimen: Arimidex (Anastrozole)	true
15969	RA_1078	Hormone/Endocrine Therapy	true	Letrozole, Pamidronate Disodium			Femara (Letrozole) + Aredia	4550	4620	NA	Recurrence		Regimen: Femara (Letrozole) + Aredia	true
15970	RA_1078	Hormone/Endocrine Therapy	true	Fulvestrant			Faslodex (Fulvestrant)	4641	4748	NA			Regimen: Faslodex (Fulvestrant)	true
15971	RA_1078	Chemotherapy	true	Capecitabine			Xeloda (Capecitabine)	4748	5221	NA			Regimen: Xeloda (Capecitabine)	true
15972	RA_1078	Other	true	Denosumab			Denosumab	5260	5321	NA			Regimen: Denosumab	true
15973	RA_1078	Chemotherapy	true	Doxorubicin Hydrochloride Liposome			Doxil	5322	5389	NA			Regimen: Doxil	true
15974	RA_1078	Precision/Targeted Therapy	true	Everolimus, Exemestane			Everolimus/Exemestane	5390	5623	NA			Regimen: Everolimus/Exemestane	true
15975	RA_1078	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			Tamoxifen	5625	5837	NA			Regimen: Tamoxifen	true
15976	RA_1078	Chemotherapy	true	Gemcitabine Hydrochloride			Gemcitabine	5837	5957	NA			Regimen: Gemcitabine	true
15977	RA_1078	Chemotherapy	true	Eribulin Mesylate			Eribulin	5959	6203	NA			Regimen: Eribulin	true
15978	RA_1078	Chemotherapy	true	Vinorelbine Tartrate			Vinorelbine	6358	6561	NA			Progression = new brain mets (cerbellar + occipital lobe) ~ Regimen: Vinorelbine	true
15979	RA_1078	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Fulvestrant, Palbociclib			Fulvestrant/ Palbociclib	6565	6594	NA			Regimen: Fulvestrant/ Palbociclib	true
15980	RA_1113	Chemotherapy	true	Cyclophosphamide, Doxorubicin, Paclitaxel			Adjuvant ddAC (Cytoxan + Adriamycin) 4 Cycles + Taxol (4 Cycles)	83	273	Completion of standard course			Regimen: Adjuvant ddAC (Cytoxan + Adriamycin) 4 Cycles + Taxol (4 Cycles)	true
15981	RA_1113	Chemotherapy	true	Cyclophosphamide, Doxorubicin, Paclitaxel			Adjuvant ddAC (Cytoxan + Adriamycin) 4 Cycles + Taxol (4 Cycles)	83	273	Completion of standard course			Regimen: Adjuvant ddAC (Cytoxan + Adriamycin) 4 Cycles + Taxol (4 Cycles)	true
15982	RA_1113	Precision/Targeted Therapy	true	Trastuzumab			Herceptin	297	396	Toxicity			d/c for congestive heart failure ~ Regimen: Herceptin	true
15983	RA_1113	Precision/Targeted Therapy	true	Trastuzumab			Herceptin	297	396	Toxicity			d/c for congestive heart failure ~ Regimen: Herceptin	true
15984	RA_1113	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			Tamoxifen	396	1924	Progression and relapse			Regimen: Tamoxifen	true
15985	RA_1113	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			Tamoxifen	396	1924	Progression and relapse			Regimen: Tamoxifen	true
15986	RA_1113	Chemotherapy	true	Exemestane, Vinorelbine Tartrate			Navelbine and Exemestane	1951	2175	Progression and relapse			Increased tumor markers ~ Regimen: Navelbine and Exemestane	true
15987	RA_1113	Chemotherapy	true	Exemestane, Vinorelbine Tartrate			Navelbine and Exemestane	1951	2175	Progression and relapse			Increased tumor markers ~ Regimen: Navelbine and Exemestane	true
15988	RA_1113		true	Exemestane			Exemestane	2175	2417	Progression and relapse			new ill-defined low hypoattenuating lesions in the liver, suspicious for hepatic metastases; Rising tumor markers ~ Regimen: Exemestane	true
15989	RA_1113		true	Exemestane			Exemestane	2175	2417	Progression and relapse			new ill-defined low hypoattenuating lesions in the liver, suspicious for hepatic metastases; Rising tumor markers ~ Regimen: Exemestane	true
15990	RA_1113	Hormone/Endocrine Therapy	true	Fulvestrant			Faslodex	2417	2478	Progression and relapse			Rising tumor markers ~ Regimen: Faslodex	true
15991	RA_1113	Hormone/Endocrine Therapy	true	Fulvestrant			Faslodex	2417	2478	Progression and relapse			Rising tumor markers ~ Regimen: Faslodex	true
15992	RA_1113	Chemotherapy	true	Capecitabine			Capecitabine	2501	2718	Progression and relapse			progression of disease within the liver and increaing pleural metastases. ~ Regimen: Capecitabine	true
15993	RA_1113	Chemotherapy	true	Capecitabine			Capecitabine	2501	2718	Progression and relapse			progression of disease within the liver and increaing pleural metastases. ~ Regimen: Capecitabine	true
15994	RA_1113	Chemotherapy	true	Eribulin Mesylate			Eribulin	2725	2862	Progression and relapse			D/C for grade 4 peripheral neuropathy (minimal progression in the lung and liver) ~ Regimen: Eribulin	true
15995	RA_1113	Chemotherapy	true	Eribulin Mesylate			Eribulin	2725	2862	Progression and relapse			D/C for grade 4 peripheral neuropathy (minimal progression in the lung and liver) ~ Regimen: Eribulin	true
15996	RA_1113	Chemotherapy	true	Gemcitabine Hydrochloride			Gemcitabine	2890	2937	Toxicity			intercurrent pneumonia, tolerated poorly ~ Regimen: Gemcitabine	true
15997	RA_1113	Chemotherapy	true	Gemcitabine Hydrochloride			Gemcitabine	2890	2937	Toxicity			intercurrent pneumonia, tolerated poorly ~ Regimen: Gemcitabine	true
15998	RA_1113	Chemotherapy	true	Paclitaxel			Taxol	3001	3232	Progression and relapse			Regimen: Taxol	true
15999	RA_1113	Chemotherapy	true	Paclitaxel			Taxol	3001	3232	Progression and relapse			Regimen: Taxol	true
16000	RA_1113	Hormone/Endocrine Therapy	true	Fulvestrant			BYL-719 [PI3K inhibitor] + Fulvestrant (X 12 Cycles)	3273	3608	Progression and relapse			Interval increase in size of multiple metastatic lesions in the liver. PD per RECIST. // Best Response = (-49.9%) ~ Regimen: BYL-719 [PI3K inhibitor] + Fulvestrant (X 12 Cycles)	true
16001	RA_1113	Hormone/Endocrine Therapy	true	Fulvestrant			BYL-719 [PI3K inhibitor] + Fulvestrant (X 12 Cycles)	3273	3608	Progression and relapse			Interval increase in size of multiple metastatic lesions in the liver. PD per RECIST. // Best Response = (-49.9%) ~ Regimen: BYL-719 [PI3K inhibitor] + Fulvestrant (X 12 Cycles)	true
16002	RA_1184	Chemotherapy	true	Carboplatin, Paclitaxel			carboplatin/paclitaxel (6 Cycles)  - Adjuvant	75	183	Completion of standard course			Regimen: carboplatin/paclitaxel (6 Cycles)  - Adjuvant	true
16003	RA_1184	Chemotherapy	true	Carboplatin, Gemcitabine Hydrochloride			carboplatin/gemcitabine (5 cycles)	479	618	Completion of standard course			Regimen: carboplatin/gemcitabine (5 cycles)	true
16004	RA_1184	Precision/Targeted Therapy	true	Golvatinib, Lenvatinib Mesylate			Golvatinib (E7050)/ lenvatinib (E7080) -[VEGFR Inhibitor] (16 Cycles)	1518	1959	Progression and relapse			Best Response = SD per RECIST (-20.5%) // Final Response = PD (-8% from BL // +22.1% from nadir) ~ Regimen: Golvatinib (E7050)/ lenvatinib (E7080) -[VEGFR Inhibitor] (16 Cycles)	true
16005	RA_1187	Chemotherapy	true	Gemcitabine Hydrochloride			Gemcitabine	87	101	Toxicity			Neutropenia ~ Regimen: Gemcitabine	true
16006	RA_1187		true		FU-LV		5-FU/LV deGramont [9 Cycles]	143	275	Completion of standard course			Regimen: 5-FU/LV deGramont [9 Cycles]	true
16007	RA_1326	Hormone/Endocrine Therapy	true	Letrozole			Letrozole	10	1063	NA	Recurrence		progression of osteoblastic metastasis and LEFT breast soft tissue mass ~ Regimen: Letrozole	true
16008	RA_1326	Hormone/Endocrine Therapy	true	Letrozole			Letrozole + BYL719 +LEE011 (X 2 Cycles)	1572	1602	NA			Clinical Trial:  Best Response = SD (-14.8%) D/C due to Nausea/Vomiting ~ Regimen: Letrozole + BYL719 +LEE011 (X 2 Cycles)	true
16009	RA_1326	Hormone/Endocrine Therapy	true	Cabozantinib-S-Malate, Fulvestrant			Cabozantinib + Faslodex (X 6 Cycles)	1652	1818	NA			Clinical Trial: Best Response = SD (-11.7%) // progression = new liver lesions and (-17.4 %) change from BL ~ Regimen: Cabozantinib + Faslodex (X 6 Cycles)	true
16010	RA_1326	Chemotherapy	true	Cyclophosphamide			cytoxan	2043	2065	NA			Regimen: cytoxan	true
16011	RA_1373	Chemotherapy	true	Cyclophosphamide, Doxorubicin			Adriamycin + Cytoxan (x 4 cycles)	17	140	NA			Regimen: Adriamycin + Cytoxan (x 4 cycles)	true
16012	RA_1373	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			Tamoxifen	140	505	NA			Regimen: Tamoxifen	true
16013	RA_1373	Hormone/Endocrine Therapy	true	Fulvestrant			Faslodex	5527	5619	NA	Recurrence		Regimen: Faslodex	true
16014	RA_1373	Chemotherapy	true	Capecitabine, Doxorubicin Hydrochloride Liposome			Doxil + Xeloda	5649	5831	NA			Regimen: Doxil + Xeloda	true
16015	RA_1373	Chemotherapy, Precision/Targeted Therapy	true	Capecitabine, Trastuzumab			Herceptin  (Trastuzumab) + Xeloda	5892	6410	NA			Regimen: Herceptin  (Trastuzumab) + Xeloda	true
16016	RA_1373		true		CMF		CMF	6410	6502	NA			Regimen: CMF	true
16017	RA_1373	Chemotherapy	true	Paclitaxel			Taxol	6502	6561	NA			Regimen: Taxol	true
16018	RA_1373	Chemotherapy	true	Eribulin Mesylate			Eribulin	6822	6843	NA			Regimen: Eribulin	true
16019	RA_1373	Chemotherapy	true	Eribulin Mesylate			Eribulin	6983	7046	NA			Regimen: Eribulin	true
16020	RA_1373	Chemotherapy	true	Cisplatin			Cisplatin	7053	7087	NA			Regimen: Cisplatin	true
16021	RA_1511	Biological Therapy	true	Bevacizumab			Carboplatin/Pemetrexed/Avastin	15	95	Progression and relapse			Progression = New Liver Mets, increased size of liver mets, R. Adrenal Met, Mesenteric Nodule // decreased size right lower lobe lung nodules, right paratracheal and right hilar lymphadenopathy consistent with treatment response ~ Regimen: Carboplatin/Pemetrexed/Avastin	true
16022	RA_1511	Immunotherapy	true	Nivolumab			Nivolumab	186	186	Toxicity			nivolumab-related pneumonitis ~ Regimen: Nivolumab	true
16023	RA_1526	Chemotherapy	true	Carboplatin, Paclitaxel			Taxol and carboplatin (Adjuvant)	46	116	NA			Regimen: Taxol and carboplatin (Adjuvant)	true
16024	RA_1526		true	Megestrol Acetate			Megace	686	714	NA	Recurrence		Regimen: Megace	true
16025	RA_1526		true	Ziv-Aflibercept			Aflibercept (GOG-0229F) - VEGF-trap	715	795	NA			Clinical Trial: Discontinued for proteinuria ~ Regimen: Aflibercept (GOG-0229F) - VEGF-trap	true
16026	RA_1526	Biological Therapy	true	Bevacizumab			Avastin (Bevacizumab)	820	1098	NA			Regimen: Avastin (Bevacizumab)	true
16027	RA_1526	Chemotherapy	true	Paclitaxel			weekly Taxol	1099	1253	NA			Regimen: weekly Taxol	true
16028	RA_1526	Biological Therapy	true	Bevacizumab			Consolidation Avastin (Bevacizumab)	1260	1736	NA			Regimen: Consolidation Avastin (Bevacizumab)	true
16029	RA_1526	Chemotherapy	true	Carboplatin, Doxorubicin Hydrochloride Liposome			Doxil + Carboplatin. Last platinum (#6)  then consolidation	1757	1918	NA			Regimen: Doxil + Carboplatin. Last platinum (#6)  then consolidation	true
16030	RA_1526	Biological Therapy	true	Bevacizumab			Consolidation Avastin (Bevacizumab)  15 mg/kg IV Q21D	1946	2009	NA			Regimen: Consolidation Avastin (Bevacizumab)  15 mg/kg IV Q21D	true
16031	RA_1526	Chemotherapy	true	Paclitaxel			MLN2480 + PACLITAXEL	2885	3036	NA			Clinical Trial:  Best Response = SD (-19.2%) // Progression = +7% from BL, +32.4% from Nadir -- Increased size of pulmonary nodules ~ Regimen: MLN2480 + PACLITAXEL	true
16032	RA_1526	Precision/Targeted Therapy	true	Navitoclax, Trametinib			TRAMETINIB + NAVITOCLAX	3074	3186	NA			Clinical Trial:  Best Response = SD (-4.0%) // Progression = +7.3% from BL, +11.5% from Nadir -- PD of Lung mult sites/Pleura mult sites ~ Regimen: TRAMETINIB + NAVITOCLAX	true
16033	RA_1526	Chemotherapy	true	Carboplatin, Doxorubicin Hydrochloride Liposome			Carboplatin + Doxil	3196	3374	NA			Regimen: Carboplatin + Doxil	true
16034	RA_1526	Immunotherapy	true	Avelumab			Avelumab (MSB0010718C) - anti PDL-1	3416	3461	NA			progression of mets in lung pleura and parenchyma with likely tumor in left lower lobe bronchus. ~ Regimen: Avelumab (MSB0010718C) - anti PDL-1	true
16035	RA_1534	Hormone/Endocrine Therapy	true	Anastrozole			Anastrazole	6	495	NA			Metastatic at Diagnosis ~ Regimen: Anastrazole	true
16036	RA_1534	Other	true	Exemestane, Zoledronic Acid			Exemestane + Zometa	496	555	NA			Regimen: Exemestane + Zometa	true
16037	RA_1534	Chemotherapy	true	Paclitaxel			Taxol	619	718	NA			Stable disease ~ Regimen: Taxol	true
16038	RA_1534	Precision/Targeted Therapy	true	Everolimus, Exemestane, Ribociclib			LEE011(Ribociclib)/everolimus/exemestane X 10 Cycles	746	1026	NA			Clinical Trial: Best Response = Partial Response (-36.3%) ~ Regimen: LEE011(Ribociclib)/everolimus/exemestane X 10 Cycles	true
16039	RA_1542	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			Cisplatin/Gemcitabine (x 3 cycles)	18	66	Progression and relapse			Progression = Enlarged left and right diaphragmatic lymph nodes, concerning for metastasis; numerous bilobar liver metastases slightly enlarged ~ Regimen: Cisplatin/Gemcitabine (x 3 cycles)	true
16040	RA_1542		true		FOLFOX		FOLFOX, 5-FU	190	243	Progression and relapse			Progression = Increase in metastatic burden throughout the liver; Mild increase in size of lung mets. ~ Regimen: FOLFOX, 5-FU	true
16041	RA_1547		true		TAC		TAC (6 Cycles)	56	161	NA			Regimen: TAC (6 Cycles)	true
16042	RA_1547	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			Tamoxifen	232	295	NA			Regimen: Tamoxifen	true
16043	RA_1547	Hormone/Endocrine Therapy	true	Toremifene			Toremifene	295	818	NA			Regimen: Toremifene	true
16044	RA_1547	Hormone/Endocrine Therapy	true	Anastrozole			Anastrozole	818	1036	Progression and relapse	Recurrence		Regimen: Anastrozole	true
16045	RA_1547	Hormone/Endocrine Therapy, Other	true	Fulvestrant, Zoledronic Acid			Fulvestrant + Zometa	1048	1268	Progression and relapse			Regimen: Fulvestrant + Zometa	true
16046	RA_1547	Precision/Targeted Therapy	true	Everolimus, Exemestane, Ribociclib			LEE011 (Ribociclib) /exemestane/everolimus (X 17 Cycles)	1309	1779	Progression and relapse			Clinical Trial #: Best Response = SD (0.0%) - Bone only, eventual PD in Bone single site ~ Regimen: LEE011 (Ribociclib) /exemestane/everolimus (X 17 Cycles)	true
16047	RA_1547	Chemotherapy	true	Capecitabine			Xeloda (Capecitabine)	1792	1958	Progression and relapse			Progression = new liver lesions ~ Regimen: Xeloda (Capecitabine)	true
16048	RA_1558	Chemotherapy	true	Cyclophosphamide, Doxorubicin, Paclitaxel Albumin-stabilized Nanoparticle Formulation			Adriamycin/Cytoxan [4 Cycles] + Abraxane [4 Cycles]	70	168	Completion of standard course			Regimen: Adriamycin/Cytoxan [4 Cycles] + Abraxane [4 Cycles]	true
16049	RA_1558	Hormone/Endocrine Therapy	true	Anastrozole			Arimidex (Adjuvant)	239	2053	Completion of standard course			Regimen: Arimidex (Adjuvant)	true
16050	RA_1558		true	Exemestane			Exemestane	2334	2611	Progression and relapse			PD in internal mammary nodes ~ Regimen: Exemestane	true
16051	RA_1558	Hormone/Endocrine Therapy	true	Fulvestrant			BYL719/fulvestrant [2 Cycles]	2642	2691	Toxicity			D/C for toxicity (Rash) - Overal RECIST Response = SD (-17.3%) ~ Regimen: BYL719/fulvestrant [2 Cycles]	true
16052	RA_1558	Hormone/Endocrine Therapy	true	Fulvestrant			Fulvestrant (single agent)	2696	3245	Progression and relapse			PD in left parasternal region ~ Regimen: Fulvestrant (single agent)	true
16053	RA_1558	Chemotherapy	true	Capecitabine			Xeloda	3586	3894	Progression and relapse			Progression in Liver ~ Regimen: Xeloda	true
16054	RA_1558	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Fulvestrant, Palbociclib			Fulvestrant/Palbociclib	3895	3977	Progression and relapse			Progression in Liver ~ Regimen: Fulvestrant/Palbociclib	true
16055	RA_1558	Hormone/Endocrine Therapy	true	Letrozole			GDC-0077 + Letrozole [2 Cycles]	4120	4176	Progression and relapse			Final Response = PD (+14.78%) + New Liver Lesions ~ Regimen: GDC-0077 + Letrozole [2 Cycles]	true
16056	RA_1558	Chemotherapy	true	Eribulin Mesylate			Eribulin [11 Cycles]	4183	4405	Progression and relapse			Progression of Hepatic metastases ~ Regimen: Eribulin [11 Cycles]	true
16057	RA_1558	Chemotherapy	true	Doxorubicin Hydrochloride Liposome			Doxil [2 Cycles]	4708	4750	Progression and relapse			liver, peritoneal, and bony progression ~ Regimen: Doxil [2 Cycles]	true
16058	RA_1558	Precision/Targeted Therapy	true	Abemaciclib			Abemaciclib	4763	4868	Progression and relapse			Patient passed away ~ Regimen: Abemaciclib	true
16059	RA_1568		true		AC		neoadjuvant AC (4 Cycles)	26	68	Completion of standard course			Regimen: neoadjuvant AC (4 Cycles)	true
16060	RA_1568	Chemotherapy	true	Paclitaxel			Taxol	83	159	Completion of standard course			Regimen: Taxol	true
16061	RA_1568	Chemotherapy	true	Cisplatin			Cisplatin	224	238	Toxicity			Regimen: Cisplatin	true
16062	RA_1598	Chemotherapy	true	Paclitaxel	AC		dose dense AC + taxol	64	166	NA			Regimen: dose dense AC + taxol	true
16063	RA_1598	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			Tamoxifen	257	621	NA			Regimen: Tamoxifen	true
16064	RA_1598	Hormone/Endocrine Therapy	true	Leuprolide Acetate			Lupron	654	698	NA	Recurrence		Regimen: Lupron	true
16065	RA_1598	Hormone/Endocrine Therapy, Other	true	Letrozole, Zoledronic Acid			Letrozole + Zometa	699	1652	NA			Regimen: Letrozole + Zometa	true
16066	RA_1598	Hormone/Endocrine Therapy	true	Exemestane, Leuprolide Acetate			Lupron + Exemestane	1652	2136	NA			Regimen: Lupron + Exemestane	true
16067	RA_1598	Chemotherapy	true	Capecitabine			Xeloda	2136	2262	NA			Regimen: Xeloda	true
16068	RA_1598		true	Cabozantinib-S-Malate			CABOZANITINIB (X 67 Cycles)	2294	3724	NA			Clinical Trial, Best Response = SD (0.0%) - Bone only disease // Progression = "Interval increase in uptake intensity involving right precarinal and periportal lymph nodes, suspicious for disease progression. " ~ Regimen: CABOZANITINIB (X 67 Cycles)	true
16069	RA_1598	Hormone/Endocrine Therapy	true	Letrozole			GDC-0032 + Letrozole (X 10 Cycles)	3747	4012	NA			Clinical Trial, Best Response = SD (0.0%) // Progression = New Liver Lesions (multiple sites) ~ Regimen: GDC-0032 + Letrozole (X 10 Cycles)	true
16070	RA_1598	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Fulvestrant, Palbociclib			Fulvestrant/Palbociclib (X 2 Cycles)	4040	4087	NA			Regimen: Fulvestrant/Palbociclib (X 2 Cycles)	true
16071	RA_1613	Chemotherapy	true	Gemcitabine Hydrochloride			Gemcitabine	11	211	NA			Progression = "interval progression of liver metastatic disease with new and enlarging metastases" ~ Regimen: Gemcitabine	true
16072	RA_1613		true	Neratinib  Maleate			Neratinib	224	247	NA			Clinical Trial: Best Response = PD ("worsening metastatic disease particularly intrahepatic") ~ Regimen: Neratinib	true
16073	RA_1613		true		FOLFOX		FOLFOX	248	258	NA			Regimen: FOLFOX	true
16074	RA_1644	Chemotherapy	true	Cyclophosphamide, Doxorubicin			Doxorubicin(Adriamycin) + cyclophosphamide	69	152	NA			Regimen: Doxorubicin(Adriamycin) + cyclophosphamide	true
16075	RA_1644	Chemotherapy, Precision/Targeted Therapy	true	Paclitaxel, Trastuzumab			Taxol and Herceptin (Trastuzumab)	153	230	NA			Regimen: Taxol and Herceptin (Trastuzumab)	true
16076	RA_1644	Precision/Targeted Therapy	true	Trastuzumab			Herceptin (Trastuzumab)	243	517	NA			Regimen: Herceptin (Trastuzumab)	true
16077	RA_1644	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			Tamoxifen	349	1011	NA			Regimen: Tamoxifen	true
16078	RA_1644	Hormone/Endocrine Therapy	true	Anastrozole			Arimidex (Anastrazole)	1012	1875	NA			Regimen: Arimidex (Anastrazole)	true
16079	RA_1644	Chemotherapy, Precision/Targeted Therapy	true	Cyclophosphamide, Docetaxel, Pegfilgrastim, Trastuzumab			Taxotere/Cytoxan/Herceptin with neulasta	1889	1952	NA			Regimen: Taxotere/Cytoxan/Herceptin with neulasta	true
16080	RA_1644	Precision/Targeted Therapy	true	Trastuzumab			Herceptin (Trastuzumab)	1973	2078	NA			Regimen: Herceptin (Trastuzumab)	true
16081	RA_1644		true	Exemestane			Exemestane	1985	2402	NA			Progression = enlarging mediastinal nodes ~ Regimen: Exemestane	true
16082	RA_1644	Hormone/Endocrine Therapy	true	Fulvestrant			GDC0032 + Faslodex (Fulvestrant) - (X 17 Cycles)	2435	2903	NA			Clinical Trial: Best Response = PR (-35.1 %) // Progression = interval increase in size of bilateral lung nodules and left hilar nodes. (-16.2%) change from BL // (+29.2%) change from  Nadir ~ Regimen: GDC0032 + Faslodex (Fulvestrant) - (X 17 Cycles)	true
16083	RA_1644	Precision/Targeted Therapy	true	Everolimus, Exemestane			exemestane/everolimus/LEE011 - (X14 Cycles)	2920	3312	NA			Clinical Trial: Best Response = SD (+5.5%) // Progression =progression in lungs, overall (+23.67 %) Increase from BL ~ Regimen: exemestane/everolimus/LEE011 - (X14 Cycles)	true
16084	RA_1644	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Letrozole, Palbociclib			GDC0077 + palbociclib + Letrozole (X 4 Cycles)	3325	3410	NA			Clinical Trial: Best Response = SD (-14.31%) // D/C d/t dysphagia, admission ~ Regimen: GDC0077 + palbociclib + Letrozole (X 4 Cycles)	true
16085	RA_1657	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			Gemcitabine/Cisplatin [7 Cycles]	26	159	Progression and relapse			new lesion in segment V (Liver) ~ Regimen: Gemcitabine/Cisplatin [7 Cycles]	true
16086	RA_1657		true		FOLFOX		FOLFOX [3 Cycles]	173	211	Progression and relapse			intrahepatic progression and likely extrahepatic spread to the retroperitoneal lymph nodes and possibly to the lungs ~ Regimen: FOLFOX [3 Cycles]	true
16087	RA_1657	Immunotherapy	true	Pembrolizumab			Pembrolizumab [1 Cycles]	215	229	Other			Single Dose - Drug held for increased fluid retention, platelet increase ~ Regimen: Pembrolizumab [1 Cycles]	true
16088	RA_1726	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			Cisplatin/Gemcitabine	24	117	Progression and relapse			Progression = Mixed response in bony and visceral sites, with new satellite lesions identified in liver ~ Regimen: Cisplatin/Gemcitabine	true
16089	RA_1726		true		FOLFOX		FOLFOX	124	201	Progression and relapse			Progression = Increase in lymphadenopathy in chest and abdomen, and increase in hepatic masses and peritoneal carcinomatosis, and increase in right liac bone lesion. ~ Regimen: FOLFOX	true
16090	RA_1726		true	Dasatinib			Dasatinib	231	258	Progression and relapse			Clinical Progression ~ Regimen: Dasatinib	true
16091	RA_1926		true		FOLFOX		FOLFOX (X 7 Cycles)	15	103	Completion of standard course			Regimen: FOLFOX (X 7 Cycles)	true
16092	RA_1926		true		FOLFOX		FOLFOX (X 6 Cycles)	1577	1644	Completion of standard course			response of primary tumor, no new sites of metastatic disease ~ Regimen: FOLFOX (X 6 Cycles)	true
16093	RA_1926	Chemotherapy	true	Carboplatin, Paclitaxel			Carbo (AUC 5) + Taxol	2282	2282	Other			One dose, pursued Hospice ~ Regimen: Carbo (AUC 5) + Taxol	true
16094	RA_1939	Chemotherapy	true	Gemcitabine Hydrochloride			Gemcitabine (X 7 Doses)	117	200	Toxicity			Regimen: Gemcitabine (X 7 Doses)	true
16095	RA_1939		true		FU-LV		deGramont 5-fu (X 4 Cycles)	207	258	Completion of standard course			Regimen: deGramont 5-fu (X 4 Cycles)	true
16096	RA_1939		true		FOLFOX		FOLFOX	488	712	Progression and relapse	Recurrence		Progression of hepatic metastatic disease burden ~ Regimen: FOLFOX	true
16097	RA_1939	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			Gemcitabine + Cisplatin	1175	1278	Progression and relapse			Progression = new left ischial spine met ~ Regimen: Gemcitabine + Cisplatin	true
16098	RA_2024		true		FOLFOX		FOLFOX	19	208	Completion of standard course			Regimen: FOLFOX	true
16099	RA_2024		true		FOLFOX		FOLFOX	19	208	Completion of standard course			Regimen: FOLFOX	true
16100	RA_2024		true		FOLFIRI-BEVACIZUMAB		FOLFIRI + bevacizumab	440	713	Progression and relapse			Regimen: FOLFIRI + bevacizumab	true
16101	RA_2024		true		FOLFIRI-BEVACIZUMAB		FOLFIRI + bevacizumab	440	713	Progression and relapse			Regimen: FOLFIRI + bevacizumab	true
16102	RA_2024		true		FOLFIRI-CETUXIMAB		FOLFIRI + cetuximab	727	797	Progression and relapse			interval increase in size of paraesophageal lymph nodes, concerning for nodal metastasis. new retroperitoneal lymphadenopathy and abdominal  wall soft tissue nodularity, consistent with progressive metastatic disease with peritoneal carcinomatosis. ~ Regimen: FOLFIRI + cetuximab	true
16103	RA_2024		true		FOLFIRI-CETUXIMAB		FOLFIRI + cetuximab	727	797	Progression and relapse			interval increase in size of paraesophageal lymph nodes, concerning for nodal metastasis. new retroperitoneal lymphadenopathy and abdominal  wall soft tissue nodularity, consistent with progressive metastatic disease with peritoneal carcinomatosis. ~ Regimen: FOLFIRI + cetuximab	true
16104	RA_2024	Precision/Targeted Therapy	true	Lapatinib Ditosylate, Trastuzumab			trastuzumab/lapatinib	825	901	Progression and relapse			slight increase in size of mediastinal, pericardial, left supraclavicular, left subpectoral, left axillary lymphadenopathy, which remains concerning  for progressive disease. unchanged pulmonary nodules.  CT abdomen and pelvis: metastatic retroperitoneal adenopathy. Several lymph nodes have increased in size in the interim. Peritoneal carcinomatosis and ascites is unchanged. ~ Regimen: trastuzumab/lapatinib	true
16105	RA_2024	Precision/Targeted Therapy	true	Lapatinib Ditosylate, Trastuzumab			trastuzumab/lapatinib	825	901	Progression and relapse			slight increase in size of mediastinal, pericardial, left supraclavicular, left subpectoral, left axillary lymphadenopathy, which remains concerning  for progressive disease. unchanged pulmonary nodules.  CT abdomen and pelvis: metastatic retroperitoneal adenopathy. Several lymph nodes have increased in size in the interim. Peritoneal carcinomatosis and ascites is unchanged. ~ Regimen: trastuzumab/lapatinib	true
16106	RA_2085		true		FOLFOX		FOLFOX [4 Cycles]	22	64	Completion of standard course			partial response ~ Regimen: FOLFOX [4 Cycles]	true
16107	RA_2085		true		FOLFOX		FOLFOX	148	204	Completion of standard course			Regimen: FOLFOX	true
16108	RA_2085		true		FU-LV		5FU + Radiation	231	269	Completion of standard course			Regimen: 5FU + Radiation	true
16109	RA_2085	Biological Therapy	true	Bevacizumab	FOLFOX		FOLFOX with Avastin [8 Cycles]	640	745	Completion of standard course			Regimen: FOLFOX with Avastin [8 Cycles]	true
16110	RA_2085	Biological Therapy	true	Bevacizumab	FOLFIRI		FOLFIRI plus Avastin [8 Cycles]	983	1103	Completion of standard course			Regimen: FOLFIRI plus Avastin [8 Cycles]	true
16111	RA_2085		true	Cetuximab			Cetuximab	1341	1451	Progression and relapse			rising tmor markers/new disease ~ Regimen: Cetuximab	true
16112	RA_2085	Immunotherapy	true	Ipilimumab, Nivolumab			Ipilimumab/Nivolumab	1654	1752	Toxicity			checkpoint inhibitor colitis ~ Regimen: Ipilimumab/Nivolumab	true
16113	RA_209	Immunotherapy	true	Atezolizumab, Cobimetinib, Vemurafenib			Vemurafenib + Cobimetinib+ Atezolizumab	4740	4754	Toxicity			hypersensitivity reaction (Rash, pharyngitis, odynophagia) -  partial response to treatment ~ Regimen: Vemurafenib + Cobimetinib+ Atezolizumab	true
16114	RA_209	Immunotherapy	true	Pembrolizumab			Pembrolizumab	4803	4845	Progression and relapse			New innumerable tiny centrilobular groundglass nodules throughout the lungs; 8 mm soft tissue nodule in the (L) posterior lateral mid chest SC fat; Growth of a peritoneal implant adjacent to the duodenal bulb, concerning for progression of a metastasis. ~ Regimen: Pembrolizumab	true
16115	RA_209	Immunotherapy	true	Ipilimumab			Ipilimumab	5342	5342	Toxicity			Rash - Mixed response: decrease in FDG avidity of LUE, liver met, RUQ peritoneal nodule. New FDG avid nodule in L chest wall, enlargement of nodule in R pelvis.  New and increasing soft tissue nodules in L supraclav fossa, axilla, B breasts, chest wall. ~ Regimen: Ipilimumab	true
16116	RA_209	Precision/Targeted Therapy	true	Dabrafenib Mesylate, Trametinib			Dabrafenib + Trametinib	5567	5793	Progression and relapse			Marked increase in size of L breast masses, less pronounced increase in other truncal soft tissue/SC masses and R groin mass.  growing subq mets + new subq mets ~ Regimen: Dabrafenib + Trametinib	true
16117	RA_209	Precision/Targeted Therapy	true	Binimetinib, Encorafenib			Encorafenib + Binimetinib	5801	5846	Progression and relapse			Marked progression of diffuse metastatic disease; innumerable diffuse, enhancing and intensely FDG avid soft tissue nodules throughout all imaged subcutaneous space, all imaged peritoneal spaces, and also involving musculature and bowel.  interval development of innumerable diffuse enlarged, enhancing and intensely FDG avid subcutaneous nodules, axillary lymph nodes, supraclavicular lymph nodes, internal mammary lymph nodes, mediastinal and hilar lymph nodes. ~ Regimen: Encorafenib + Binimetinib	true
16118	RA_2098	Chemotherapy	true	Carboplatin, Paclitaxel			Carboplatin/ Paclitaxel (x 6 cycles)	44	181	Progression and relapse		Recurrence	Progression = Multiple new enhancing nodules along the anterior right and left upper abdomen, in the left anterior pelvis, and within and along the left rectus abdominus musculature ~ Regimen: Carboplatin/ Paclitaxel (x 6 cycles)	true
16119	RA_2098	Immunotherapy	true	Pembrolizumab, Ziv-Aflibercept			Ziv-Aflibercept and Pembrolizumab (x 8 cycles)	221	335	Progression and relapse			Progression = progression in L rectus muscle lesion and L pelvic side wall lymph node ~ Regimen: Ziv-Aflibercept and Pembrolizumab (x 8 cycles)	true
16120	RA_2098	Chemotherapy	true	Gemcitabine Hydrochloride			Gemcitabine  (x 2 cycles)	366	398	Progression and relapse			Progression = increased abdominal and pelvic adenopathy, pelvic masses and perihepatic lesions. ~ Regimen: Gemcitabine  (x 2 cycles)	true
16121	RA_2098	Biological Therapy, Precision/Targeted Therapy	true	Palbociclib, Ramucirumab			Palbociclib + Gedatolisib (PI3K/mTORi)	471	513	Progression and relapse			Progression = increasing intrathoracic LAD, peritoneal disease, abdominopelvic lymphadenopathy, and soft tissue masses ~ Regimen: Palbociclib + Gedatolisib (PI3K/mTORi)	true
16122	RA_2098	Immunotherapy	true	Nivolumab			TAK-659 + Nivolumab	590	674	Progression and relapse			Best Response = SD (+13.79% from BL) // Progression = PD (+22.7% from BL) Increased size of left peritoneal lesion ~ Regimen: TAK-659 + Nivolumab	true
16123	RA_2113	Immunotherapy	true	Ipilimumab			Nivolumab + Ipilimumab	56	69	Toxicity			stopped after a single dose of ipi/nivo due to increased dyspnea and likely autoimmune pneumonitis ~ Regimen: Nivolumab + Ipilimumab	true
16124	RA_2168		true		FOLFIRI		FOLFIRI	32	228	Other			Regimen: FOLFIRI	true
16125	RA_2177	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			Gemcitabine + Cisplatin [6 Cycles]	28	151	Progression and relapse			Regimen: Gemcitabine + Cisplatin [6 Cycles]	true
16126	RA_2177	Precision/Targeted Therapy	true	Sorafenib			Sorafenib (2 Days)	181	183	Toxicity			Rash ~ Regimen: Sorafenib (2 Days)	true
16127	RA_2185	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			Gemcitabine/Cisplatin [12 Cycles]	25	329	Progression and relapse			Marked worsening of hepatic disease. Growth of supraclavicular lymph nodes. ~ Regimen: Gemcitabine/Cisplatin [12 Cycles]	true
16128	RA_2185	Immunotherapy	true	Pembrolizumab			Pembrolizumab [3 Cycles]	371	420	Progression and relapse			Clinical Progression - Worsenning Ascites & Pain ~ Regimen: Pembrolizumab [3 Cycles]	true
16129	RA_2185		true		FU-LV		5FU + IVCI [7 Cycles]	441	560	Progression and relapse			Regimen: 5FU + IVCI [7 Cycles]	true
16130	RA_2389	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			Tamoxifen	0	103	Other			mixed response with decrease in liver lesions, stable bone disease, decrease in left axillary disease and increase in left breast disease. ~ Regimen: Tamoxifen	true
16131	RA_2389	Hormone/Endocrine Therapy	true	Leuprolide Acetate, Tamoxifen Citrate			Tamoxifen/Lupron	103	284	Other			Regimen: Tamoxifen/Lupron	true
16132	RA_2389	Hormone/Endocrine Therapy	true	Anastrozole, Leuprolide Acetate			Anastrozole/ Lupron	284	391	Toxicity			previous left axillary and subpectoral region lymph nodes appeared to have regressed and no longer showed increased uptake, improvement in bony metastatic disease with diminished activity in all bony lesions and no evidence of liver metastases. ~ Regimen: Anastrozole/ Lupron	true
16133	RA_2389	Hormone/Endocrine Therapy	true	Leuprolide Acetate, Tamoxifen Citrate			Tamoxifen/ Lupron	391	489	Progression and relapse			Regimen: Tamoxifen/ Lupron	true
16134	RA_2389	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Fulvestrant, Leuprolide Acetate, Palbociclib			fulvestrant/palbociclib/Lupron	489	573	Progression and relapse			Regimen: fulvestrant/palbociclib/Lupron	true
16135	RA_2389	Chemotherapy	true	Capecitabine			Capecitabine	573	822	Progression and relapse			Bilateral hypermetabolic breasts lesions concerning for active tumor in both breasts. Multiple hypermetabolic and non hypermetabolic sclerotic foci within the skeleton. ~ Regimen: Capecitabine	true
16136	RA_2389	Hormone/Endocrine Therapy	true	Fulvestrant, Goserelin Acetate, Neratinib  Maleate			Fulvestrant/Neratinib (TKI) with Goserelin (#13-615)	877	891	Progression and relapse			rapid deterioration of her performance status ~ Regimen: Fulvestrant/Neratinib (TKI) with Goserelin (#13-615)	true
16137	RA_2402	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Letrozole, Palbociclib			Palbociclib/Letrozole [19 Cycles]	116	647	Progression and relapse			progression in the liver ~ Regimen: Palbociclib/Letrozole [19 Cycles]	true
16138	RA_2402	Chemotherapy	true	Capecitabine			Xeloda	919	1140	Progression and relapse			Initial Response of liver lesions // PD = New and enlarging hepatic metastases ~ Regimen: Xeloda	true
16139	RA_2402	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Abemaciclib, Fulvestrant			Abemaciclib/Fulvestrant [1 Cycle]	1224	1256	Progression and relapse			Rising Tumor Markers ~ Regimen: Abemaciclib/Fulvestrant [1 Cycle]	true
16140	RA_2402	Chemotherapy	true	Doxorubicin Hydrochloride Liposome			Doxil [2 Cycles]	1259	1287	Progression and relapse			Regimen: Doxil [2 Cycles]	true
16141	RA_2402	Chemotherapy	true	Paclitaxel			Taxol [4 Cycles]	1297	1406	Progression and relapse			Decrease in size of hepatic lesions ~ Regimen: Taxol [4 Cycles]	true
16142	RA_2402	Chemotherapy	true	Vinorelbine Tartrate			Vinorelbine	1406	1413	Progression and relapse			Regimen: Vinorelbine	true
16143	RA_2408	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			Gemcitabine/ Cisplatin (X 3 Cycles)	105	177	Progression and relapse			Best Response = Progression in Liver ~ Regimen: Gemcitabine/ Cisplatin (X 3 Cycles)	true
16144	RA_2460	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			Gemcitabine/Cisplatin/DKN-01	25	53	Progression and relapse			progression of disease with mild new biliary dilation ~ Regimen: Gemcitabine/Cisplatin/DKN-01	true
16145	RA_2460	Precision/Targeted Therapy	true	Olaparib			Olaparib + AZD5363	291	373	Progression and relapse			Overall stable disease "slightly increased size of right hepatic lesions, stable left hepatic lesions, and slightly decreased abdominal lymphadenopathy" ~ Regimen: Olaparib + AZD5363	true
16146	RA_2542		true		CAF		CAF (cyclophosphamide/ Adriamycin/ Fluorouracil) - 6 Cycles	29	182	Completion of standard course			Exact dates of treatment unknown ~ Regimen: CAF (cyclophosphamide/ Adriamycin/ Fluorouracil) - 6 Cycles	true
16147	RA_2542	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			Tamoxifen (Adjuvant)	335	2161	Completion of standard course			Regimen: Tamoxifen (Adjuvant)	true
16148	RA_2542	Hormone/Endocrine Therapy	true	Letrozole			Letrozole	2826	4656	Completion of standard course			Regimen: Letrozole	true
16149	RA_2542	Hormone/Endocrine Therapy	true	Letrozole			Letrozole	4912	6104	Progression and relapse			New Bone Lesions ~ Regimen: Letrozole	true
16150	RA_2542	Chemotherapy	true	Capecitabine			Capecitabine	6105	7746	Progression and relapse			Regimen: Capecitabine	true
16151	RA_2542	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Fulvestrant, Palbociclib			Fulvestrant/Palbociclib	7749	7811	Progression and relapse			Regimen: Fulvestrant/Palbociclib	true
16152	RA_2542	Chemotherapy	true	Paclitaxel			Paclitaxel	8447	8610	Other			Patient pursued hospice care ~ Regimen: Paclitaxel	true
16153	RA_2544	Chemotherapy	true	Carboplatin, Paclitaxel			Carboplatin AUC 5 + Taxol	41	253	Completion of standard course			Near complete interval resolution of the previously described bilateral pulmonary nodules.  Marked interval decrease in size of the right hepatic lobe and right retroperitoneal mass. Persistent right posterior retroperitoneal soft tissue infiltration of the intercostal spaces and infiltration of the posterior 11th rib with interval sclerosis. Interval decrease in size of the right renal posterior infiltrative mass in continuity with the large posterior retroperitoneal mass. Interval development of coarse calcifications within theretroperitoneal mass. ~ Regimen: Carboplatin AUC 5 + Taxol	true
16154	RA_2544	Hormone/Endocrine Therapy	true	Letrozole			Letrozole	259	793	Progression and relapse			Progression =  Enlargement of pulmonary nodules; progression of necrotic pulmonary metastasis; no change in R hepatic lobe lesion with adjacent soft tissue mass ~ Regimen: Letrozole	true
16155	RA_255	Chemotherapy	true	Carboplatin, Paclitaxel			Carboplatin / Paclitaxel [2 Cycles]	15	36	Completion of standard course			Previously identifiable 5 mm right anterior enhancing extrapleural lymph node is no longer identifiable. Biapical changes and complex calcifications in the left lower lobe are most consistent with chronic granulomatous changes. Complete disappearance of omental metastases and ascites. ~ Regimen: Carboplatin / Paclitaxel [2 Cycles]	true
16156	RA_255	Immunotherapy	true	Ipilimumab			Ipilimumab [4 Cycles]	65	127	Completion of standard course			no evidence of CNS disease and no evidence of other visceral metastases except for a number of new lytic lesions ~ Regimen: Ipilimumab [4 Cycles]	true
16157	RA_255	Immunotherapy	true	Pembrolizumab			Pembrolizumab	275	337	Progression and relapse			?Interval development of approximately 10 enhancing lesions within the supra and infratentorial brain, measuring up to 17 mm in the left posterior temporal lobe and right cerebellum ~ Regimen: Pembrolizumab	true
16158	RA_255	Precision/Targeted Therapy	true	Dabrafenib Mesylate, Trametinib			Dabrafenib / Trametinib	344	586	Toxicity			Fevers and chills ~ Regimen: Dabrafenib / Trametinib	true
16159	RA_255	Immunotherapy	true	Pembrolizumab			Pembrolizumab [15 Cycles]	435	675	Progression and relapse			MRI Brain: Interval development of a 10 mm enhancing lesion with mild surrounding edema in the left inferior frontal gyrus. New punctate focus of enhancement in the left posterior superior temporal gyrus, which is concerning for a new metastatic lesion.  CT CAP:  Slight interval increase in size of the soft tissue component involving a left eighth rib lesion. Other osseous lesions appear essentially unchanged. Pulmonary nodules measuring up to 4 mm are unchanged.No new or enlarging pulmonary nodules. Multifocal lytic metastasis appears similar to before. Otherwise, no metastatic disease within the abdomen or pelvis. ~ Regimen: Pembrolizumab [15 Cycles]	true
16160	RA_255	Precision/Targeted Therapy	true	Dabrafenib Mesylate, Trametinib			Dabrafenib / Trametinib	696	706	Toxicity			Fevers ~ Regimen: Dabrafenib / Trametinib	true
16161	RA_255		true	Cobimetinib, Vemurafenib			Vemurafenib / Cobimetinib	706	1121	Progression and relapse			MRI Brain: at least 3 new enhancing lesions suspicious for metastases; CTCAP: Pathologic fracture of the left transverse process of T8 with increased adjacent soft tissue component consistent with progression of a bone metastasis.  Additional osseous metastases in multiple thoracic vertebral bodies are stable, ~ Regimen: Vemurafenib / Cobimetinib	true
16162	RA_255	Chemotherapy	true	Carboplatin, Paclitaxel			Carboplatin/Taxol	1123	1123	Progression and relapse			Increased nodular soft tissue in left paraspinal region, left T8-9 neural foramen, and left central spinal canal at T8 increase in size of a left paraspinal nodule or extrapleural lymph node at T9. Multiple 2-4 mm pulmonary nodules are increased. Hepatic metastatic disease burden has progressed. Increasing left adrenal nodularity is also suspicious for a metastasis.  Bony metastatic disease burden is unchanged ~ Regimen: Carboplatin/Taxol	true
16163	RA_255	Immunotherapy	true	Ipilimumab, Nivolumab			Ipilimumab + Nivolumab	1151	1151	Other			Patient chose not to pursue further treatment ~ Regimen: Ipilimumab + Nivolumab	true
16164	RA_2736	Chemotherapy	true	Gemcitabine Hydrochloride			Gemcitabine [6 Cycles] - adjuvant	62	223	Completion of standard course			Regimen: Gemcitabine [6 Cycles] - adjuvant	true
16165	RA_2736	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			Gemcitabine / Cisplatin	875	882	Other			transitioned to hospice ~ Regimen: Gemcitabine / Cisplatin	true
16166	RA_2754	Precision/Targeted Therapy	true	Sorafenib			Sorafenib	24	80	Progression and relapse			increase in size and distribution of the multifocal intrahepatic tumor; new focus of tumor thrombus in the right portal vein. Increased periportal, portacaval, gastrohepatic, paraesophageal and cardiophrenic metastatic lymphadenopathy.Increased in size of anterior peritoneal implant. ~ Regimen: Sorafenib	true
16167	RA_2754	Precision/Targeted Therapy	true	Sorafenib			Sorafenib	24	80	Progression and relapse			increase in size and distribution of the multifocal intrahepatic tumor; new focus of tumor thrombus in the right portal vein. Increased periportal, portacaval, gastrohepatic, paraesophageal and cardiophrenic metastatic lymphadenopathy.Increased in size of anterior peritoneal implant. ~ Regimen: Sorafenib	true
16168	RA_2754	Immunotherapy	true	Nivolumab			Nivolumab (4 Cycles)	87	197	Progression and relapse			DISEASE PROGRESSION AS EVIDENCED BY ENLARGING LIVER LESIONS AND PERITONEAL NODULES ~ Regimen: Nivolumab (4 Cycles)	true
16169	RA_2754	Immunotherapy	true	Nivolumab			Nivolumab (4 Cycles)	87	197	Progression and relapse			DISEASE PROGRESSION AS EVIDENCED BY ENLARGING LIVER LESIONS AND PERITONEAL NODULES ~ Regimen: Nivolumab (4 Cycles)	true
16170	RA_2754	Immunotherapy, Precision/Targeted Therapy	true	Lenvatinib Mesylate, Nivolumab			Nivolumab + Lenvatinib (4 Cycles)	200	311	Progression and relapse			Interval increase in retroperitoneal metastatic burden. Stable hepatic and osseous metastasis ~ Regimen: Nivolumab + Lenvatinib (4 Cycles)	true
16171	RA_2754	Immunotherapy, Precision/Targeted Therapy	true	Lenvatinib Mesylate, Nivolumab			Nivolumab + Lenvatinib (4 Cycles)	200	311	Progression and relapse			Interval increase in retroperitoneal metastatic burden. Stable hepatic and osseous metastasis ~ Regimen: Nivolumab + Lenvatinib (4 Cycles)	true
16172	RA_2754		true	Regorafenib			Regorafenib	317	322	Other			Stopped for inpatient admission ~ Regimen: Regorafenib	true
16173	RA_2754		true	Regorafenib			Regorafenib	317	322	Other			Stopped for inpatient admission ~ Regimen: Regorafenib	true
16174	RA_2785	Biological Therapy	true	Bevacizumab	FOLFIRINOX		FOLFIRINOX/FOLFOXIRI/FOLFIRI + Bevacizumab (13 Cycles)	14	182	Progression and relapse			Progression in Liver ~ Regimen: FOLFIRINOX/FOLFOXIRI/FOLFIRI + Bevacizumab (13 Cycles)	true
16175	RA_2785	Immunotherapy	true	Ipilimumab, Nivolumab			Ipilimumab + Nivolumab	219	306	Progression and relapse			Enlarging pulmonary nodules and mediastinal lymphadenopathy consistent with worsening metastatic disease; Interval progression of disease with marked interval increase in number and size of metastatic liver lesions and worsened retroperitoneal lymphadenopathy. ~ Regimen: Ipilimumab + Nivolumab	true
16176	RA_2785		true		FOLFOX		FOLFOX (4 Cycles)	315	355	Progression and relapse			CT scan demonstrates progression in liver ~ Regimen: FOLFOX (4 Cycles)	true
16177	RA_2785	Chemotherapy	true	Cetuximab, Irinotecan Hydrochloride			Irinotecan + Cetuximab (7 Cycles)	369	464	Progression and relapse			Restating CT with progression in the liver ~ Regimen: Irinotecan + Cetuximab (7 Cycles)	true
16178	RA_2785		true	Panitumumab			Panitumumab (4 Cycles)	506	546	Progression and relapse			Patient passed away prior to scans ~ Regimen: Panitumumab (4 Cycles)	true
16179	RA_2819	Precision/Targeted Therapy	true	Exemestane, Palbociclib			exemestane/palbociclicb	7024	7719	Progression and relapse	Recurrence		Progression = Interval development of greater than 20 hepatic metastasis; New Lung nodules in the RIGHT middle lobe and Left Medial Lobe ~ Regimen: exemestane/palbociclicb	true
16180	RA_2819	Chemotherapy	true	Capecitabine			Xeloda	7748	7888	Progression and relapse			progression in the liver ~ Regimen: Xeloda	true
16181	RA_2819	Chemotherapy	true	Doxorubicin Hydrochloride Liposome			Doxil	7955	7984	Toxicity			D/C for Rising LFTS ~ Regimen: Doxil	true
16182	RA_2819	Chemotherapy	true	Eribulin Mesylate			Eribulin	7986	8131	Progression and relapse			a decrease in the size of her hepatic metastases, however rising tumor markers ~ Regimen: Eribulin	true
16183	RA_2819	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Abemaciclib, Fulvestrant			Abemaciclib/Fulvestrant	8161	8183	Toxicity			D/C for Rising LFTS ~ Regimen: Abemaciclib/Fulvestrant	true
16184	RA_2819	Chemotherapy	true	Paclitaxel			Paclitaxel	8186	8223	Other			Pursued Hospice ~ Regimen: Paclitaxel	true
16185	RA_2917	Chemotherapy	true	Cyclophosphamide, Doxorubicin			Neoadjuvant Adriamycin + Cytoxan [x 4 Cycles]	4	46	Completion of standard course			Regimen: Neoadjuvant Adriamycin + Cytoxan [x 4 Cycles]	true
16186	RA_2917	Chemotherapy	true	Paclitaxel			Taxol	63	141	Progression and relapse			New Liver Lesion ~ Regimen: Taxol	true
16187	RA_2917	Chemotherapy, Immunotherapy	true	Eribulin Mesylate, Pembrolizumab			Eribulin + pembrolizumab	185	276	Progression and relapse			increase in mediastinal node and nodules on left chest wall ~ Regimen: Eribulin + pembrolizumab	true
16188	RA_2917	Chemotherapy	true	Cisplatin			cisplatin/ATR inhibitor (2 Cycles)	308	355	Progression and relapse			Regimen: cisplatin/ATR inhibitor (2 Cycles)	true
16189	RA_2917	Chemotherapy	true	Vinorelbine Tartrate			Navelbine	662	718	Progression and relapse			chest wall progression on exam ~ Regimen: Navelbine	true
16190	RA_2917	Chemotherapy	true	Doxorubicin Hydrochloride Liposome			Doxil	718	746	Other			Held for hyperbilirubinemia / not restarted ~ Regimen: Doxil	true
16191	RA_2974		true		TAC		TAC - Taxotere + Adriamycin + Cytoxan (X 6 Cycles)	7293	7398	NA	Recurrence		Regimen: TAC - Taxotere + Adriamycin + Cytoxan (X 6 Cycles)	true
16192	RA_2974	Hormone/Endocrine Therapy	true	Fulvestrant			Fulvestrant	7442	7504	NA			Regimen: Fulvestrant	true
16193	RA_2974	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Fulvestrant, Palbociclib			Fulvestrant + Palbociclib	7505	7561	NA			Regimen: Fulvestrant + Palbociclib	true
16194	RA_2974	Chemotherapy	true	Capecitabine			Xeloda	7562	7959	NA			Regimen: Xeloda	true
16195	RA_2974	Chemotherapy	true	Vinorelbine Tartrate			Navelbine	7974	8072	NA			Regimen: Navelbine	true
16196	RA_2974	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			3 Cycles - MSC2363318A (p70S6K/Akt inhibitor) + Tamoxifen	8141	8203	NA			Clinical Trial: Best Response = SD (-5.84%) ~ Regimen: 3 Cycles - MSC2363318A (p70S6K/Akt inhibitor) + Tamoxifen	true
16197	RA_3035	Immunotherapy	true	Nivolumab			Nivolumab + CCR2 inhibitor (TAK202).	78	120	NA			Metastatic at Diagnosis //  Clinical Trial: Best Response = PD ("Worsening of liver mets") ~ Regimen: Nivolumab + CCR2 inhibitor (TAK202).	true
16198	RA_3035	Immunotherapy	true	Nivolumab			Nivolumab (monotherapy)	120	173	NA			Regimen: Nivolumab (monotherapy)	true
16199	RA_3130		true		FOLFOX		adjuvant FOLFOX	280	386	Progression and relapse			incompletely characterized ill-defined hypo-attenuating area in hepatic segment IVa ~ Regimen: adjuvant FOLFOX	true
16200	RA_3130	Biological Therapy, Chemotherapy	true	Paclitaxel, Ramucirumab			Paclitaxel/Ramucirumab [6 Cycles]	519	680	Progression and relapse			new mesenteric and worsening retroperitoneal lymphadenopathy ; no evidence of metastatic disease in the chest ~ Regimen: Paclitaxel/Ramucirumab [6 Cycles]	true
16201	RA_3130	Precision/Targeted Therapy	true	Crizotinib			Crizotinib and TAS-120 [3 Cycles]	911	984	Progression and relapse			Patient Passed away ~ Regimen: Crizotinib and TAS-120 [3 Cycles]	true
16202	RA_3181	Chemotherapy	true	Carboplatin, Paclitaxel			Carboplatin AUC 6 & Taxol	30	146	Completion of standard course			Regimen: Carboplatin AUC 6 & Taxol	true
16203	RA_3181	Biological Therapy	true	Bevacizumab			IMGN853/Bevacizumab	357	602	Toxicity			discontinued due to neuropathy ~ Regimen: IMGN853/Bevacizumab	true
16204	RA_3181	Biological Therapy, Immunotherapy	true	Bevacizumab, Nivolumab			Nivolumab/Bevacizumab	686	791	Other			admitted and passed away inpatient (Encephalopathy) ~ Regimen: Nivolumab/Bevacizumab	true
16205	RA_3226	Chemotherapy, Other	true	Fluorouracil, Folinic Acid, Oxaliplatin			Folinic Acic/Fluorouracil/Oxaliplatin	22	300	Progression and relapse			Regimen: Folinic Acic/Fluorouracil/Oxaliplatin	true
16206	RA_3226	Biological Therapy, Chemotherapy	true	Bevacizumab, Fluorouracil			deGramont 5-fluorouracil/Bevacizumab	412	1213	Progression and relapse			Regimen: deGramont 5-fluorouracil/Bevacizumab	true
16207	RA_3226		true	Cetuximab			Cetuximab	1379	1379	Toxicity			HSR 30 min into first dose ~ Regimen: Cetuximab	true
16208	RA_3226		true	Panitumumab			Panitumumab	1388	1451	Progression and relapse			Regimen: Panitumumab	true
16209	RA_3226	Precision/Targeted Therapy	true	Trastuzumab	FU-LV		Trastuzumab/5-Fluorouracil/L-Leucovorin	1514	1619	Progression and relapse			Regimen: Trastuzumab/5-Fluorouracil/L-Leucovorin	true
16210	RA_3226	Precision/Targeted Therapy	true	Lapatinib Ditosylate, Trastuzumab			Lapatinib/Traztuzumab	1682	1910	Progression and relapse			Regimen: Lapatinib/Traztuzumab	true
16211	RA_3226	Chemotherapy	true	Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium			Leucovorin Calcium/Fluorouracil/Irinotecan	1945	2122	Progression and relapse			Regimen: Leucovorin Calcium/Fluorouracil/Irinotecan	true
16212	RA_3226		true	Trifluridine and Tipiracil Hydrochloride			Trifluridine/Tipiracil (Lonsurf)	2153	2282	Other			Mixed response (prev slow progression), switched to FOLFOX ~ Regimen: Trifluridine/Tipiracil (Lonsurf)	true
16213	RA_3226	Biological Therapy, Chemotherapy	true	Bevacizumab, Fluorouracil, Leucovorin Calcium, Oxaliplatin			Fluorouracil/Leucovorin Calcium/Oxaliplatin/Bevacizumab	2291	2513	Progression and relapse			Regimen: Fluorouracil/Leucovorin Calcium/Oxaliplatin/Bevacizumab	true
16214	RA_3226	Immunotherapy	true	Ipilimumab, Nivolumab			Ipilimumab/Nivolumab	2548	2548	Toxicity			pneumonitis, didn't receive XRT that would've occurred later ~ Regimen: Ipilimumab/Nivolumab	true
16215	RA_3231	Chemotherapy	true	Gemcitabine Hydrochloride, Paclitaxel Albumin-stabilized Nanoparticle Formulation			Gemcitabine/ Abraxane	35	35	Other			Palliative - single dose ~ Regimen: Gemcitabine/ Abraxane	true
16216	RA_3244	Immunotherapy	true	Ipilimumab, Nivolumab			Ipilimumab + Nivolumab [1 Cycle]	3698	3698	Other			Patient passed away after one dose ~ Regimen: Ipilimumab + Nivolumab [1 Cycle]	true
16217	RA_3274	Precision/Targeted Therapy	true	Gefitinib			nazartinib + gefitinib [7 Cycles]	37	203	Progression and relapse			Partial Response (-44%) ~ Regimen: nazartinib + gefitinib [7 Cycles]	true
16218	RA_3328	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			Cisplatin/Gemcitabine (X 8 Cycles)	26	148	Progression and relapse			progression of disease in the abdomen ~ Regimen: Cisplatin/Gemcitabine (X 8 Cycles)	true
16219	RA_3328		true		FOLFOX		FOLFOX (X 4 Cycles)	179	248	Progression and relapse			progressive hepatic metastases ~ Regimen: FOLFOX (X 4 Cycles)	true
16220	RA_3343	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			Gemcitabine / Cisplatin [3 Cycles]	28	91	Progression and relapse			showed disease progression in the liver by report;  increased in number and size of lung metastases. ~ Regimen: Gemcitabine / Cisplatin [3 Cycles]	true
16221	RA_3343	Chemotherapy	true	Capecitabine, Oxaliplatin			Capecitabine/ Oxaliplatin [1 Cycle]	102	116	Toxicity			complications of phlebitis ~ Regimen: Capecitabine/ Oxaliplatin [1 Cycle]	true
16222	RA_3451	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			Gemcitabine and Cisplatin	1	90	Progression and relapse			stable disease in the abdomen with several slightly enlarged lung nodules ~ Regimen: Gemcitabine and Cisplatin	true
16223	RA_3451		true		FOLFOX		FOLFOX	251	251	Other			Single Dose - Patient Passed away ~ Regimen: FOLFOX	true
16224	RA_3533	Immunotherapy	true	Pembrolizumab			pembrolizumab [ 2 Cycles]	411	456	Toxicity			checkpoint-induced encephalitis ~ Regimen: pembrolizumab [ 2 Cycles]	true
16225	RA_3612	Precision/Targeted Therapy	true	Vandetanib			Vandetanib	337	2325	Progression and relapse			evidence of progression on liver MRI and CEA and CTN are rising ; Multiple enhancing hepatic lesions, adjacent to ablation zone and elsewhere in both hepatic lobes, increased in size and number, suspicious for metastatic disease. CT Chest: Unchanged 8 mm left lower lobe nodule. Attention to new 3 mm left apical nodule can be made on follow-up. No new suspicious nodule. ~ Regimen: Vandetanib	true
16226	RA_3612		true	Cabozantinib-S-Malate			Cabozantinib	2333	2427	Toxicity			oral dysesthesia/burning mouth secondary to carbozantinib ~ Regimen: Cabozantinib	true
16227	RA_3612		true	Regorafenib			Regorafenib	2446	2565	Progression and relapse			Progression in liver and Lumbar spine ~ Regimen: Regorafenib	true
16228	RA_3612	Immunotherapy	true	Ipilimumab, Nivolumab			Ipilimumab/Nivolumab [2 Cycles]	2580	2661	Progression and relapse			Progression of bone disease in Spine ~ Regimen: Ipilimumab/Nivolumab [2 Cycles]	true
16229	RA_3634	Chemotherapy	true	Carboplatin			Carboplatin + Paclitaxel (5 Cycles)	15	178	Progression and relapse			Disease progression. Interval increase of the right hilar mass, now measuring 3.1 x 2.5 cm, previously 2.9 x 1.8 cm. Slightly increased mediastinal lymph nodes since November 2016. Numerous (more than 10) solid bilateral pulmonary nodules, many of which have increased in size since November 2016. ~ Regimen: Carboplatin + Paclitaxel (5 Cycles)	true
16230	RA_3634	Immunotherapy	true	Nivolumab			Nivolumab	190	392	Toxicity			responded to 2nd-line nivolumab which was ultimately held for skin rash ~ Regimen: Nivolumab	true
16231	RA_3634	Immunotherapy	true	Nivolumab			Nivolumab (Rechallenge)	499	499	Toxicity			D/C for recurrent skin rash ~ Regimen: Nivolumab (Rechallenge)	true
16232	RA_3634	Chemotherapy	true	Docetaxel			Taxotere	579	625	Progression and relapse			symptomatic neuropathy ad progressive disease; New faint patchy ground glass opacities in the right upper lobe favored to reflect post radiation change. Slightly nodular pleural thickening in the right minor and major fissures is noted is nonspecific but should be monitored on subsequent studies. Several pulmonary nodules have slightly increased in size; Approximately stable right axillary and right subpectoral lymphadenopathy ; Slightly increasing left axillary and left subpectoral lymphadenopathy. ~ Regimen: Taxotere	true
16233	RA_3634	Chemotherapy	true	Gemcitabine Hydrochloride			Gemzar (1 dose)	661	661	Progression and relapse			Enrolled in Hospice ~ Regimen: Gemzar (1 dose)	true
16234	RA_3649	Immunotherapy	true	Ipilimumab			Ipilimumab [4 cycles]	275	338	Progression and relapse			Multiple intrinsically T1 hyperintense lesions in the supratentorial brain, consistent with intracranial metastatic; Interval increase in size and number of bilateral lung nodules, consistent with progression of metastases. Slight interval increase in size of 2.7 cm subcutaneous nodule in the posterior chest wall to represent a sebaceous cyst or focus of metastases. [No evidence of metastatic disease in the abdomen or pelvis] ~ Regimen: Ipilimumab [4 cycles]	true
16235	RA_3649	Immunotherapy	true	Pembrolizumab			Pembrolizumab [17 Cycles]	364	725	Toxicity			held d/t increasing arthralgias ~ Regimen: Pembrolizumab [17 Cycles]	true
16236	RA_3649	Immunotherapy	true	Ipilimumab, Nivolumab			ipilimumab + nivolumab [1 dose]	1563	1563	Other			Patient Passed away ~ Regimen: ipilimumab + nivolumab [1 dose]	true
16237	RA_3689	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			gemcitabine/cisplatin [single dose]	25	25	Progression and relapse			Marked interval progression of disease demonstrating extensive hepatic metastases which almost replace the entirety of the liver and demonstrate similar enhancing tumor throughout the portal venous system. ~ Regimen: gemcitabine/cisplatin [single dose]	true
16238	RA_3689		true		FOLFOX		FOLFOX [single dose]	50	50	Progression and relapse			Regimen: FOLFOX [single dose]	true
16239	RA_3738		true		R-CHOP		RCHOP (6 cycles)	214	318	Progression and relapse			large gastroesophageal mass ~ Regimen: RCHOP (6 cycles)	true
16240	RA_3738	Chemotherapy	true	Gemcitabine Hydrochloride, Oxaliplatin, Rituximab			Rituximab gemcitabine and oxaliplatin	388	388	Other			Maintenance Therapy ~ Regimen: Rituximab gemcitabine and oxaliplatin	true
16241	RA_3738		true	Rituximab			Rituximab and ALX148 (CD47 Blocker)	535	535	Other			Single Dose - patient passed away ~1 week later ~ Regimen: Rituximab and ALX148 (CD47 Blocker)	true
16242	RA_3773	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			Gemcitabine/Cisplatin	25	292	Progression and relapse			progression in liver ~ Regimen: Gemcitabine/Cisplatin	true
16243	RA_3773	Chemotherapy	true	Fluorouracil, Leucovorin Calcium, Oxaliplatin			Oxaliplatin/Fluorouracil/Leucovorin	376	376	Other			single dose, d/c'ed on hospice ~ Regimen: Oxaliplatin/Fluorouracil/Leucovorin	true
16244	RA_3781	Immunotherapy	true	Pembrolizumab			Pembrolizumab [4 Cycles]	3327	3399	Progression and relapse			INCREASING RIGHT HYDRONEPHROSIS SECONDARY TO TUMORS ARISING IN AND ADJACENT TO THE RIGHT KIDNEY. Increase interval increase in RIGHT hilar and subcarinal lymphadenopathy.  Stable subcentimeter cervical lymph nodes Stable enhancing subcutaneous nodules in the RIGHT shoulder region and the RIGHT ~ Regimen: Pembrolizumab [4 Cycles]	true
16245	RA_3781	Immunotherapy	true	Pembrolizumab			Pembrolizumab + CMP001 [3 Cycles]	3426	3468	Progression and relapse			progression of intracranial metastatic disease; Enlargement of multiple abdominopelvic metastases/implants with a suspected new splenic metastasis. Worsening right moderate hydronephrosis with obstructive uropathy secondary to enlarging renal/perirenal metastases. CT neck/chest: Increased LEFT jugulodigastric lymph node increased RIGHT anterior chest wall nodule , increased RIGHT middle lobe metastasis and increased subcarinal lymph node. T ~ Regimen: Pembrolizumab + CMP001 [3 Cycles]	true
16246	RA_3781	Immunotherapy	true	Ipilimumab			Ipilimumab [2 Cycles]	3488	3517	Progression and relapse			Multiple new supratentorial metastases as described above with the largest lesion measuring 17 mm within the right inferior frontal gyrus. The left medullary metastasis is also mildly increased in size ~ Regimen: Ipilimumab [2 Cycles]	true
16247	RA_3782		true		FOLFOX		FOLFOX (4 Cycles)	6	55	Progression and relapse			worsening FDG avid peritoneal disease c/w progression // mixed response ~ Regimen: FOLFOX (4 Cycles)	true
16248	RA_3782	Chemotherapy	true	Carboplatin, Paclitaxel			Carboplatin + Paclitaxel	69	73	Other			Patient admitted/passed away 1 week after starting d/t primary disease ~ Regimen: Carboplatin + Paclitaxel	true
16249	RA_3792	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			Gemcitabine / Cisplatin [6 Cycles]	23	264	Progression and relapse			Partial right chest CT-Increased size and number of the pulmonary nodules since the previous study, most consistent w/increasing metastatic disease; Mild increase in the size of a subcarinal node; MRI Liver In the periphery of the posterior segment of the right hepatic lobe, there is a 2.7 x 2.9cm T2 heterogeneous signal intensity mass w/peripheral focus of decreased signal intensity on the delayed Eovist phase measuring 1.6 x 1.3cm concerning for tumor. There are scattered subcentimeter metastatic nodules w/in the right hepatic lobe. ~ Regimen: Gemcitabine / Cisplatin [6 Cycles]	true
16250	RA_3792	Chemotherapy	true	Capecitabine			Xeloda [5 Cycles]	325	422	Progression and relapse			dominant mass w/in the posterior segment of the right lobe is unchanged; there are multiple new lesions w/in both lobes of the liver. In addition, previously noted lesions w/in both lobes of increased in size. The findings are consistent w/progression of disease in the liver; Pulmonary nodules increased in size ~ Regimen: Xeloda [5 Cycles]	true
16251	RA_3792	Immunotherapy	true	Atezolizumab, Cobimetinib			Atezolizumab / Cobimetinib [1 Cycle]	448	476	Toxicity			grade 2/3 diarrhea and grade 3 thrombocytopenia ~ Regimen: Atezolizumab / Cobimetinib [1 Cycle]	true
16252	RA_3817		true		R-CHOP		RCHOP (6 Cycles)	8	114	Completion of standard course			Regimen: RCHOP (6 Cycles)	true
16253	RA_3817	Chemotherapy	true	Methotrexate			HD Methotrexate (4 Cycles)	63	137	Completion of standard course			Regimen: HD Methotrexate (4 Cycles)	true
16254	RA_3817	Chemotherapy	true	Cytarabine, Etoposide			Cytarabine (X3) /Etoposide (X2)	243	294	Progression and relapse			Disease Progression extra-nodal recurrence ~ Regimen: Cytarabine (X3) /Etoposide (X2)	true
16255	RA_3817		true	Ibrutinib			Iburitnib	309	400	Progression and relapse			Palliative Intent ~ Regimen: Iburitnib	true
16256	RA_3817	Immunotherapy	true	Nivolumab			Nivolumab [1 dose]	400	400	Other			Single dose day before passsing away ~ Regimen: Nivolumab [1 dose]	true
16257	RA_3859	Immunotherapy	true	Pembrolizumab			Pembrolizumab	419	504	Progression and relapse			New and enlarging hepatic and osseous metastasis ~ Regimen: Pembrolizumab	true
16258	RA_3861	Chemotherapy, Other	true	Fluorouracil, Folinic Acid, Oxaliplatin			Folinic Acic/Fluorouracil/Oxaliplatin	72	240	Completion of standard course			Regimen: Folinic Acic/Fluorouracil/Oxaliplatin	true
16259	RA_3861	Biological Therapy, Chemotherapy	true	Bevacizumab, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Oxaliplatin			Fluorouracil/Leucovorin Calcium/Oxaliplatin/Irinotecan/Bevacizumab	940	1034	Other			used as bridge to clinical trial ~ Regimen: Fluorouracil/Leucovorin Calcium/Oxaliplatin/Irinotecan/Bevacizumab	true
16260	RA_3861	Precision/Targeted Therapy	true	Dabrafenib Mesylate, Trametinib			Debrafinib/Tremitinib/PDR001	1127	1237	Other			Physician Decision (pt not clinically benefiting) ~ Regimen: Debrafinib/Tremitinib/PDR001	true
16261	RA_3861	Biological Therapy, Chemotherapy	true	Bevacizumab, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Oxaliplatin			Fluorouracil/Leucovorin Calcium/Oxaliplatin/Irinotecan/Bevacizumab	1269	1325	Progression and relapse			Regimen: Fluorouracil/Leucovorin Calcium/Oxaliplatin/Irinotecan/Bevacizumab	true
16262	RA_3873	Immunotherapy	true	Nivolumab			Anti-KIR (lirilumab) + Nivolumab [1 Cycle]	12209	12313	Toxicity			Pneumonitis ~ Regimen: Anti-KIR (lirilumab) + Nivolumab [1 Cycle]	true
16263	RA_3873	Immunotherapy	true	Ipilimumab			ipilimumab [4 Cycles]	12556	12646	Progression and relapse			mixed response, overall SD. Unchanged left lateral abdominal wall intramuscular metastases. Increased size of right ventricular metastatic lesion and increased sclerosis of the T2 vertebral body sclerotic lesion. Slightly increased likely metastatic pericardial effusion. Additional sites of disease, including the left ventricular apex, right T5 lamina, and soft tissue nodule posterior to the T3 spinous process, are not significantly changed; Slight interval decrease in the overall size of the soft tissue mass related to the right-sided posterior elements at T4 and T5 with no significant change in the region of soft tissue enhancement along the right posterolateral epidural space. Interval decrease in the size of the enhancing lesion in the soft tissues overlying the T3 and T4 spinous process. ~ Regimen: ipilimumab [4 Cycles]	true
16264	RA_3912	Chemotherapy	true	Paclitaxel			paclitaxel	131	208	Completion of standard course			Regimen: paclitaxel	true
16265	RA_3912	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			Tamoxifen	290	1153	Progression and relapse			metastatic recurrence in the brain with additional disease in liver, T7 vertabrae, and L hilar and R scv nodes. ~ Regimen: Tamoxifen	true
16266	RA_3912	Immunotherapy	true	Pembrolizumab			Pembrolizumab [1 dose]	1280	1280	Other			Patient Passed Away ~ Regimen: Pembrolizumab [1 dose]	true
16267	RA_4215	Immunotherapy	true	Ipilimumab, Nivolumab			Ipilimumab + nivolumab [2 Cycles]	1479	1500	Other			Patient Passed Away ~ Regimen: Ipilimumab + nivolumab [2 Cycles]	true
16268	RA_4248	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			Gemcitabine/Cisplatin	21	287	Progression and relapse			Regimen: Gemcitabine/Cisplatin	true
16269	RA_4338	Immunotherapy	true	Ipilimumab, Nivolumab			Nivolumab/Ipilimumab	5	5	Other			Control Therapy, patient passed away ~one week later ~ Regimen: Nivolumab/Ipilimumab	true
16270	RA_4340		true		FOLFOX		FOLFOX	27	54	Progression and relapse			enlarging pancreatic mass. Associated small volume pneumoperitoneum and ascites. Interval increase in size of pelvic peritoneal nodules. Increase in size of epicardial nodal metastasis. ~ Regimen: FOLFOX	true
16271	RA_4426	Chemotherapy	true	Cyclophosphamide, Doxorubicin			Adriamycin/ Cyclophosphamide [4 Cycles]	7	49	Completion of standard course			Regimen: Adriamycin/ Cyclophosphamide [4 Cycles]	true
16272	RA_4426	Chemotherapy	true	Paclitaxel			Taxol [4 Cycles]	63	105	Completion of standard course			Regimen: Taxol [4 Cycles]	true
16273	RA_4426	Chemotherapy	true	Capecitabine			Capecitabine (Xeloda)	250	277	Progression and relapse			Regimen: Capecitabine (Xeloda)	true
16274	RA_4430	Chemotherapy	true	Carboplatin			Carboplatin/Pembrolizumab/Pemetrexed	3061	3147	Completion of standard course			Regimen: Carboplatin/Pembrolizumab/Pemetrexed	true
16275	RA_4443	Chemotherapy, Other, Precision/Targeted Therapy	true	Fluorouracil, Folinic Acid, Oxaliplatin, Trastuzumab			Folinic Acid/Fluorouracil/Oxaliplatin + Trastuzumab	0	1920	Progression and relapse		initial and persistent response	intermittent administration, intermittent inclusion of oxaliplatin, was NED at one point, multiple tx holds	true
16276	RA_4443	Chemotherapy, Precision/Targeted Therapy	true	Capecitabine, Trastuzumab			Capecitabine/Trastuzumab	1757	1795	Completion of standard course				true
16277	RA_4443	Immunotherapy	true	Pembrolizumab			Pembrolizumab	1969	2011	Progression and relapse				true
16278	RA_4443	Biological Therapy, Chemotherapy	true	Paclitaxel, Ramucirumab			Ramucirumab/Paclitaxel	2502	2549	Progression and relapse				true
16279	RA_4443	Chemotherapy, Precision/Targeted Therapy	true	Paclitaxel, Trastuzumab			Trastuzumab/Paclitaxel	2562	2576	Other		Clinical Progression		true
16280	RA_4484		true	Vemurafenib			Vemurafinib (Zelboraf)	43	114	Other			~90% response in renal metastases - switched to I/O with hope for more durable response ~ Regimen: Vemurafinib (Zelboraf)	true
16281	RA_4484	Immunotherapy	true	Ipilimumab			Ipilimumab	115	178	Progression and relapse			Mixed Response, Progression in Kideys and Abdominal Wall ~ Regimen: Ipilimumab	true
16282	RA_4484	Immunotherapy	true	Pembrolizumab			Pembrolizumab [5 Cycles]	324	419	Progression and relapse			Continued increase in size of the (R) occipital lobe rim-enhancing lesion ~ Regimen: Pembrolizumab [5 Cycles]	true
16283	RA_4484	Precision/Targeted Therapy	true	Binimetinib, Encorafenib			Encorafenib (BRAF inhibitor) + Binimetinib (MEK inhibitor) [71 Cycles]	555	2543	Other			Partial Response (-72.3%) - came off due to need to commence imatinib for CML ~ Regimen: Encorafenib (BRAF inhibitor) + Binimetinib (MEK inhibitor) [71 Cycles]	true
16284	RA_4484		true	Imatinib Mesylate			Imatinib	2543	2832	Other			for secondary diagnosis of CML ~ Regimen: Imatinib	true
16285	RA_4484	Immunotherapy	true	Ipilimumab, Nivolumab			Ipilimumab + Nivolumab	2727	2769	Toxicity			duodenitis and colitis ~ Regimen: Ipilimumab + Nivolumab	true
16286	RA_4484	Precision/Targeted Therapy	true	Binimetinib, Encorafenib			encorafenib + binimetinib + infliximab	2776	2844	Progression and relapse			Rapidly growing leptomeningeal disease ~ Regimen: encorafenib + binimetinib + infliximab	true
16287	RA_4518		true	Bicalutamide			Bicalutamide	2	413	Progression and relapse			PSA elevated ~ Regimen: Bicalutamide	true
16288	RA_4518	Chemotherapy	true	Docetaxel			Docetaxel	41	145	Completion of standard course			Regimen: Docetaxel	true
16289	RA_4518		true	Abiraterone Acetate			Abiraterone	413	1086	Progression and relapse			PSA elevated ~ Regimen: Abiraterone	true
16290	RA_4518		true	Enzalutamide			Enzalutamide	1093	1271	Progression and relapse			PSA elevated ~ Regimen: Enzalutamide	true
16291	RA_4518	Immunotherapy	true	Pembrolizumab			Pembrolizumab	1527	1527	Toxicity			admitted for myocarditis ~ Regimen: Pembrolizumab	true
16292	RA_4523	Immunotherapy	true	Ipilimumab, Nivolumab			Ipilimumab/Nivolumab	89	89	Toxicity			IO-related pneumonitis ? ~ Regimen: Ipilimumab/Nivolumab	true
16293	RA_4575	Immunotherapy	true	Pembrolizumab			Pembrolizumab	122	122	Other			Single Dose - Control ~ Regimen: Pembrolizumab	true
16294	RA_4816	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			Gemcitabine/Cisplatin	15	70	Progression and relapse				true
16295	RA_4816	Chemotherapy, Other	true	Fluorouracil, Folinic Acid, Oxaliplatin			Folinic Acid/Fluorouracil/Oxaliplatin	85	120	Other		Clinical Progression		true
16296	RA_4848	Chemotherapy	true	Cyclophosphamide, Doxorubicin			Adriamycin/Cyclophosphamide	0	92	Completion of standard course			Regimen: Adriamycin/Cyclophosphamide	true
16297	RA_4848	Hormone/Endocrine Therapy	true	Anastrozole			Anastrozole	182	2008	Completion of standard course			Regimen: Anastrozole	true
16298	RA_4848	Chemotherapy	true	Cyclophosphamide, Docetaxel			docetaxel/cyclophosphamide	2377	2441	Completion of standard course			Regimen: docetaxel/cyclophosphamide	true
16299	RA_4848	Hormone/Endocrine Therapy	true	Tamoxifen Citrate			Tamoxifen	2441	3439	Progression and relapse			Regimen: Tamoxifen	true
16300	RA_4848	Chemotherapy	true	Gemcitabine Hydrochloride, Paclitaxel			Gemcitabine/Paclitaxel	3472	3611	Toxicity			Regimen: Gemcitabine/Paclitaxel	true
16301	RA_4848	Hormone/Endocrine Therapy, Precision/Targeted Therapy	true	Fulvestrant, Palbociclib			Palbociclib/Fulvestrant	3630	3926	Progression and relapse			Regimen: Palbociclib/Fulvestrant	true
16302	RA_4848	Chemotherapy	true	Capecitabine			Capecitabine	3926	4045	Progression and relapse			complicated by side effects (incl. skin blisters) but d/c'ed d/t PD ~ Regimen: Capecitabine	true
16303	RA_4848	Chemotherapy	true	Doxorubicin			Doxorubicin	4050	4110	Progression and relapse			Regimen: Doxorubicin	true
16304	RA_4848	Chemotherapy	true	Eribulin Mesylate			Eribulin	4177	4353	Progression and relapse			Regimen: Eribulin	true
16305	RA_4848	Hormone/Endocrine Therapy	true	Fulvestrant			Ipatasertib/Fulvesterant	4367	4382	Other			Regimen: Ipatasertib/Fulvesterant	true
16306	RA_4875	Chemotherapy	true	Fluorouracil, Leucovorin Calcium, Oxaliplatin			Leucovorin Calcium/Fluorouracil/Oxaliplatin	11	12	Other			Regimen: Leucovorin Calcium/Fluorouracil/Oxaliplatin	true
16307	RA_4957	Precision/Targeted Therapy	true	Dabrafenib Mesylate, Trametinib			Dabrafenib and Trametinib	184	323	Progression and relapse			Two enhancing soft tissue nodule in the left inguinal postsurgical bed, concerning for metastasis. ~ Regimen: Dabrafenib and Trametinib	true
16308	RA_4957	Immunotherapy	true	Pembrolizumab			Pembrolizumab [4 Cycles]	338	400	Progression and relapse			progression of malignancy, with marked increase in the degree and extent of FDG uptake in 2 foci in the left groin/inguinal region and 2 additional foci of uptake in the medial left thigh. ~ Regimen: Pembrolizumab [4 Cycles]	true
16309	RA_4957		true	Cobimetinib, Vemurafenib			Vemurafenib and Cobimetinib	433	456	Toxicity			Fevers, Total body rash, pharyngitis, and marked fatigue ~ Regimen: Vemurafenib and Cobimetinib	true
16310	RA_4957	Immunotherapy	true	Entinostat, Pembrolizumab			Pembrolizumab + Entinostat	723	762	Progression and relapse			Interval progression of disease, as evidenced by progression of pulmonary metastatic disease; soft tissue disease at the left posterior chest wall, left groin resection site, and anteromedial left thigh; nodal disease at the left external iliac/inguinal nodal stations, and more intense uptake associated with a probable bony metastasis at the intertrochanteric left femur ~ Regimen: Pembrolizumab + Entinostat	true
16311	RA_4957	Precision/Targeted Therapy	true	Dabrafenib Mesylate, Trametinib			Dabrafenib + Trametinib	774	1095	Progression and relapse			Regimen: Dabrafenib + Trametinib	true
16312	RA_4957	Precision/Targeted Therapy	true	Binimetinib, Encorafenib			Encorafenib + Binimetinib	1143	1401	Progression and relapse			Recurrence of Left Upper Back Lesion, mild progression on CT imaging ~ Regimen: Encorafenib + Binimetinib	true
16313	RA_4957	Immunotherapy	true	Ipilimumab, Nivolumab			Nivolumab / Ipilimumab	1464	1464	Toxicity			checkpoint inhibitor colitis ~ Regimen: Nivolumab / Ipilimumab	true
16314	RA_4965	Immunotherapy	true	Axitinib, Pembrolizumab			Axitinib/Pembrolizumab	37	84	Toxicity			Regimen: Axitinib/Pembrolizumab	true
16315	RA_4979	Immunotherapy	true	Pembrolizumab			Pembrolizumab [5 Cycles]	944	1031	Progression and relapse			Multiple new hepatic lesions; Interval decrease in the perihilar LEFT lower lobe nodule and LEFT hilar lymph nodes consistent with response to therapy.  New lytic lesion in the T4 vertebra; New nodules in the LEFT lower lobe and along the LEFT major fissure (Lung) ~ Regimen: Pembrolizumab [5 Cycles]	true
16316	RA_4979	Immunotherapy	true	Ipilimumab, Nivolumab			Ipilimumab/Nivolumab	1052	1052	Toxicity			Gastritis and duodenitis secondary to ICI ~ Regimen: Ipilimumab/Nivolumab	true
16317	RA_4979	Precision/Targeted Therapy	true	Binimetinib			Binimetinib (MEK inhibitor)	1123	1218	Progression and relapse			interval enlargement of metastatic disease involving the liver, pancreas, left adrenal gland, kidneys and perirenal spaces, appendix, axial and appendicular skeleton, and multiple muscle groups. New portacaval lymphadenopathy ~ Regimen: Binimetinib (MEK inhibitor)	true
16318	RA_498	Immunotherapy	true	Ipilimumab, Nivolumab			Ipilimumab and Nivolumab [2 Cycles]	4527	4527	Progression and relapse			Interval progression of subcutaneous nodules. Stable to increased small bowel metastases. Mesenteric lymphadenopathy. Unchanged indeterminate liver lesion. Interval slightly decreased size and number of chest wall subcutaneous nodules along with slightly decreased right axillary lymphadenopathy. Interval slightly decreased prominence of right upper lobe metastatic mass,. Interval slightly decreased mediastinal lymphadenopathy. ;  Brain MRI: Redemonstrated postsurgical findings of prior right temporal craniotomy and resection of a lesion in the superior temporal gyrus without evidence of local recurrence at this site. Interval increase in size and associated mass effect of a lesion in the right inferior parietal lobule with increased effacement of the posterior right lateral ventricle. Other metastatic lesions along the cerebral falx and in the left post central gyrus have decreased in the interval, and have decreased associated vasogenic edema but remain increased compared to baseline ~ Regimen: Ipilimumab and Nivolumab [2 Cycles]	true
16319	RA_498	Precision/Targeted Therapy	true	Dabrafenib Mesylate, Trametinib			Dabrafenib and Trametinib	4606	4707	Other			Discontinued to enroll on clinical trial ; Response = improvement in the brain lesions; regression of abdominal metastasis but lung disease is stable ~ Regimen: Dabrafenib and Trametinib	true
16320	RA_498	Precision/Targeted Therapy	true	Dabrafenib Mesylate, Trametinib			AT13387 + DABRAFENIB + TRAMETINIB	4708	4820	Progression and relapse			CT CAP: New small bowel/mesenteric metastases, slightly increased size of dominant right upper lobe mass. Stable SC nodules.   Brain MRI: increase in the size and T2 FLAIR hyperintensity in the enhancing left postcentral gyrus lesion, with a possible focus of leptomeningeal extension along the left central sulcus.  Other lesions stable. ~ Regimen: AT13387 + DABRAFENIB + TRAMETINIB	true
16321	RA_552	Immunotherapy	true	Pembrolizumab			Pembrolizumab [6 Cycles]	1984	2110	Progression and relapse			Regimen: Pembrolizumab [6 Cycles]	true
16322	RA_571	Immunotherapy	true	Pembrolizumab			Pembrolizumab	16713	16713	Other			Single Dose - Patient Passed Away ~ Regimen: Pembrolizumab	true
16323	RA_858		true	Imiquimod			Imiquimod	1045	1171	Progression and relapse			new lesions on her R lateral thigh ~ Regimen: Imiquimod	true
16324	RA_858	Immunotherapy	true	Ipilimumab, Nivolumab			ipilimumab + Nivolumab [2 Cycles]	1217	1253	Toxicity			immune related hepatitis and colitis ~ Regimen: ipilimumab + Nivolumab [2 Cycles]	true
16325	RA_858	Immunotherapy	true	Nivolumab			nivolumab monotherapy	1594	1661	Toxicity			immune related hepatitis ~ Regimen: nivolumab monotherapy	true
16326	RA_858	Precision/Targeted Therapy	true	Dabrafenib Mesylate, Trametinib			Dabrafenib + Trametinib	1810	2205	Progression and relapse			increase in size of (R) breast metastasis; (R) adnexal cystic structure without change since prior scan (likely physiologic changes); no other clear sites of disease progression. Brain MRI negative ~ Regimen: Dabrafenib + Trametinib	true
16327	RA_858		true	Cobimetinib, Vemurafenib			vemurafenib+cobimetinib+CSF1R inhibitor (LY3022855) [4 Cycles]	2206	2324	Progression and relapse			increasing size and number of liver metastases, newly enlarged upper abdominal lymph nodes, as well as increased size of splenic and subcutaneous metastases. increasing pulmonary metastases, axillary, hilar and internal mammary adenopathy and soft tissue masses ~ Regimen: vemurafenib+cobimetinib+CSF1R inhibitor (LY3022855) [4 Cycles]	true
16328	RA_858	Chemotherapy	true	Carboplatin, Paclitaxel			Carboplatin AUC 6/Paclitaxel [6 Cycles]	2442	2557	Progression and relapse			Mixed Response: New anterior chest lesions, however ongoing regression of disease at all visceral sites ~ Regimen: Carboplatin AUC 6/Paclitaxel [6 Cycles]	true
16329	RA_858		true	Vemurafenib			VEMURAFENIB (control)	2543	2564	Other			Added Cobimetinib ~ Regimen: VEMURAFENIB (control)	true
16330	RA_858		true	Cobimetinib, Vemurafenib			VEMURAFENIB/COBIMETINIB (control)	2596	2635	Other			Regimen: VEMURAFENIB/COBIMETINIB (control)	true
16331	RA_1045	Precision/Targeted Therapy	true	Dalotuzumab, Ridaforolimus			Ridaforolimus, Dalotuzumab	1231	1514	NA	Recurrence		Clinical Trial:  Best Response = SD (0%) // Progression new L. Supraclavicular Node lesion ~ Regimen: Ridaforolimus + Dalotuzumab	true
16332	RA_1526	Precision/Targeted Therapy	true	Alpelisib, Binimetinib			MEK162, BYL719	2059	2838	NA			Clinical Trial:  Best Response = Partial Response (-30.3%) // Progression = -4.2% from BL, 37.5% from Nadir -- PD mult. Pulmonary nodules ~ Regimen: MEK162 + BYL719	true
16333	RA_3873		true	MAGE TCR			MAGE TCR Protocol	11177	11181	Completion of standard course			adoptive Tcell transfer -  patient developed neurotoxicity // eventual progression with new L adrenal nodule ~ Regimen: MAGE TCR Protocol [62 x 10E9 MAGE Cells] + 6 X Doses IL-2	true
16334	RA_2402		true	LSZ102, Ribociclib			LSZ102, LEE011	1164	1218	Progression and relapse			Best/Final Response = PD (+17.15 % from BL + New Liver Lesions) ~ Regimen: LSZ102 + LEE011 [2 Cycles]	true
16335	MGHCC0002		true	SRN-927			SRN-927	7125	7181	Progression and relapse				true
16336	MGHCC0003	Hormone/Endocrine Therapy	true	Brilanestrant			ARN810	6208	6376	Progression and relapse				true
16337	MGHCC0005	Chemotherapy	true	buthionine sulfoximine			BSO	2476	2476	NA			metastatic adenocarcinoma left ovary with extensive involvement of ovarian parenchyma consistent w/ breast	true
16338	MGHCC0006		true	LFA-102			LFA102	2182	2210	NA				true
16339	MGHCC1006	Hormone/Endocrine Therapy	true	H3B-6545			H3B-6545	5671	5895	Progression and relapse				true
16340	MGHCC1009	ADC	true	IMMU-132			IMMU132	1947	2006	Progression and relapse				true
16341	MGHCC1015	Chemotherapy	true	buthionine sulfoximine			BSO	4158	4158	NA				true
16342	MGHCC1015	Precision/Targeted Therapy	true	Taselisib			GDC0032	4598	5063	NA				true
16343	MGHCC1041	Hormone/Endocrine Therapy	true	Brilanestrant			ARN810	2079	2135	Progression and relapse				true
16344	MGHCC1041	ADC	true	IMMU-132			IMMU132	2181	2349	Progression and relapse				true
16345	MGHCC1041	Immunotherapy	true	Atezolizumab, Emactuzumab			RO5509554/MPDL3280A	2433	2461	Progression and relapse				true
16346	MGHCC1099		true	LSZ102			LSZ102	2512	2540	NA			progression in liver	true
16347	MGHCC1108		true	Halotestin			Halotestin	3617	3666	NA				true
16348	MGHCC1173	Hormone/Endocrine Therapy	true	Brilanestrant			ARN810	1219	1269	Progression and relapse				true
16349	MGHCC1328	Hormone/Endocrine Therapy	true	H3B-6545			H3B-6545	7302	7469	NA				true
16350	MGHCC1328		true	LSZ102, Ribociclib			LSZ102/LEE011, CDK 4/6	7495	7547	NA				true
16351	MGHCC1573	Precision/Targeted Therapy	true	Dalotuzumab, Ridaforolimus			Ridaforolimus/dalotuzumab, PIK3CA/mTOR	973	1407	NA				true
16352	MGHCC1573	Hormone/Endocrine Therapy	true	Brilanestrant			ARN810 (13-043)	1447	1510	NA				true
16353	MGHCC1573	ADC	true	IMMU-132			IMMU132	2357	2422	Progression and relapse				true
16354	RA_1002		true	LSZ102			LSZ102	10217	10258	NA			Clinical Trial  - Best Response = PD (+60.11%) and New Lesions: Cervical LN, Mediastinum, Mediast & Hilar LN, Lung (mult sites) ~ Regimen: LSZ102	true
16355	RA_1002		true	Lurbinectedin			PM01183 (2 Cycles)	10449	10494	NA			Clinical Trial - Best Response = Progression of Chest wall (multiple sites) and abdominal wall (multiple sites), +1.07% from BL ~ Regimen: PM01183 (2 Cycles)	true
16356	RA_1011	ADC	true	IMMU-132			IMMU-132 [anti- Trop-2 ADC]	1066	1099	Progression and relapse			Interval increase in left lung pleural effusion and metastatic disease (Pleura). PD per RECIST (+78% increase of Left Pleura lesion) ~ Regimen: IMMU-132 [anti- Trop-2 ADC]	true
16357	RA_1035		true	CLR-457			CLR457 [PI3K Inhibitor]	3562	3590	Progression and relapse			D/C for symptomatic progression of her disease ~ Regimen: CLR457 [PI3K Inhibitor]	true
16358	RA_1035		true	CLR-457			CLR457 [PI3K Inhibitor]	3562	3590	Progression and relapse			D/C for symptomatic progression of her disease ~ Regimen: CLR457 [PI3K Inhibitor]	true
16359	RA_1078		true	CLR-457			CLR457 (PI3K Inhibitor) X 4 Cycles	6232	6329	NA			Clinical Trial : Best Response = SD (0.0%) -- D/C for grade 3 diarrhea/ Pneumonitis ~ Regimen: CLR457 (PI3K Inhibitor) X 4 Cycles	true
16360	RA_1113	Precision/Targeted Therapy	true	Sapanisertib, Serabelisib			MLN1117(mTORC1/2 Inhibitor) / MLN128 (PI3K? Inhibitor)	3642	3656	Progression and relapse			Regimen: MLN1117(mTORC1/2 Inhibitor) / MLN128 (PI3K? Inhibitor)	true
16361	RA_1113	Precision/Targeted Therapy	true	Sapanisertib, Serabelisib			MLN1117(mTORC1/2 Inhibitor) / MLN128 (PI3K? Inhibitor)	3642	3656	Progression and relapse			Regimen: MLN1117(mTORC1/2 Inhibitor) / MLN128 (PI3K? Inhibitor)	true
16362	RA_1184	Precision/Targeted Therapy	true	MK-2206			MK2206 [AKT inhibitor] (2 Cycles)	944	992	Progression and relapse			Mixed response with decrease in size of left pelvic node and  peritoneal node. But interval increase in size of left para-aortic node (15 mm x 18 mm) which measured 7 mm x 10 mm in baseline. Interval increase in retroperitoneal & pelvic nodes. Increase in size of some peritoneal nodules. Overall progression ~ Regimen: MK2206 [AKT inhibitor] (2 Cycles)	true
16363	RA_1184	Precision/Targeted Therapy	true	Dinaciclib, Veliparib			Velaparib ABT888 [PARP Inhib]/Dinaciclib -SCH727965 [CDK Inhibitor]  (10 Cycles)	1077	1355	Progression and relapse			increase in her current tumor burden as well as the presence of a new pathologic lymph node ~ Regimen: Velaparib ABT888 [PARP Inhib]/Dinaciclib -SCH727965 [CDK Inhibitor]  (10 Cycles)	true
16364	RA_1184	Precision/Targeted Therapy	true	Serabelisib			MLN1117 (PI3K? Inhibitor) (4 Cycles)	1384	1468	Toxicity			off study for Grade 3 LFTs ; significant interval decrease in retroperitoneal lymphadenopathy and left pelvic sidewall mass. ~ Regimen: MLN1117 (PI3K? Inhibitor) (4 Cycles)	true
16365	RA_1184	ADC	true	IMMU-132			IMMU-132 [anti- Trop-2 ADC]	2010	2094	Progression and relapse			Best Response = SD per RECIST (-23.2%) // Final Response =  Mixed Response - interval increase in subcarinal lymph node mass with new borderline left hilar node, however significant improvement of the abdominal and pelvic metastasis ~ Regimen: IMMU-132 [anti- Trop-2 ADC]	true
16366	RA_1187		true	Infigratinib			BGJ398 [4 Cycles] - FGFRi	806	915	Progression and relapse			Best Response: -27% RECIST // Progression = progression of at least 1 hepatic met and has a new hepatic dome lesion; lung nodules are stable ~ Regimen: BGJ398 [4 Cycles] - FGFRi	true
16367	RA_1326	Hormone/Endocrine Therapy	true	Brilanestrant			ARN810 (X 16 Cycles)	1089	1553	NA			Clinical Trial: Best Response = SD (-4%) // Progression = new liver lesions (multiple sites) and (+18.2%) % change from BL ~ Regimen: ARN-810 (X 16 Cycles)	true
16368	RA_1326		true	Seviteronel			VT-464 (X 1 Cycle)	1995	2036	NA			Clinical Trial Best Response = PD (+22%) and New Right liver Lesion ~ Regimen: VT-464 (X 1 Cycle)	true
16369	RA_1373	Precision/Targeted Therapy	true	Taselisib			GDC-0032	6871	6981	NA			Clinical Trial Best Response = SD (+2.9%) // Progression = New Liver lesions and (+ 19.3 %) change from BL "increase in hepatic tumor burden. Stable sclerotic bony metastasis" ~ Regimen: GDC-0032	true
16370	RA_1511	Precision/Targeted Therapy	true	Taselisib			GDC-0032 (PIK3CAi)	138	181	Progression and relapse			Progression = (+25% Increase from Baseline) increase in size of multiple hepatic metastases, New Lesion in Liver Segment 6, Increased size of both adrenal masses // decrease in the size of multiple mediastinal and right hilar lymph nodes and slight decrease in right lung nodules, consistent with response to therapy ~ Regimen: GDC-0032 (PIK3CAi)	true
16371	RA_1534	Hormone/Endocrine Therapy	true	Fulvestrant			Faslodex (Fulvestrant)	556	607	NA			Progression of bone disease with new L rib fractures, rising markers ~ Regimen: Faslodex (Fulvestrant)	true
16372	RA_1542		true	Futibatinib			TAS-120	92	169	Progression and relapse			Best Response = SD (-2.6% from BL) // Progression = New Liver Lesions/ PD of Liver Lesions (Overall +1.7% from BL / +4.4% from Nadir) ~ Regimen: TAS-120	true
16373	RA_1558		true	LSZ102			LSZ102 (Single Agent) [4 Cycles]	3993	4105	Progression and relapse			Best Response = SD (+13.31% from BL) // Final Response = PD (+32.96 % from BL) ~ Regimen: LSZ102 (Single Agent) [4 Cycles]	true
16374	RA_1558	Hormone/Endocrine Therapy	true	H3B-6545			H3B-6545 [8 Cycles]	4441	4665	Progression and relapse			Best Response = PR (-30.98% from BL) // Final Response = PD (+8.3% from Nadir) ~ Regimen: H3B-6545 [8 Cycles]	true
16375	RA_1939		true	Futibatinib			TAS-120 (2 Cycles)	748	1152	Progression and relapse			Best Response = Stable Disease (-21 % from BL) Progression = PD of Liver Multiple Sites + New Liver Lesions (RECIST1.1 +6.5% from BL // +34.4% from Nadir) ~ Regimen: TAS-120 (2 Cycles)	true
16376	RA_1939		true	SAR-439459			SAR439459 (single agent) - 1.5 Cycles	1320	1334	Progression and relapse			Regimen: SAR439459 (single agent) - 1.5 Cycles	true
16377	RA_2024		true	Floxuridine			chemoradiation with infusional 5-FU	296	331	Completion of standard course			Regimen: chemoradiation with infusional 5-FU	true
16378	RA_2024		false				chemoradiation with infusional 5-FU	296	331	Completion of standard course			Regimen: chemoradiation with infusional 5-FU	true
16379	RA_2024		true	Trifluridine and Tipiracil Hydrochloride			LONSURF (trifluridine and tipiracil)	917	943	Progression and relapse			interval increase in size of paraesophageal lymph nodes, new retroperitoneal lymphadenopathy and abdominal wall soft tissue nodularity, consistent with progressive metastatic disease; multiple slightly enlarging retroperitoneal, mesenteric, pelvic lymph nodes ~ Regimen: LONSURF (trifluridine and tipiracil)	true
16380	RA_2024		true	Trifluridine and Tipiracil Hydrochloride			LONSURF (trifluridine and tipiracil)	917	943	Progression and relapse			interval increase in size of paraesophageal lymph nodes, new retroperitoneal lymphadenopathy and abdominal wall soft tissue nodularity, consistent with progressive metastatic disease; multiple slightly enlarging retroperitoneal, mesenteric, pelvic lymph nodes ~ Regimen: LONSURF (trifluridine and tipiracil)	true
16381	RA_2024		true	Losatuxizumab Vedotin			ABBV-221	996	1011	Toxicity			anaphylactic reaction to ABBV-221 ~ Regimen: ABBV-221	true
16382	RA_2024		true	Losatuxizumab Vedotin			ABBV-221	996	1011	Toxicity			anaphylactic reaction to ABBV-221 ~ Regimen: ABBV-221	true
16383	RA_2098		true	Mevociclib			SY-1365 (CDK7 Inhibitor)	828	879	Progression and relapse			Progression = +29.36 % from BL (New Retroperitoneal LN, Mesenteric LN and Peritoneum/Omentum Lesions) ~ Regimen: SY-1365 (CDK7 Inhibitor)	true
16384	RA_2168		true	Debio-1347			Debio 1347 (4 Cycles)	266	368	Progression and relapse			Best Response = Stable Disease "Increase in size of mesenteric node bears watching, Increase in sclerosis of some of the bone lesions which could be due to treatment response, need to follow up"   Progression = PD of Retroperitoneal LN, Mesenteric LN and Peritoneum ~ Regimen: Debio 1347 (4 Cycles)	true
16385	RA_2177		true	Tislelizumab			BGB-A317 (FGFRi) - [18 Cycles]	231	578	Progression and relapse			Best Response = Partial Response // Progression = progression of disease in liver ~ Regimen: BGB-A317 (FGFRi) - [18 Cycles]	true
16386	RA_2177		true	AFP-C332			AFPc332T	742	742	Completion of standard course			Eventual Progression 4 months post trx = Numerous (greater than 50) new arterially enhancing liver lesions consistent with hepatic metastases ~ Regimen: AFPc332T	true
16387	RA_2402		true	Inavolisib			GDC-0077 (Single Agent) [8 Cycles]	671	891	Progression and relapse			Best Response = SD (+1.39%) // Final Respone = PD (+50.4% from BL + New Liver Lesions) ~ Regimen: GDC-0077 (Single Agent) [8 Cycles]	true
16388	RA_2408		true	LY-3214996			ERK 1/2 Inhibitor (LY3214996) X 3 Cycles	211	276	Progression and relapse			Best Response = Progression; New nodules in the lower lobes are indeterminate but concerning for metastases;  progression of metastatic disease in the thorax, interval increase in size/ number LYTIC metastases involving the thoracic skeleton and left lower lobe nodule ; Worsening hepatic and bony metastases ~ Regimen: ERK 1/2 Inhibitor (LY3214996) X 3 Cycles	true
16389	RA_2460		true	Futibatinib			TAS-120 (4 Cycles)	85	246	Progression and relapse			Best Response = Stable Disease (-22%) Progression = new 1.4cm segment VIII lesion, Progression in Liver Multiple sites (Overall RECIST Response = -22.77% from BL// -0.99% from Nadir) ~ Regimen: TAS-120 (4 Cycles)	true
16390	RA_2542		true	Inavolisib			GDC-0077 (Single Agent) [19 Cycles]	7841	8384	Progression and relapse			Best/Final Response = SD (+0.0% from BL) -- patient has bone only disease ~ Regimen: GDC-0077 (Single Agent) [19 Cycles]	true
16391	RA_2544		true	Dostarlimab			TSR-042	836	962	Progression and relapse			Progression = -8.54% from BL// New Pleura Lesion, Interval increase in left pleural mass ~ Regimen: TSR-042	true
16392	RA_2544		true	Cemiplimab-rwlc, SAR-439459			SAR439459 and REGN2810	1135	1178	Progression and relapse			Progression = -0.82% from BL // enlargement of the left anterior mediastinal pleural mass and multiple new left pleural nodules. Increased size of subpleural LLL nodule along with a new 2 cm subpleural left lower lobe nodul New anterior pericardial lymph node metastasis. ~ Regimen: SAR439459 and REGN2810	true
16393	RA_2544		true	Mevociclib			SY-1365 (CDK7 Inhibitor)	1225	1225	Other			Pt. only received a single dose ~ Regimen: SY-1365 (CDK7 Inhibitor)	true
16394	RA_2736		true	Futibatinib			TAS-120 (FGFRi) - [10 Cycles]	483	693	Progression and relapse			Continued past progression (Cycle 7) progression in number and size of lesions in liver and lungs ~ Regimen: TAS-120 (FGFRi) - [10 Cycles]	true
16395	RA_2736	Immunotherapy	true	CAR-T, Interleukin 2			Autologous T cell infusion / 5 doses of IL-2	804	813	Completion of standard course			Regimen: Autologous T cell infusion / 5 doses of IL-2	true
16396	RA_2819		true	LSZ102			LSZ102	7909	7952	Progression and relapse			Progression = +23.51% from BL, progression of liver lesions + New Liver Lesions ~ Regimen: LSZ102	true
16397	RA_2917	ADC	true	Ladiratuzumab vedotin			SGN-LIV1A (ADC)	358	396	Progression and relapse			new nodule in the right breast ~ Regimen: SGN-LIV1A (ADC)	true
16398	RA_2917	ADC	true	IMMU-132			IMMU-132 (9 Cycles)	417	617	Progression and relapse			Best Response = Partial Response (-45.7) // Final Response = progression in lungs/chest wall and progressive brain mets ~ Regimen: IMMU-132 (9 Cycles)	true
16399	RA_3130	Chemotherapy	true	Capecitabine, Epirubicin	ECF		Neoadjuvant ECF (3 Cycles) / ECX (3 Cycles)	42	182	Completion of standard course			Regimen: Neoadjuvant ECF (3 Cycles) / ECX (3 Cycles)	true
16400	RA_3130		true	Futibatinib			TAS-120 [7 Cycles] - FGFRi	724	898	Progression and relapse			Treated x 5 Cycles with progression of retroperitoneal and mesenteric lymphadenopathy; Treated 2 cycles past progression with further PD of lymphadenopathy ~ Regimen: TAS-120 [7 Cycles] - FGFRi	true
16401	RA_321		true	Sotrastaurin acetate			AEB071 (Protein Kinase Ci) - [<1 Cycle]	11851	11865	Other			Withdrew Consent ~ Regimen: AEB071 (Protein Kinase Ci) - [<1 Cycle]	true
16402	RA_3328		true	Futibatinib			TAS120	306	376	Progression and relapse			Best Response = -25.4% from Baseline Progression = New Peritoneum/Omentum Lesions (RECIST -22.93% from BL // _3.31% from Nadir) ~ Regimen: TAS120	true
16403	RA_3343		true	Futibatinib			TAS-120 (FGFRi) - [9 Cycles]	161	343	Progression and relapse			disease progression in his liver.  His CA19-9 is rising ~ Regimen: TAS-120 (FGFRi) - [9 Cycles]	true
16404	RA_3343		true	Mevociclib			SY-1365 (CDK7i) - [2 Cycles]	354	399	Progression and relapse			Interval progression with enlarging and new hepatic metastasis as well as new peritoneal nodules and enlarging retroperitoneal lymphadenopathy Enlarging bilateral pulmonary parenchymal metastases as described involving all lobes of the lungs. Slight interval enlargement of a right paratracheal lymph node. Other mediastinal lymph nodes remain stable. ~ Regimen: SY-1365 (CDK7i) - [2 Cycles]	true
16405	RA_3451		true	Futibatinib			TAS-120 (FGFRi)	140	228	Progression and relapse			Multiple 3-20 mm pulmonary nodules consistent with metastasis.  multiple nodules are increased in size. Increased mediastinal and hilar lymphadenopathy. Multiple new lytic bone lesions consistent with bone metastasis. ; New Liver lesions ~ Regimen: TAS-120 (FGFRi)	true
16406	RA_3612	Precision/Targeted Therapy	true	Selpercatinib			LOXO-292 (RETi) - [2 Cycles]	2724	2780	Toxicity			stopped for hepatotoxicity (LFTs) with biopsy showing immune infiltrate - checkpoint hepatitis ~ Regimen: LOXO-292 (RETi) - [2 Cycles]	true
16407	RA_3612	Precision/Targeted Therapy	true	Selpercatinib			LOXO-292 (RETi)	2881	2933	Toxicity			presumed autoimmune hepatitis ~ Regimen: LOXO-292 (RETi)	true
16408	RA_3738		true		R-ICE		R-ICE (2 Cycles)	350	382	Progression and relapse			decreased avidity in the gastroesophageal junction extending to the proximal stomach but remains far above hepatic background ~ Regimen: R-ICE (2 Cycles)	true
16409	RA_3738	Immunotherapy	true	Lisocabtagene maraleucel			CAR T (JCAR017) - chimeric antigen receptor T cells	416	416	Progression and relapse			FDG avidity at the gastroesophageal junction suspicious for persistent disease ~ Regimen: CAR T (JCAR017) - chimeric antigen receptor T cells	true
16410	RA_3773		true	Olutasidenib			FT2102	341	376	Progression and relapse			Regimen: FT2102	true
16411	RA_3817		true	Tisagenlecleucel			KYMRIAH [CAR-T]	377	377	Progression and relapse			Regimen: KYMRIAH [CAR-T]	true
16412	RA_3859		true	Ulixertinib			BVD523 (ERK 1/2 Inhibitor)	519	575	Toxicity			Grade 4 AST/ALT ~ Regimen: BVD523 (ERK 1/2 Inhibitor)	true
16413	RA_3861		true	Cobicistat, PLX-8394			PLX8394/Cobcicstat	756	924	Progression and relapse			progression in omentum ~ Regimen: PLX8394/Cobcicstat	true
16414	RA_3873		true	Roferon-A			Adjuvant High Dose Interferon-alpha 2b	8439	8527	Toxicity			Regimen: Adjuvant High Dose Interferon-alpha 2b	true
16415	RA_3873		true	Interleukin 2			Interleukin 2	9314	9388	Progression and relapse			partial/mixed response: regression of the two largest pulmonary metastases, and stability of the smaller nodules. However, there is further progression of the subcarinal node, now measuring 2.5 cm ~ Regimen: Interleukin 2	true
16416	RA_3912		true		AC-T		ADJUVANT  ddAC	75	117	Completion of standard course			Regimen: ADJUVANT  ddAC	true
16417	RA_4248	Immunotherapy	true	DKN-01, Nivolumab			DKN-01/Nivolumab	298	329	Progression and relapse			Regimen: DKN-01/Nivolumab	true
16418	RA_4248		true	Subasumstat			TAK-981	361	371	Progression and relapse			d/c'ed on hospice ~ Regimen: TAK-981	true
16419	RA_4443		true	XMT-1522			XMT-1522	2025	2095	Toxicity				true
16420	RA_4443		true	ALX-148			ALX148	2254	2485	Progression and relapse		initial SD w/ overall decrease in tumor burden, did treat past progression		true
16421	RA_4957		true	Talimogene Laherparepvec			TVEC: Left Upper Back	1410	1458	Progression and relapse			Regimen: TVEC: Left Upper Back	true
16422	MGHCC0002		false				SIRT to right liver	8216	8216	NA				true
16423	MGHCC0003		false				XRT to left chest wall	317	348	NA				true
16424	MGHCC0003		false				xrt to right humerus	4886	4886	NA				true
16425	MGHCC0003		false				WBRT	6710	6734	NA				true
16426	MGHCC0004		false				Spine XRT	8491	8491	NA				true
16427	MGHCC0004		false				WBRT	9162	9162	NA				true
16428	MGHCC0005		false				XRT	384	384	NA				true
16429	MGHCC0005		false				proton therapy to left eye	2736	2737	NA			metastases to the choroid	true
16430	MGHCC0006		false				whole brain radiation	1754	1754	NA				true
16431	MGHCC0007		false				palliative xrt to l chest wall, cervical and axillary nodes	651	696	NA				true
16432	MGHCC0007		false				xeloda	651	695	NA				true
16433	MGHCC1005		false				xrt to r chest wall, axilla, supraclavicular LNs	206	245	NA				true
16434	MGHCC1005		false				XRT to T6-T11, L1-L3, C6-T4, base of skull	724	749	NA				true
16435	MGHCC1009		false				SRS to brain lesions	2196	2196	NA				true
16436	MGHCC1015		false				XRT	254	254	NA				true
16437	MGHCC1015		false				SBRT to Liver	5384	5392	NA				true
16438	MGHCC1015		false				Xeloda	5751	5800	NA				true
16439	MGHCC1015		false				XRT to Neck	5793	5794	NA				true
16440	MGHCC1015		false				WBRT	5810	5830	NA				true
16441	MGHCC1030		false				radiation to right breast	156	186	NA				true
16442	MGHCC1030		false				radiation to left breast	927	927	NA				true
16443	MGHCC1030		false				cranial xrt	6155	6173	Progression and relapse			transition to hospice	true
16444	MGHCC1041		false				XRT to breast	172	222	NA				true
16445	MGHCC1041		false				radiation to lumbo-sacral spine	1202	1215	NA				true
16446	MGHCC1041		false				palliative XRT to right scapula	1754	1768	Progression and relapse				true
16447	MGHCC1099		false				xrt to left chest wall	326	360	NA				true
16448	MGHCC1101		false				radiation to left chest wall, left axilla, subclavian area	2550	2597	NA				true
16449	MGHCC1101		false				radiation to frontal skull mets	3726	3741	NA				true
16450	MGHCC1101		false				whole brain radiation	3827	3858	NA				true
16451	MGHCC1101		false				radiation to T10-L2 & mediastinum	4314	4323	NA				true
16452	MGHCC1108		false				radiation to breast	207	253	NA				true
16453	MGHCC1108		false				xrt to skull, right femur, and hemipelvis	2169	2188	NA				true
16454	MGHCC1108		false				xrt to skull	2858	2884	NA				true
16455	MGHCC1108		false				palliative xrt to left shoulder/skin and right hip/glute	2918	2931	NA				true
16456	MGHCC1112		false				palliative xrt to right hip	1900	1912	NA				true
16457	MGHCC1173		false				XRT to right breast & right SC Lymph Nodes	124	167	NA				true
16458	MGHCC1173		false				XRT to T7-9, L-13	1164	1184	NA				true
16459	MGHCC1173		false				XRT to left proximal tibia/fibula	1876	1882	NA				true
16460	MGHCC1173		false				XRT to brain, calvarium, and left arm	2179	2191	NA				true
16461	MGHCC1328		false				xrt to right breast	14	29	NA				true
16462	MGHCC1328		false				XRT to spine	7627	7649	NA				true
16463	MGHCC1573		false				xrt to chest wall	215	259	NA				true
16464	MGHCC1573	Chemotherapy	true	Capecitabine			xeloda	1644	2061	Progression and relapse				true
16465	RA_1002		false				Radiation (to Right Breast)	0	0	NA			Regimen: Radiation (to Right Breast)	true
16466	RA_1002		false				Radiation	5478	5478	NA			Regimen: Radiation	true
16467	RA_1011		false				postoperative XRT	292	315	Completion of standard course			Regimen: postoperative XRT	true
16468	RA_1011		false				XRT to the R scalp lesion and L hip	1114	1139	Completion of standard course			Regimen: XRT to the R scalp lesion and L hip	true
16469	RA_1035		false				Postmastectomy radiation therapy	212	291	Completion of standard course			Regimen: Postmastectomy radiation therapy	true
16470	RA_1035		false				Postmastectomy radiation therapy	212	291	Completion of standard course			Regimen: Postmastectomy radiation therapy	true
16471	RA_1045		false				Radiation + Concurrent Trastuzumab/Capecitabine	217	260	NA			Regimen: Radiation + Concurrent Trastuzumab/Capecitabine	true
16472	RA_1078		false				Radiation (50 Gy)	252	288	NA			Regimen: Radiation (50 Gy)	true
16473	RA_1078		false				Cyberknife stereotactic therapy	5249	5251	NA			Regimen: Cyberknife stereotactic therapy	true
16474	RA_1078		false				Palliative radiotherapy to the R humerus	6167	6173	NA			Regimen: Palliative radiotherapy to the R humerus	true
16475	RA_1078		false				XRT to Cerebellum (30 Gy X 10 Fractions)	6437	6452	NA			Regimen: XRT to Cerebellum (30 Gy X 10 Fractions)	true
16476	RA_1113		false				WBRT	3658	3684	Completion of standard course			Regimen: WBRT	true
16477	RA_1113		false				WBRT	3658	3684	Completion of standard course			Regimen: WBRT	true
16478	RA_1184		false				vaginal brachytherapy	192	192	Completion of standard course			Regimen: vaginal brachytherapy	true
16479	RA_1187		false				Microwave ablation (liver lesion)	464	464	Completion of standard course			Regimen: Microwave ablation (liver lesion)	true
16480	RA_1187		false				SIRT to liver	654	654	Completion of standard course			Regimen: SIRT to liver	true
16481	RA_1373		false				XRT to the R iliac crest	6589	6609	NA			Regimen: XRT to the R iliac crest	true
16482	RA_1526		false				IMRT: 42.5 Gy.  (proximal/distal vagina)	142	184	NA			Regimen: IMRT: 42.5 Gy.  (proximal/distal vagina)	true
16483	RA_1547		false				Radiation Therapy (Left Breast)	188	232	NA			Regimen: Radiation Therapy (Left Breast)	true
16484	RA_1547		false				Radiation Therapy (Cervical Spine)	1020	1043	NA			Regimen: Radiation Therapy (Cervical Spine)	true
16485	RA_1547		false				RT Therapy Right Humerus Lesion	1826	1846	NA			Regimen: RT Therapy Right Humerus Lesion	true
16486	RA_1558		false				Radiation: Left parasternal mass and IMN's	3269	3306	Completion of standard course			Regimen: Radiation: Left parasternal mass and IMN's	true
16487	RA_1558		false				palliative XRT to pubis/R ischium	4083	4097	Completion of standard course			Regimen: palliative XRT to pubis/R ischium	true
16488	RA_1558		false				XRT to sacrum	4791	4797	Completion of standard course			Regimen: XRT to sacrum	true
16489	RA_1568		false				L breast Radiation Therapy	224	268	Completion of standard course			Regimen: L breast Radiation Therapy	true
16490	RA_1598		false				Radiation	183	233	NA			Regimen: Radiation	true
16491	RA_1598		false				XRT (Right Hip) - 30 Gy	735	735	NA			Regimen: XRT (Right Hip) - 30 Gy	true
16492	RA_1598		false				XRT (Right Hip)	2100	2107	NA			Regimen: XRT (Right Hip)	true
16493	RA_1598		false				XRT to left hip	4023	4027	NA			Regimen: XRT to left hip	true
16494	RA_1644		false				Radiation: Right chest wall and SCV	259	301	NA			Regimen: Radiation: Right chest wall and SCV	true
16495	RA_1644		false				Radiation (50.4 Gy to chest wall & LN + 10 Gy boost to area of reccurence)	1985	2036	NA			Regimen: Radiation (50.4 Gy to chest wall & LN + 10 Gy boost to area of reccurence)	true
16496	RA_1926		false				Radiation	86	127	Completion of standard course			Regimen: Radiation	true
16497	RA_1926		false				Radiation (Esophagous)	1577	1616	Completion of standard course			Regimen: Radiation (Esophagous)	true
16498	RA_1939		false				Radiation (liver) + CI 5FU	283	327	Completion of standard course			Regimen: Radiation (liver) + CI 5FU	true
16499	RA_2085		false				Radiation: Liver lesions	527	536	NA			Regimen: Radiation: Liver lesions	true
16500	RA_2085		false				Radiation: Liver	1187	1207	Completion of standard course			67.5 Gy / 15 fractions ~ Regimen: Radiation: Liver	true
16501	RA_2085		false				Radiation: perihepatic lymph node	1498	1516	Completion of standard course			52.5 Gy in 15 fractions ~ Regimen: Radiation: perihepatic lymph node	true
16502	RA_2085		false				Radiation: Liver	1701	1701	Completion of standard course			8 Gy X 3 fractions ~ Regimen: Radiation: Liver	true
16503	RA_2098		false				XRT to the L pelvic mass	555	569	Completion of standard course			Regimen: XRT to the L pelvic mass	true
16504	RA_2098		false				Radiation to abdominal lesions	723	745	Completion of standard course			Regimen: Radiation to abdominal lesions	true
16505	RA_2389		false				Left chest wall radiation	611	637	Completion of standard course			Regimen: Left chest wall radiation	true
16506	RA_2544		false				Palliative radiation therapy to the oblique right flank	20	24	Completion of standard course			Regimen: Palliative radiation therapy to the oblique right flank	true
16507	RA_2544		false				XRT to R adrenal gland and L lung	1074	1084	Completion of standard course			Regimen: XRT to R adrenal gland and L lung	true
16508	RA_255		false				SRS 18 Gy to brain met	1087	1087	NA			Regimen: SRS 18 Gy to brain met	true
16509	RA_255		false				Palliative XRT for T8 pathologic fracture	1147	1156	NA			Regimen: Palliative XRT for T8 pathologic fracture	true
16510	RA_255		false				RT to T-spine lesion	1157	1158	NA			Regimen: RT to T-spine lesion	true
16511	RA_2736		false				SRS to L3-L4 lesion	853	854	Completion of standard course			Regimen: SRS to L3-L4 lesion	true
16512	RA_2785		false				palliative xrt to primary	271	282	Completion of standard course			Regimen: palliative xrt to primary	true
16513	RA_2917		false				Radiation (Cerebellum)	540	553	Completion of standard course			Regimen: Radiation (Cerebellum)	true
16514	RA_2917		false				Stereotactic Body Radiation Therapy (Liver)	639	639	Completion of standard course			Regimen: Stereotactic Body Radiation Therapy (Liver)	true
16515	RA_2974		false				Radiation (Left Breast)	85	85	NA			Regimen: Radiation (Left Breast)	true
16516	RA_3130		false				Radiation: L Supraclav Node	898	906	Completion of standard course			Regimen: Radiation: L Supraclav Node	true
16517	RA_321		false				Radiation: abdominal metastatic disease  (IMRT)	13252	13272	Completion of standard course			Regimen: Radiation: abdominal metastatic disease  (IMRT)	true
16518	RA_321		false				Radiation:  left hepatic lobe (SIRT)	13411	13411	Completion of standard course			Regimen: Radiation:  left hepatic lobe (SIRT)	true
16519	RA_321		false				Radiation:  right hepatic lobe (SIRT)	13481	13481	Completion of standard course			Progression of metastases in the chest ~ Regimen: Radiation:  right hepatic lobe (SIRT)	true
16520	RA_3226		false				radiation to rectum	40	44	NA			short course xrt ~ Regimen: radiation to rectum	true
16521	RA_3226		false				IMRT to dominant lung mass (LLL)	1195	1238	NA			Regimen: IMRT to dominant lung mass (LLL)	true
16522	RA_3533		false				SRS to R. Frontal Brain Metastasis	561	561	Completion of standard course			17 Gy x 1 ~ Regimen: SRS to R. Frontal Brain Metastasis	true
16523	RA_3612		false				Adjuvant neck RT	78	120	Completion of standard course			Regimen: Adjuvant neck RT	true
16524	RA_3612		false				Palliative RT: T12-L3 for lesions in L1&2	2618	2620	Completion of standard course			5 fxs to 2000 cGy ~ Regimen: Palliative RT: T12-L3 for lesions in L1&2	true
16525	RA_3612		false				Palliative RT: Pelvis/Femur	2842	2863	Completion of standard course			14 fx to 3500 cGy ~ Regimen: Palliative RT: Pelvis/Femur	true
16526	RA_3634		false				XRT to right hilum of lung	526	540	Completion of standard course			Regimen: XRT to right hilum of lung	true
16527	RA_3634		false				Palliative RT to right axillary adenopathy	601	605	Completion of standard course			Regimen: Palliative RT to right axillary adenopathy	true
16528	RA_3649		false				SRS to Brain	443	443	Completion of standard course			R frontal #1 18 Gy, R frontal #2 18 Gy, L parietal 18 Gy, and L temporal cavity 30 Gy over 10 fractions ~ Regimen: SRS to Brain	true
16529	RA_3738		false				Radiotherapy (stomach)	460	497	Completion of standard course			Regimen: Radiotherapy (stomach)	true
16530	RA_3781		false				Radiation Therapy (Brain)	3481	3501	Completion of standard course			Regimen: Radiation Therapy (Brain)	true
16531	RA_3782		false				RFA Ablation	-1776	-1776	Completion of standard course			Regimen: RFA Ablation	true
16532	RA_3782		false				Radiation (Stomach)	65	73	Completion of standard course			Regimen: Radiation (Stomach)	true
16533	RA_3792		false				CyberKnife (SBRT)	205	205	Completion of standard course			Regimen: CyberKnife (SBRT)	true
16534	RA_3812		false				Photon Radiation: Liver	55	78	Completion of standard course			Regimen: Photon Radiation: Liver	true
16535	RA_3859		false				Radiation: Right uveal melanoma	14	20	Completion of standard course			Regimen: Radiation: Right uveal melanoma	true
16536	RA_3859		false				Radiation: left iliac metastasis	540	552	Completion of standard course			Regimen: Radiation: left iliac metastasis	true
16537	RA_3859		false				SIRT: right lobe of liver	623	623	Completion of standard course			Regimen: SIRT: right lobe of liver	true
16538	RA_3859		false				SBRT (Palliative): T12-L1 and L5-S2	664	664	Completion of standard course			Regimen: SBRT (Palliative): T12-L1 and L5-S2	true
16539	RA_3873		false				SRS to cervical spine (C4-C6), 18 Gy in one fraction	12137	12137	Completion of standard course			Regimen: SRS to cervical spine (C4-C6), 18 Gy in one fraction	true
16540	RA_3873		false				Proton SRS to L frontal lobe resection cavity 21 Gy in 3 fractions	12139	12143	Completion of standard course			Regimen: Proton SRS to L frontal lobe resection cavity 21 Gy in 3 fractions	true
16541	RA_3873		false				Radiation single fraction (1800cGy)to T4-T5	12571	12571	Completion of standard course			Regimen: Radiation single fraction (1800cGy)to T4-T5	true
16542	RA_3873		false				Gated XRT to cardiac met	12682	12710	Completion of standard course			20 fractions for a total of 40 Gy ~ Regimen: Gated XRT to cardiac met	true
16543	RA_3873		false				Cardiac met ITV2 - 1000 cGy	12781	12788	Completion of standard course			Regimen: Cardiac met ITV2 - 1000 cGy	true
16544	RA_3873		false				30 Gy SBRT in 4 fractions to C3-C5	12926	12930	Completion of standard course			Regimen: 30 Gy SBRT in 4 fractions to C3-C5	true
16545	RA_3912		false				right breast XRT	228	269	Completion of standard course			Regimen: right breast XRT	true
16546	RA_3912		false				WBRT	1156	1162	Completion of standard course			Regimen: WBRT	true
16547	RA_4426		false				Radiation: Mastectomy Site	178	217	Completion of standard course			Regimen: Radiation: Mastectomy Site	true
16548	RA_4430		false				IMRT to LUL tumor	228	265	Completion of standard course			Regimen: IMRT to LUL tumor	true
16549	RA_4443		false				Radiation to Esophagus	1757	1792	Completion of standard course				true
16550	RA_4443		false				Radiation to Right Adrenal Gland	1785	1794	Completion of standard course				true
16551	RA_4443		false				Radiation to Esophagus (Cone Down)	1793	1795	Completion of standard course				true
16552	RA_4484		false				Proton SRS:  (L) anterior sub-insular Brain Lesion	81	81	Completion of standard course			Regimen: Proton SRS:  (L) anterior sub-insular Brain Lesion	true
16553	RA_4484		false				SRS to lesions: R frontal, (R) occipital lobe & cerebellar vermis	207	207	Completion of standard course			Regimen: SRS to lesions: R frontal, (R) occipital lobe & cerebellar vermis	true
16554	RA_4484		false				SRS: new brain metastases	498	498	Completion of standard course			Regimen: SRS: new brain metastases	true
16555	RA_4484		false				SRS R posterior temporal metastasis	1915	1915	Completion of standard course			Regimen: SRS R posterior temporal metastasis	true
16556	RA_4484		false				post-operative radiation to resection bed	2499	2517	Completion of standard course			Regimen: post-operative radiation to resection bed	true
16557	RA_4484		false				SRS to L temporal horn and R temporal horn	2734	2734	Completion of standard course			New bilateral temporal horn lesions ~ Regimen: SRS to L temporal horn and R temporal horn	true
16558	RA_4518		false				RA223	1271	1425	Completion of standard course			Regimen: RA223	true
16559	RA_4518		false				Radiation to T9-S2	1489	1502	NA			Regimen: Radiation to T9-S2	true
16560	RA_4523		false				C7-T1 xrt	0	0	NA			Regimen: C7-T1 xrt	true
16561	RA_4523		false				XRT to R 4th Rib & L3 Vertebrae	0	0	NA			Regimen: XRT to R 4th Rib & L3 Vertebrae	true
16562	RA_4848		false				Breast Radiation	121	121	NA			Regimen: Breast Radiation	true
16563	RA_4848		false				L Axillary Radiotherapy	2441	2441	NA			Regimen: L Axillary Radiotherapy	true
16564	RA_4957		false				Radiation (Adjuvant)	501	545	Completion of standard course			Regimen: Radiation (Adjuvant)	true
16565	RA_4965		false				SRS to multiple brain lesions	23	24	NA			Regimen: SRS to multiple brain lesions	true
16566	RA_4965		false				SRS to R femur lesion	27	36	NA			Regimen: SRS to R femur lesion	true
16567	RA_4979		false				XRT to third rib	1205	1210	Completion of standard course			Regimen: XRT to third rib	true
16568	RA_498		false				SRS to right frontal, right parietal and left parietal lesions	4651	4651	NA			Regimen: SRS to right frontal, right parietal and left parietal lesions	true
16569	RA_552		false				XRT to cerebellar surgical resection	1919	1936	NA			Regimen: XRT to cerebellar surgical resection	true
16570	RA_552		false				SRS to R parietal metastasis	2053	2053	NA			Regimen: SRS to R parietal metastasis	true
16571	RA_552		false				SRS to R parietal metastasis	2202	2202	NA			Regimen: SRS to R parietal metastasis	true
16572	RA_858		false				XRT to R breast	2364	2368	Completion of standard course			Regimen: XRT to R breast	true
16573	RA_4484		true	Interleukin 2			IL-2	273	277	Toxicity			10 of 14 doses of planned course, complicated by diarrhea, hypotension, mental status changes.  (Suspected Colitis) ~ Regimen: IL-2	true
16574	RA_858		true	Interleukin 2			High dose IL-2	2329	2347	Progression and relapse			increased tumor burden, evidenced by increase in size of lung nodules/masses, thoracic and abdominal lymphadenopathy, hepatic lesions, splenic lesion, right breast masses, and subcutaneous nodules. New possible ulceration at the right nipple. New lytic area in the L1 vertebral body likely represents a metastasis. New gastric nodule at the lesser curvature could represent a metastasis ~ Regimen: High dose IL-2	true
16575	RA_1373	ADC	true	IMMU-132			IMMU-132 (X 7 Cycles)	6638	6791	NA			Clinical Trial, Best Response = SD (-21.9%) // Progression = New liver lesions and (+ 0.5%)  change from BL "Increased size of some of the multiple metastases involving both lobes of the liver" ~ Regimen: IMMU-132 (X 7 Cycles)	true
16576	RA_1547	ADC	true	IMMU-132			IMMU-132 (X 8 Cycles)	1988	2177	Progression and relapse			Clinical Trial #: Best Response = SD (-15.8%) - D/C for Increasing tumor markers ~ Regimen: IMMU-132 (X 8 Cycles)	true
16577	RA_209		true	Roferon-A			Interferon  (Adjuvant)	168	210	Toxicity			Nausea/Vomiting ~ Regimen: Interferon  (Adjuvant)	true
16578	RA_3244		true	Roferon-A			Interferon	706	1016	Toxicity			D/C due to transaminitis ~ Regimen: Ineterferon	true
16579	RA_2785		true	Lamivudine			Lamivudine	482	503	Progression and relapse			New and increasing hepatic metastases.  Increased periportal and aortocaval lymphadenopathy.  New small volume ascites with stranding and nodularity in the lower abdomen/pelvis, suggestive of new peritoneal disease ~ Regimen: Lamivudine	true
16580	RA_209		true	Talimogene Laherparepvec			TVEC - Left Breast lesion [5 Cycles]	5751	5821	Completion of standard course			Regimen: TVEC - Left Breast lesion [5 Cycles]	true
16581	RA_3533		true	Talimogene Laherparepvec			TVEC to R foot nodules - [6 Cycles]	520	597	Progression and relapse			Progression in Brain: Progression Multiple new and enlarging intracranial metastases as described above, which measure up to 3.2 cm in diameter within the right middle frontal gyrus. Several of these metastases demonstrate intrinsic T1 hyperintense signal and susceptibility, consistent with intralesional hemorrhage. There is also suggestion of new leptomeningeal and pachymeningeal disease, most notably along the right frontal operculum. ~ Regimen: TVEC to R foot nodules - [6 Cycles]	true
16582	RA_209		true	WDVAX			WDVAX	5468	5510	Progression and relapse			Interval increase in number and extent of multiple intensely FDG avid soft tissue and pelvic metastases ~ Regimen: WDVAX	true
16583	RA_1045		false					162	162	NA			Partial mastectomy	true
16584	RA_1045		false					181	181	NA			Mastectomy	true
16585	RA_1078		false					51	51	NA			Left Modified Radical Mastectomy	true
16586	RA_1373		false					17	17	NA			Mastectomy	true
16587	RA_1526		false					26	26	NA			Hysterectomy	true
16588	RA_1547		false				Lumpectomy	15	15	NA			Lumpectomy	true
16589	RA_1547		false				R. Breast Reduction	257	257	NA			R. Breast Reduction	true
16590	RA_1598		false					28	28	NA			Simple mastectomy	true
16591	RA_1644		false					26	26	NA			Bilateral Mastectomy	true
16592	RA_1644		false					819	819	NA			Total abdominal hysterectomy/ Bilateral Salpingo-oophorectomy	true
16593	RA_1644		false					1860	1860	NA			Pectoralis major resection	true
16594	RA_2974		false					85	85	NA			Left Lumpectomy, Partial mastectomy	true
16595	RA_1002		false					0	0	NA			Lumpectomy	true
16596	RA_1002		false					5478	5478	NA			Lumpectomy	true
16597	RA_1002		false					8920	8920	NA			Bilateral Mastectomy	true
16598	RA_2408		false					0	0	NA			Endoscopic Resection of Ampullary Mass	true
16599	RA_1939		false					20	20	NA			right hepatectomy	true
16600	RA_1939		false					1288	1288	NA			Cryoablation of pelvic met - ablation	true
16601	RA_1568		false					173	173	NA			Left lumpectomy	true
16602	RA_1926		false					188	188	NA			esophagectomy, jejunostomy, and omental pedicle to anastomosis	true
16603	RA_2098		false					0	0	NA			Laparoscopic ovarian cystectomy	true
16604	RA_2098		false					34	34	NA			laparoscopic salpingo-oophorectomy	true
16605	RA_2819		false					26	26	NA			R breast mastectomy	true
16606	RA_3130		false					231	231	NA			Subtotal gastrectomy	true
16607	RA_1113		false					0	0	NA			Mastectomy	true
16608	RA_1113		false					0	0	NA			Mastectomy	true
16609	RA_1035		false					151	151	NA			Right breast lumpectomy	true
16610	RA_1035		false					151	151	NA			Right breast lumpectomy	true
16611	RA_1035		false					210	210	NA			Right Mastectomy	true
16612	RA_1035		false					210	210	NA			Right Mastectomy	true
16613	RA_1011		false					0	0	NA			R-sided Lumpectomy	true
16614	RA_1011		false					276	276	NA			Mastectomy	true
16615	RA_1011		false					943	943	NA			left lower lobe (Lung) superior segmentectomy	true
16616	RA_1184		false					30	30	NA			Laparoscopic hysterectomy, BSO, lymph adenectomy, omentectomy	true
16617	RA_1184		false					408	408	NA			exploratory laparotomy - removal of abdominal mass, bowel resection	true
16618	RA_2024		false					95	95	NA			Left/ Right Hepatectomy	true
16619	RA_2024		false					95	95	NA			Left/ Right Hepatectomy	true
16620	RA_2024		false					234	234	NA			Low anterior Resection of the rectum	true
16621	RA_2024		false					234	234	NA			Low anterior Resection of the rectum	true
16622	RA_2917		false					161	161	NA			Left Mastectomy	true
16623	RA_3781		false					17	17	NA			Posterior Neck Melanoma Local Excision	true
16624	RA_3781		false					3299	3299	NA			BILATERAL SUBOCCIPITAL CRANIOTOMY	true
16625	RA_3873		false					8363	8363	NA			Resection of in transit metastasis from (Left) inner thigh	true
16626	RA_3873		false					9420	9420	NA			Thoracotomy - (Right) middle lobectomy	true
16627	RA_3873		false					10120	10120	NA			resection of proximal jejunal metastasis	true
16628	RA_3873		false					11646	11646	NA			Left adrenalectomy (melanoma metastasis)	true
16629	RA_3873		false					12090	12090	NA			(L) frontal craniotomy	true
16630	RA_3873		false					12114	12114	NA			Anterior cervical partial C4 and complete C5 vertebrectomy	true
16631	RA_3873		false					12887	12887	NA			C4 + C6 corpectomy / posterior C3-T1 fusion	true
16632	RA_3873		false					12951	12951	NA			Local excision of metastasis on left side of scalp	true
16633	RA_1187		false					45	45	NA			Left lobe liver resection and hilar lymphadenectomy	true
16634	RA_1187		false					310	310	NA			Recurrence: Liver, Pulmonary Nodules	true
16635	RA_3649		false					0	0	NA			Left shoulder lesion biopsy showing malignant melanoma	true
16636	RA_3649		false					45	45	NA			Wide excision	true
16637	RA_3649		false					78	78	NA			Re-excision of primary	true
16638	RA_2085		false					99	99	NA			Left hepatectomy and cholecystectomy	true
16639	RA_2085		false					444	444	NA			Recurrence: Liver	true
16640	RA_2085		false					469	469	NA			Partial right hepatectomy	true
16641	RA_2177		false					683	683	NA			Right sided TACE - chemoembolization	true
16642	RA_3612		false					0	0	NA			Thyroidectomy and neck dissection	true
16643	RA_3612		false					45	45	NA			Excision of R submandibular mass	true
16644	RA_3612		false					217	217	NA			Revision neck surgery	true
16645	RA_3612		false					2166	2166	NA			Cryoablation: Liver lesions in segments 5/6 - ablation	true
16646	RA_2736		false					17	17	NA			Left Hepatectomy	true
16647	RA_2736		false					727	727	NA			Lung Resection	true
16648	RA_4340		false					-5195	-5195	NA			L sigmoid colectomy	true
16649	RA_3244		false					14	14	NA			Excision (Upper Back)	true
16650	RA_3244		false					638	638	NA			Excision (Left Lower Back)	true
16651	RA_3533		false					47	47	NA			Excision of right heel melanoma	true
16652	RA_3533		false					392	392	NA			Resection: Right Temporal Mass	true
16653	RA_4215		false					35	35	NA			wide excision - RIGHT UPPER BACK	true
16654	RA_4215		false					1470	1470	NA			Craniotomy and resection (Brain Right Frontal)	true
16655	RA_209		false					53	53	NA			Excision: Left Upper Back	true
16656	RA_209		false					2970	2970	NA			Resection: SC nodule of (L) upper back	true
16657	RA_209		false					3248	3248	NA			lingular wedge resection (left)	true
16658	RA_209		false					3921	3921	NA			Resection: Right Adrenal gland	true
16659	RA_209		false					4543	4543	NA			Excision of (R) axillary & (R) back melanoma	true
16660	RA_209		false					5434	5434	NA			Resection: Left Back tumor	true
16661	RA_321		false					0	0	NA			Enucleation	true
16662	RA_321		false					10605	10605	NA			Distal pancreatectomy with splenectomy	true
16663	RA_321		false					13124	13124	NA			Gastrectomy	true
16664	RA_571		false					0	0	NA			excision: Left Shoulder Melanoma	true
16665	RA_571		false					14536	14536	NA			Excision: right flank melanoma	true
16666	RA_552		false					1882	1882	NA			Midline suboccipital craniotomy	true
16667	RA_552		false					2159	2159	NA			R frontal craniotomy	true
16668	RA_498		false					0	0	NA			Excision of T2a melanoma of the back	true
16669	RA_498		false					4498	4498	NA			Craniotomy and resection of R temporal lesion	true
16670	RA_498		false					4608	4608	NA			Right parietal craniotomy	true
16671	RA_4426		false					124	124	NA			Left mastectomy	true
16672	RA_2542		false					0	0	NA			left modified radical mastectomy	true
16673	RA_2542		false					243	243	NA			peripheral stem cell transplant	true
16674	RA_2542		false					4898	4898	NA			hysterectomy and bilateral salpingo-oophorectomy	true
16675	RA_4443		false					495	495	NA			Laparaoscopic BSO (L Fallopian Tube & Ovary)	true
16676	RA_4443		false					1004	1004	NA			Left Adrenalectomy	true
16677	RA_3861		false					34	34	NA			Right Colon Resection	true
16678	RA_3861		false					667	667	NA			Lung Wedge Resections	true
16679	RA_4848		false					0	0	NA			Lumpectomy/Sentinel Lymph Node Procedure	true
16680	RA_4848		false					2345	2345	NA			Left Axillary Resection	true
16681	RA_4484		false					445	445	NA			Right occipital craniotomy	true
16682	RA_4484		false					795	795	NA			Laparoscopic BSO	true
16683	RA_4484		false					1694	1694	NA			Craniotomy: Right Frontal Lesion	true
16684	RA_4484		false					2466	2466	NA			craniotomy tumor resection	true
16685	RA_3226		false					47	47	NA			Laparoscopic low anterior resection with total mesorectal excision	true
16686	RA_3226		false					187	187	NA			Flexible bronchoscopy/clamshell thoracotomy/multiple bilateral wedge resections	true
16687	RA_4430		false					0	0	NA			LUL wedge resection	true
16688	RA_4430		false					166	166	NA			mediastinoscopy	true
16689	RA_4430		false					194	194	NA			thoracotomy + ACA in LUL	true
16690	RA_4430		false					3037	3037	NA			RLL Lung Lobectomy	true
16691	RA_858		false					33	33	NA			Wide excision of Right hip melanoma	true
16692	RA_858		false					2113	2113	NA			Resection: right breast	true
16693	RA_858		false					2378	2378	NA			Resection: left side of back	true
16694	RA_4957		false					458	458	NA			Resection: left inguinal disease	true
16695	RA_4957		false					1547	1547	NA			Cryo ablation: right upper back mass - ablation	true
16696	RA_4979		false					1094	1094	NA			T3 to T7 decompression and fusion	true
16697	RA_3181		false					16	16	NA			Bilateral Salpingo-Oophorectomy	true
16698	MGHCC0001		false					831	831	NA			mastectomy	true
16699	MGHCC0002		false					41	41	NA			left mastectomy and TRAM reconstruction	true
16700	MGHCC0003		false					0	0	NA			left lumpectomy	true
16701	MGHCC0003		false					13	13	NA			axillary lymph node dissection	true
16702	MGHCC0003		false					137	137	NA			left breats re-excision	true
16703	MGHCC0003		false					154	154	NA			left partial mastectomy w/ TRAM flap reconstruction	true
16704	MGHCC0004		false					0	0	NA			mastectomy (PPX)	true
16705	MGHCC0005		false					384	384	NA			R modified radical mastectomy	true
16706	MGHCC0006		false					0	0	NA			right lumpectomy	true
16707	MGHCC0006		false					35	35	NA			re-excision/axillary dissection	true
16708	MGHCC0007		false					49	49	NA			left mastectomy	true
16709	MGHCC1006		false					29	29	NA			mastectomy	true
16710	MGHCC1009		false					21	21	NA			bilateral mastectomy	true
16711	MGHCC1009		false					947	947	NA			bilateral salpingo-oophorectomy	true
16712	MGHCC1015		false					20	20	NA			mastectomy & reconstruction	true
16713	MGHCC1015		false					489	489	NA			left axillary lymph node excision	true
16714	MGHCC1030		false					0	0	NA			lumpectomy	true
16715	MGHCC1030		false					20	20	NA			re-excision	true
16716	MGHCC1030		false					41	41	NA			re-excision	true
16717	MGHCC1030		false					156	156	NA			right mastectomy	true
16718	MGHCC1030		false					807	807	NA			lumpectomy	true
16719	MGHCC1030		false					828	828	NA			lymph node excision	true
16720	MGHCC1030		false					1928	1928	NA			bilateral salpingo-oophorectomy	true
16721	MGHCC1041		false					0	0	NA			right lumpectomy w/ right axillary LN dissection	true
16722	MGHCC1099		false					70	70	NA			bilateral mastectomy	true
16723	MGHCC1099		false					102	102	NA			lymph node dissection	true
16724	MGHCC1099		false					1670	1670	NA			bilateral salpingo-oophorectomy	true
16725	MGHCC1101		false					57	57	NA			right lumpectomy	true
16726	MGHCC1101		false					92	92	NA			right mastectomy	true
16727	MGHCC1101		false					2381	2381	NA			left mastectomy	true
16728	MGHCC1108		false					26	26	NA			mastectomy	true
16729	MGHCC1112		false					0	0	NA			bilateral mastectomy	true
16730	MGHCC1112		false					730	730	NA			oophorectomy	true
16731	MGHCC1173		false					43	43	NA			lumpectomy	true
16732	MGHCC1173		false					1143	1143	NA			spinal cord decompression L1-L3	true
16733	MGHCC1328		false					0	0	NA			right lumpectomy and axillary dissection	true
16734	MGHCC1328		false					882	882	NA			right mastectomy	true
16735	MGHCC1328		false					1615	1615	NA			right simple masectomy  and TRAM reconstruction	true
16736	MGHCC1328		false					7589	7589	NA			spinal decompression/resection of epidural tumor	true
16737	MGHCC1573		false					167	167	NA			right radical mastectomy	true
16738	MGHCC1573		false					278	278	NA			total abdominal hysterectomy (TAH), bilateral salpingo-oophorectomy (BSO)	true
16739	RA_1039		false				XRT to T spine	3	24	NA			Regimen: XRT to T spine	true
16740	RA_1039	Chemotherapy, Precision/Targeted Therapy	true	Paclitaxel, Trastuzumab			trastuzumab/taxol	5	42	NA			Regimen: trastuzumab/taxol	true
16741	RA_1039	Precision/Targeted Therapy	true	Trastuzumab			trastuzumab	74	85	NA			Regimen: trastuzumab	true
16742	RA_1039	Chemotherapy, Precision/Targeted Therapy	true	Capecitabine, Trastuzumab			trastuzumab/capecitabine	85	1158	Progression and relapse			Regimen: trastuzumab/capecitabine	true
16743	RA_1039	Precision/Targeted Therapy	true	Lapatinib Ditosylate, Trastuzumab			trastuzumab/lapatinib	1174	1288	NA			Regimen: trastuzumab/lapatinib	true
16744	RA_1039		false				BYL single agent	1323	1740	Progression and relapse			CT c/a/p: progressive disease per RECIST with increasing liver and adnexal lesions ~ Regimen: BYL single agent	true
16745	RA_1039	Precision/Targeted Therapy	true	Lapatinib Ditosylate, Trastuzumab			trastuzumab/lapatinib	1786	1901	NA			Regimen: trastuzumab/lapatinib	true
16746	RA_1039		false				LJM716 (anti-HER3)	1935	1984	Progression and relapse			Regimen: LJM716 (anti-HER3)	true
16747	RA_1039		false				TDM1	1991	2129	Progression and relapse			Regimen: TDM1	true
16748	RA_1039	Chemotherapy, Precision/Targeted Therapy	true	Eribulin Mesylate, Pertuzumab, Trastuzumab			trastuzumab/pertuzumab/eribulin	2166	2449	Progression and relapse			Regimen: trastuzumab/pertuzumab/eribulin	true
16749	RA_1039	Chemotherapy, Precision/Targeted Therapy	true	Trastuzumab, Vinorelbine Tartrate			trastuzumab/vinorelbine	2551	2588	NA			Regimen: trastuzumab/vinorelbine	true
16750	RA_4793	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			gemcitabine, cisplatin (4 cycles)	21	82	Progression and relapse				true
16751	RA_4793		false				SIRT with Y-90	170	170	Completion of standard course				true
16752	RA_4793		false				SIRT with Y-90	207	207	Completion of standard course				true
16753	RA_4793		true	Futibatinib			Futibatinib (TAS-120) 20mg daily on protocol 14-135	393	849	Progression and relapse				true
16754	RA_4793		true	RLY-4008			20-577, a phase I protocol of a new covalent FGFR inhibitor, RLY-4008	904	1325	Progression and relapse				true
16755	RA_4793		false				SIRT with Y-90	1325	1325	Completion of standard course				true
16756	RA_4793		false				SIRT with Y-90	1373	1373	Completion of standard course				true
16757	RA_1547		false				Recurrence (New T10 Spinal Cord Lesion)	813	813	NA			Regimen: Recurrence (New T10 Spinal Cord Lesion)	true
16758	RA_2917	Chemotherapy	true	unknown_chemotherapy			Chemotherapy + Immunotherapy	34	143	Progression and relapse				true
16759	RA_2917	Immunotherapy	true	unknown_immunotherapy			Chemotherapy + Immunotherapy	34	143	Progression and relapse				true
16760	RA_2917	Chemotherapy	true	unknown_chemotherapy			Chemotherapy + Targeted Therapy	157	204	Progression and relapse				true
16761	RA_2917	Precision/Targeted Therapy	true	unknown_targeted			Chemotherapy + Targeted Therapy	157	204	Progression and relapse				true
16762	RA_2917	ADC	true	unknown_ADC			ADC	207	252	Progression and relapse				true
16763	RA_2917	ADC	true	IMMU-132			IMMU-132 (9 Cycles)	398	676	Progression and relapse				true
16764	RA_2917	Chemotherapy	true	unknown_chemotherapy			Chemotherapy	511	567	Progression and relapse				true
16765	RA_2917		false				Radiation (Cerebellum)	540	553	Completion of standard course				true
16766	RA_2917	Chemotherapy	true	unknown_chemotherapy			Chemotherapy	567	606	Progression and relapse				true
16767	RA_2917	Chemotherapy	true	unknown_chemotherapy			Chemotherapy	608	632	Progression and relapse				true
16768	RA_1133	Chemotherapy	true	Cisplatin			Cisplatin/Pemetrexed	18	39	Other			EGFR results returned after 1 week	true
16769	RA_1133	Precision/Targeted Therapy	true	Erlotinib			Erlotinib	53	529	Progression and relapse				true
16770	RA_1133	Precision/Targeted Therapy	true	Nazartinib			EGF816	529	1564	Progression and relapse				true
16771	RA_1133		false				RT 50 Gy to liver lesion	1315	1325	Completion of standard course				true
16772	RA_1133	Chemotherapy	true	Carboplatin			Carboplatin/Pemetrexed	1566	1566	Toxicity				true
16773	RA_1133	Precision/Targeted Therapy	true	osimertinib			Osimertinib	1574	1751	Progression and relapse				true
16774	RA_2700	Precision/Targeted Therapy	true	Erlotinib			Erlotinib	10	104	Progression and relapse				true
16775	RA_2700	Chemotherapy	true	Carboplatin			Carboplatin/Gemcitabine	106	134	Progression and relapse				true
16776	RA_2700	Precision/Targeted Therapy	true	osimertinib			Osimertinib/Savolitinib	179	220	Progression and relapse				true
16777	RA_2700	Immunotherapy	true	Pembrolizumab			Pembrolizumab	227	227	Progression and relapse				true
16778	RA_2700	Precision/Targeted Therapy	true	osimertinib			Osimertinib	250	296	Other			Taken until date of death	true
16779	RA_2700	Chemotherapy	true	Carboplatin			Carboplatin/Abraxane	267	267	Progression and relapse			alongside Osimertinib	true
16780	RA_1592	Precision/Targeted Therapy	true	Afatinib Dimaleate			Afatinib	19	299	Progression and relapse				true
16781	RA_1592	Precision/Targeted Therapy	true	osimertinib			Osimertinib	309	390	Progression and relapse				true
16782	RA_1592		false				30 Gy to C3 post-op bed and 30 Gy to T10 post-op bed	343	357	Completion of standard course				true
16783	RA_1592	Chemotherapy	true	Carboplatin			Carbo/taxol/osimertinib	391	543	Progression and relapse				true
16784	RA_1592	Chemotherapy	true	Gemcitabine Hydrochloride			Gemcitabine/osimertinib	545	643	Progression and relapse				true
16785	RA_1592	Chemotherapy	true	Vinorelbine Tartrate			Navelbine/osimertinib	643	679	Progression and relapse				true
16786	RA_1592		false				8 Gy x 1 to scapular lesion	648	648	Completion of standard course				true
16787	RA_1592	Immunotherapy	true	Nivolumab			Nivolumab	679	679	Progression and relapse				true
16788	RA_5432	Chemotherapy	true	Carboplatin			Carboplatin/pemetrexed	19	39	Other			Day 0: RLL mass biopsy - PDL1 5%, ALK and ROS negative, EGFR negative	true
16789	RA_5432	Precision/Targeted Therapy	true	osimertinib			Osimertinib - EGFR inhibitor	41	244	Progression and relapse		Day 244: PETCT with decreased FDG at L anterior rib, RUL nodule, L iliac, R iliac, but FDG avidity at T12, L3, R side of T10, ? L adrenal. MRI with T10 and T12, L3 and L5 mets, no cord compression	Day 35: Snapshot EGFR Leu861Gln and TP53; CTs show response in lung and liver, brain MRI with decreased mets; Day 469 dose increased 80 -> 160mg qd due to interval progression in MRI brain, with the two largest lesions measuring 9 x 7 mm and 1.1 x 0.9 cm. Saw subsequent SD with decrease in mets	true
16790	RA_5432		false				RT to T9-L1	263	270	Completion of standard course			Day 273: ctDNA - EGFR L861Q, PDGFR I476I, TMB 5.3, MSS	true
16791	RA_5432		false				SRS to left parietal, left frontal parasagittal and left vertex metastases, 18 Gy x 1 to each	425	425	Completion of standard course				true
16792	RA_5432		false				SRS to right cerebellar and left cerebellar metastases, 18 Gy x 1	700	700	Completion of standard course				true
16793	RA_5432	Precision/Targeted Therapy	true	osimertinib			PEMETREXED/CARBOPLATIN/OSIMERTINIB	780	992	Progression and relapse		Brain MRI with increase in mets		true
16794	RA_5432	Chemotherapy	true	Carboplatin			PEMETREXED/CARBOPLATIN/OSIMERTINIB	780	992	Progression and relapse		Brain MRI with increase in mets		true
16795	RA_5432		false				WBRT 3000cGy in 10 fractions	885	896	Completion of standard course				true
16796	RA_5432	Precision/Targeted Therapy	true	osimertinib			PEMETREXED/OSIMERTINIB	901	1013	Progression and relapse		shortness of breath		true
16797	RA_5432	Chemotherapy	true	Pemetrexed			PEMETREXED/OSIMERTINIB	901	1013	Progression and relapse		shortness of breath		true
16798	RA_6667	Precision/Targeted Therapy	true	Trastuzumab				5441	5495	NA			Patient had refused treatment for 15 years until the right breast mass grew outside her skin for at least 6 months. There was discoloration and drainage which weeps into her clothes.	true
16799	RA_6667	Precision/Targeted Therapy	true	Pertuzumab				5441	5495	NA			Patient had refused treatment for 15 years until the right breast mass grew outside her skin for at least 6 months. There was discoloration and drainage which weeps into her clothes.	true
16800	RA_6667	Chemotherapy	true	Paclitaxel				5481	5495	NA				true
16801	RA_6667	Precision/Targeted Therapy	true	Pertuzumab, Trastuzumab				5481	5495	NA				true
16802	RA_6667	Hormone/Endocrine Therapy	true	Letrozole				5495	5648	NA				true
16803	RA_6667	Precision/Targeted Therapy	true	Pertuzumab, Trastuzumab				5495	5648	NA				true
16804	RA_6667	Precision/Targeted Therapy	true	Pertuzumab, Trastuzumab				5658	5707	NA				true
16805	RA_6667	Chemotherapy	true	Paclitaxel				5658	5707	NA				true
16806	RA_6667	ADC	true	Trastuzumab Emtansine				5728	5770	NA				true
16807	RA_6667	Precision/Targeted Therapy	true	Pertuzumab, Trastuzumab				5798	5932	NA				true
16808	RA_6667	Chemotherapy	true	Paclitaxel				5798	5932	NA				true
16809	RA_6667	Precision/Targeted Therapy	true	Trastuzumab, Tucatinib				5966	6352	NA				true
16810	RA_6667	Chemotherapy	true	Capecitabine				5966	6352	NA				true
16811	RA_6667	Precision/Targeted Therapy	true	Pertuzumab, Trastuzumab				6008	6175	NA				true
16812	RA_6667	Chemotherapy	true	Capecitabine				6008	6175	NA				true
16813	RA_6667	Precision/Targeted Therapy	true	Trastuzumab, Tucatinib				6197	6281	NA				true
16814	RA_6667	Chemotherapy	true	Capecitabine				6197	6281	NA				true
16815	RA_6667	Precision/Targeted Therapy	true	Trastuzumab				6301	6624	NA				true
16816	RA_6667		true	Margetuximab				6649	6706	NA				true
16817	RA_6667	Chemotherapy	true	Eribulin Mesylate				6649	6706	NA				true
16818	RA_6667	Precision/Targeted Therapy	true	Trastuzumab				6723	6827	Progression and relapse				true
16819	RA_6667	Chemotherapy	true	Doxorubicin Hydrochloride Liposome				6723	6827	Progression and relapse				true
16820	RA_6667	Precision/Targeted Therapy	true	RLY-2608				6827	6980	Progression and relapse				true
16821	RA_6870	Chemotherapy	true	Cyclophosphamide, Doxorubicin				64	121	NA				true
16822	RA_6870	Chemotherapy	true	Paclitaxel				121	184	NA				true
16823	RA_6870		false					317	317	Completion of standard course			Right chest wall 5000 cGy Draining lymphatics 4500 cGy	true
16824	RA_6870	Hormone/Endocrine Therapy	true	Anastrozole				344	1385	Completion of standard course			Day 1941: Diffusely abnormal marrow signal suspicious for marrow infiltrative process such as metastasis or lymphoma Day 1994: PET/CT- Extensive osseous metastatic disease.	true
16825	RA_6870		false					2015	2015	Completion of standard course			Right iliac, left iliac 800 cGy 1 fraction	true
16826	RA_6870	Precision/Targeted Therapy	true	Palbociclib				2013	2283	Progression and relapse			Held drug for due to ANC 0.42 from day 2054-2106	true
16827	RA_6870	Hormone/Endocrine Therapy	true	Fulvestrant				2013	2283	Progression and relapse			Held drug for due to ANC 0.42 from day 2054-2106	true
16828	RA_6870	Precision/Targeted Therapy	true	RLY-2608				2355	2523	Progression and relapse			Held drug Day 2376 due to Gr. 3 AST/ALT - not related to drug. Restarted Day 2411 Had PR - complete resolution of measurable disease Held drug Day 2495 due to Gr. 3 AST. Resumed Day 2505 200mg Day 2523 admitted due to transaminitis in addition to hyperbilirubinemia on C7D1	true
16829	RA_6870	Hormone/Endocrine Therapy	true	Fulvestrant				2355	2523	Progression and relapse			Held drug Day 2376 due to Gr. 3 AST/ALT - not related to drug. Restarted Day 2411 Had PR - complete resolution of measurable disease Held drug Day 2495 due to Gr. 3 AST. Resumed Day 2505 200mg Day 2523 admitted due to transaminitis in addition to hyperbilirubinemia on C7D1	true
16833	RA_4430	Chemotherapy	true	Pemetrexed			Carboplatin/Pembrolizumab/Pemetrexed	3061	3147	Completion of standard course			Regimen: Carboplatin/Pembrolizumab/Pemetrexed	true
16834	RA_2113	Immunotherapy	true	Nivolumab			Nivolumab + Ipilimumab	56	69	Toxicity			stopped after a single dose of ipi/nivo due to increased dyspnea and likely autoimmune pneumonitis ~ Regimen: Nivolumab + Ipilimumab	true
16835	RA_3274	Precision/Targeted Therapy	true	Nazartinib			nazartinib + gefitinib [7 Cycles]	37	203	Progression and relapse			Partial Response (-44%) ~ Regimen: nazartinib + gefitinib [7 Cycles]	true
16836	RA_3634	Chemotherapy	true	Paclitaxel			Carboplatin + Paclitaxel (5 Cycles)	15	178	Progression and relapse			Disease progression. Interval increase of the right hilar mass, now measuring 3.1 x 2.5 cm, previously 2.9 x 1.8 cm. Slightly increased mediastinal lymph nodes since November 2016. Numerous (more than 10) solid bilateral pulmonary nodules, many of which have increased in size since November 2016. ~ Regimen: Carboplatin + Paclitaxel (5 Cycles)	true
16837	RA_4430	Immunotherapy	true	Pembrolizumab			Carboplatin/Pembrolizumab/Pemetrexed	3061	3147	Completion of standard course			Regimen: Carboplatin/Pembrolizumab/Pemetrexed	true
16838	RA_1133	Chemotherapy	true	Pemetrexed			Cisplatin/Pemetrexed	18	39	Other			EGFR results returned after 1 week	true
16839	RA_1133	Chemotherapy	true	Pemetrexed			Carboplatin/Pemetrexed	1566	1566	Toxicity				true
16840	RA_2700	Chemotherapy	true	Gemcitabine Hydrochloride			Carboplatin/Gemcitabine	106	134	Progression and relapse				true
16841	RA_2700	Precision/Targeted Therapy	true	savolitinib			Osimertinib/Savolitinib	179	220	Progression and relapse				true
16842	RA_2700	Chemotherapy	true	Paclitaxel			Carboplatin/Abraxane	267	267	Progression and relapse			alongside Osimertinib	true
16843	RA_1592	Chemotherapy	true	Paclitaxel			Carbo/taxol/osimertinib	391	543	Progression and relapse				true
16844	RA_1592	Precision/Targeted Therapy	true	osimertinib			Carbo/taxol/osimertinib	391	543	Progression and relapse				true
16845	RA_1592	Precision/Targeted Therapy	true	osimertinib			Gemcitabine/osimertinib	545	643	Progression and relapse				true
16846	RA_1592	Precision/Targeted Therapy	true	osimertinib			Navelbine/osimertinib	643	679	Progression and relapse				true
16847	RA_1511	Chemotherapy	true	Carboplatin			Carboplatin/Pemetrexed/Avastin	15	95	Progression and relapse			Progression = New Liver Mets, increased size of liver mets, R. Adrenal Met, Mesenteric Nodule // decreased size right lower lobe lung nodules, right paratracheal and right hilar lymphadenopathy consistent with treatment response ~ Regimen: Carboplatin/Pemetrexed/Avastin	true
16848	RA_1511	Chemotherapy	true	Pemetrexed			Carboplatin/Pemetrexed/Avastin	15	95	Progression and relapse			Progression = New Liver Mets, increased size of liver mets, R. Adrenal Met, Mesenteric Nodule // decreased size right lower lobe lung nodules, right paratracheal and right hilar lymphadenopathy consistent with treatment response ~ Regimen: Carboplatin/Pemetrexed/Avastin	true
16849	MGH600		false					0	0	NA	nave			true
16850	MGH600	Precision/Targeted Therapy	true	Erlotinib			erlotinib	747	4564	Progression and relapse		T790M	prolonged response to erlotinib	true
16851	MGH770	Precision/Targeted Therapy	true	Erlotinib			erlotinib	39	2013	Progression and relapse	nave	T790M		true
16852	MGH714	Precision/Targeted Therapy	true	Erlotinib			erlotinib	1	811	Progression and relapse	nave	T790M		true
16853	MGH783		false					0	0	NA	nave			true
16854	MGH783	Precision/Targeted Therapy	true	Afatinib Dimaleate			afatinib	79	1058	Toxicity		discontinue for toxicity		true
16855	MGH783	Precision/Targeted Therapy	true	Erlotinib			erlotinib	1081	1149	Toxicity		T790M		true
16856	MGH801	Precision/Targeted Therapy	true	Nazartinib			EGF816	1345	1592	Progression and relapse	T790M		s/p erlotinib, afatinib	true
16857	MGH754	Precision/Targeted Therapy	true	Erlotinib			erlotinib	26	776	Progression and relapse	nave	T790M		true
16858	MGH754	Precision/Targeted Therapy	true	osimertinib			osimertinib	785	1310	Progression and relapse		MET amplification negative		true
16859	MGH754	Precision/Targeted Therapy	true	Nazartinib			EGF816	1310	1331	Progression and relapse				true
16860	MGH769		false					0	0	NA	nave	T3N0M0		true
16861	MGH769	Precision/Targeted Therapy	true	Erlotinib			erlotinib	101	822	Progression and relapse	adjuvant			true
16862	MGH769		false					1032	1032	NA		T2N0M0		true
16863	MGH769	Precision/Targeted Therapy	true	Erlotinib			erlotinib	1555	2290	Progression and relapse		T790M		true
16864	MGH769	Precision/Targeted Therapy	true	osimertinib			osimertinib	2299	2867	Progression and relapse		MET amplification, T790M loss		true
16865	MGH806	Precision/Targeted Therapy	true	Erlotinib			erlotinib	45	846	Progression and relapse		T790M, extended response to osimertinib		true
16866	MGH141	Precision/Targeted Therapy	true	Erlotinib			erlotinib	31	198	Completion of standard course		T790M		true
16867	MGH799	Precision/Targeted Therapy	true	Erlotinib			erlotinib	149	287	Progression and relapse	SCC	T790M		true
16868	MGH808	Precision/Targeted Therapy	true	Erlotinib			erlotinib	33	287	Progression and relapse		T90M		true
16869	MGH808	Precision/Targeted Therapy	true	Nazartinib			EGF816	289	1153	Progression and relapse		C797S; T790M retained		true
16870	MGH808	Precision/Targeted Therapy	true	osimertinib			osimertinib	1154	1608	Progression and relapse		continued		true
16871	MGH808	Chemotherapy	true	Pemetrexed			pemetrexed	1154	1608	Progression and relapse		continued		true
16872	MGH742	Precision/Targeted Therapy	true	Erlotinib			erlotinib	53	442	Progression and relapse		T790M		true
16873	MGH742	Precision/Targeted Therapy	true	Rociletinib			CO-1686	446	788	Progression and relapse				true
16874	MGH716	Precision/Targeted Therapy	true	Erlotinib			erlotinib	16	351	Progression and relapse	nave	T790M		true
16875	MGH716	Precision/Targeted Therapy	true	Rociletinib			CO-1686	357	482	Toxicity				true
16876	MGH778	Chemotherapy	true	Cisplatin			cisplatin	12	75	Other				true
16877	MGH778	Chemotherapy	true	Pemetrexed			pemetrexed	12	75	Other				true
16878	MGH778	Precision/Targeted Therapy	true	Afatinib Dimaleate			afatinib	112	878	Progression and relapse				true
16879	MGH778	Precision/Targeted Therapy	true	Nazartinib			EGF816	886	1224	Progression and relapse		MET amplification		true
16880	MGH778	Precision/Targeted Therapy	true	osimertinib			osimertinib	1229	1366	Progression and relapse		MET amplification negative		true
16881	MGH778	Precision/Targeted Therapy	true	savolitinib			savolitinib	1229	1366	Progression and relapse		MET amplification negative		true
16882	MGH10008	Precision/Targeted Therapy	true	Erlotinib			erlotinib	193	3093	Progression and relapse	chemotherapy	T790M negative in liver met	SRS to CNS at 2177 days	true
16883	MGH10008		false					1314	1314	NA	recurrance	T1N3M0; T790M positive	lobectomy	true
16884	MGH804		false					0	0	NA		T1aN0M0		true
16885	MGH804	Chemotherapy	true	Carboplatin			carboplatin	31	67	Completion of standard course				true
16886	MGH804	Chemotherapy	true	Paclitaxel			paclitaxel	31	67	Completion of standard course				true
16887	MGH804	Precision/Targeted Therapy	true	Erlotinib			erlotinib	453	1155	Progression and relapse		T790M	no treatment between day 67 and day 453	true
16888	MGH804	Precision/Targeted Therapy	true	Nazartinib			EGF816	1156	1382	Progression and relapse				true
16889	MGH130	Precision/Targeted Therapy	true	Erlotinib			erlotinib	157	882	Progression and relapse	surgery, chemotherapy	no evidence of diease, surveillance	adjuvant, surgery done in 2007 (conducted before day 0)	true
16890	MGH130	Precision/Targeted Therapy	true	Erlotinib			erlotinib	1484	3467	Progression and relapse		T790M	no treatment between day 882 and day 1484	true
16891	MGH938	Precision/Targeted Therapy	true	Crizotinib			crizotinib	58	1285	Progression and relapse				true
16892	MGH983	Chemotherapy	true	Carboplatin			carboplatin, gemcitabine	38	68	Progression and relapse				true
16893	MGH983	Chemotherapy	true	Carboplatin			carboplatin, paclitaxel	130	173	Progression and relapse				true
16894	MGH983	Chemotherapy	true	Carboplatin			carboplatin, paclitaxel	189	219	Progression and relapse				true
16895	MGH983	Immunotherapy	true	Nivolumab			nivolumab	311	361	Toxicity				true
16896	MGH983	Chemotherapy	true	Vinorelbine Tartrate			navelbine	418	454	Progression and relapse				true
16897	MGH983	Precision/Targeted Therapy	true	Crizotinib			crizotinib	547	584	Progression and relapse				true
16898	MGH959	Chemotherapy	true	Paclitaxel			taxol	22	52	Other				true
16899	MGH959	Immunotherapy	true	Atezolizumab			atezolizumab (MPDL3280A)	479	509	Progression and relapse				true
16900	MGH959	Chemotherapy	true	Gemcitabine Hydrochloride			gemcitabine	540	782	Progression and relapse				true
16901	MGH959	Precision/Targeted Therapy	true	Crizotinib			crizotinib	824	1119	Progression and relapse				true
16902	MGH959	Precision/Targeted Therapy	true	sitravatinib			sitravatinib (MGCD516)	1133	1181	Progression and relapse				true
16903	MGH959	ADC	true	Telisotuzumab			ABV399	1203	1357	Progression and relapse				true
16904	MGH959	Precision/Targeted Therapy	true	Capmatinib			capmatinib	1384	1425	Patient noncompliance				true
16905	MGH997	Chemotherapy	true	Cisplatin			etoposide, cisplatin	21	79	Progression and relapse				true
16906	MGH997	Precision/Targeted Therapy	true	Crizotinib			crizotinib	905	1019	Toxicity			no treatment between day 79 and day 905	true
16907	MGH997	Precision/Targeted Therapy	true	Capmatinib			capmatinib	1156	1171	Toxicity				true
16908	MGH997	Precision/Targeted Therapy	true	Crizotinib			crizotinib	1325	1431	Progression and relapse				true
16909	MGH997	Chemotherapy	true	Pemetrexed			pemetrexed	1438	1466	Completion of standard course				true
16910	MGH9020	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	61	180	Completion of standard course				true
16911	MGH9020	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	596	637	Progression and relapse				true
16912	MGH9020	Precision/Targeted Therapy	true	Crizotinib			crizotinib	807	1024	Progression and relapse				true
16913	MGH9020	ADC	true	Telisotuzumab			ABBV399	1043	1064	Progression and relapse				true
16914	MGH9020	Immunotherapy	true	Nivolumab			nivolumab	1099	1288	Progression and relapse				true
16915	MGH9001	Precision/Targeted Therapy	true	Crizotinib			crizotinib	144	284	Toxicity				true
16916	MGH9001	Precision/Targeted Therapy	true	Capmatinib			capmatinib	331	366	Progression and relapse				true
16917	MGH9052	Immunotherapy	true	Pembrolizumab			pembrolizumab	22	147	Progression and relapse				true
16918	MGH9052	Precision/Targeted Therapy	true	Crizotinib			crizotinib	189	426	Progression and relapse				true
16919	RA_2243	Precision/Targeted Therapy	true	Crizotinib			crizotinib	80	234	Progression and relapse				true
16920	RA_2243	Precision/Targeted Therapy	true	Capmatinib			capmatinib	242	276	Progression and relapse				true
16921	RA_2243	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	296	414	Progression and relapse				true
16922	RA_3500	Precision/Targeted Therapy	true	Crizotinib			crizotinib	16	210	Progression and relapse				true
16923	RA_3500	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	214	348	Completion of standard course				true
16924	RA_3500	Precision/Targeted Therapy	true	Capmatinib			capmatinib	365	421	Progression and relapse				true
16925	RA_3870	Precision/Targeted Therapy	true	Erlotinib			erlotinib	10	271	Progression and relapse				true
16926	RA_3870	Chemotherapy	true	Carboplatin			carboplatin/pemetrexed	272	421	Progression and relapse				true
16927	RA_3870		false				microwave ablation to liver	415	415	Completion of standard course				true
16928	RA_3870	Chemotherapy	true	Docetaxel			chemotherapy	451	619	Progression and relapse				true
16929	RA_3870	Precision/Targeted Therapy	true	osimertinib			targeted (navelbine/osimertinib 160mg (double dose))	620	791	Progression and relapse				true
16930	RA_2218		false				whole brain radiation 35 Gy	17	34	Completion of standard course				true
16931	RA_2218	Precision/Targeted Therapy	true	Afatinib Dimaleate			afatinib	49	2868	Progression and relapse				true
16932	RA_2218	Precision/Targeted Therapy	true	osimertinib			osimertinib	2895	3483	Progression and relapse				true
16933	RA_2218		false				radiation to brain	3035	3035	Completion of standard course				true
16934	RA_2218		false				radiation to lung	3041	3051	Completion of standard course				true
16935	RA_2218	Chemotherapy	true	Carboplatin			chemotherapy	3484	3547	Completion of standard course				true
16936	RA_2218	Precision/Targeted Therapy	true	osimertinib			osimertinib	3548	3695	Progression and relapse				true
16937	RA_2218	Precision/Targeted Therapy	true	Erlotinib			weekly dose erlotinib	3696	3715	Progression and relapse				true
16938	RA_1348	Precision/Targeted Therapy	true	Erlotinib			erlotinib	17	662	Progression and relapse				true
16939	RA_1348	Precision/Targeted Therapy	true	Rociletinib			CO-1686	662	815	Progression and relapse				true
16941	RA_1348	Precision/Targeted Therapy	true	savolitinib			osimertinib/savolitinib	1596	1665	Progression and relapse				true
16942	RA_1348	Chemotherapy	true	Gemcitabine Hydrochloride			chemotherapy + targeted gemcitabinel/osimertinib)	2268	2513	Progression and relapse				true
16943	RA_1348	Chemotherapy	true	Docetaxel			chemotherapy + targeted (docetaxel/osimertinib)	2527	2583	Progression and relapse				true
16944	RA_1348		false				whole brain radiation	2592	2607	Completion of standard course				true
16945	RA_1348	Precision/Targeted Therapy	true	osimertinib			chemotherapy + targeted (navelbine/osimertinib)	2632	2646	Progression and relapse				true
16946	RA_3500	Immunotherapy	true	Pembrolizumab			pembrolizumab	214	348	Progression and relapse				true
16947	RA_3870	Precision/Targeted Therapy	true	osimertinib			targeted (docetaxel/osimertinib)	451	619	Progression and relapse				true
16948	RA_3870	Chemotherapy	true	Vinorelbine Tartrate			chemotherapy, targeted (navelbine/osimertinib 160mg (double dose))	620	791	Progression and relapse				true
16949	RA_2218	Precision/Targeted Therapy	true	osimertinib			targeted therapy (carboplatin/pemetrexed/osimertinib)	3484	3547	Completion of standard course				true
16950	RA_1348	Precision/Targeted Therapy	true	osimertinib			targeted therapy (carboplatin/pemetrexed/osimertinib)	850	2267	Progression and relapse	prolonged response to multiple TKIs		s/p erlotinib (T790M, HER2 amp), CO-1686, osimertinib (MET amp), osimertinib/savolitinib (MET amp loss)	true
16951	RA_6070	Precision/Targeted Therapy	true	Erlotinib			Tarceva	19	53	Progression and relapse				true
16952	RA_6070	Precision/Targeted Therapy	true	Crizotinib			erlotinib + crizotinib	53	374	Progression and relapse				true
16953	RA_6070		false				Hippocampal-sparing WBRT (30 Gy) w/ dose intensification to gross brain metastases (37.5 Gy)	381	401	Completion of standard course				true
16954	RA_6070	Precision/Targeted Therapy	true	Erlotinib			14-438: erlotinib 75 mg qd w ABBV399 q21days	423	633	Progression and relapse				true
16955	RA_6070		false				SRS to R temporal and putamen lesions	641	641	Completion of standard course				true
16956	RA_6070		false				SRS to L pontine, L temporal, L frontal and R parietal lesions	668	668	Completion of standard course				true
16957	RA_6070	Chemotherapy	true	Carboplatin			Carboplatin /pemetrexed /pembrolizumab	676	830	Progression and relapse			CNS progression	true
16958	RA_6070		false				Left lung radiation SBRT-like, 45 Gy in 6 fx	766	780	Completion of standard course				true
16959	RA_6070	Precision/Targeted Therapy	true	Capmatinib			INC280 + gefitinib	843	2005	Progression and relapse				true
16960	RA_6070	Precision/Targeted Therapy	true	Capmatinib			Capmatinib	2020	2300	Progression and relapse				true
16961	RA_6070	Precision/Targeted Therapy	true	osimertinib			Osimertinib	2020	2300	Progression and relapse				true
16962	RA_6070		false				SRS to 8 CNS lesions	2191	2206	Completion of standard course				true
16963	RA_2244	Precision/Targeted Therapy	true	Crizotinib			crizotinib 250mg PO BID	41	195	Progression and relapse			minimal interval enlargement of L hilar and high R paratracheal node	true
16964	RA_2244	Precision/Targeted Therapy	true	Alectinib			Alectinib	196	342	Progression and relapse			Worsening pleural effusion. Pathology - adenocarcinoma	true
16965	RA_2244	Precision/Targeted Therapy	true	Ceritinib			ceritinib	343	506	Progression and relapse			Interval progression in L pleura and hilar node. Brain MRI w/ 4 new brain metastases.	true
16966	RA_2244	Chemotherapy	true	Carboplatin			carbo/pemetrexed	507	619	Progression and relapse			Brain MRI: Stable to improved; Chest CT mild progression	true
16967	RA_2244	Chemotherapy	true	Pemetrexed			pemetrexed	640	668	Progression and relapse			pemetrexe given as maintenance	true
16968	RA_2244	Precision/Targeted Therapy	true	Lorlatinib			lorlatinib	668	843	Progression and relapse			admitted to ED for SOB - passed on day 851	true
16969	RA_3624	Chemotherapy	true	Cisplatin			4 cycles of cisplatin/etoposide	30	121	Completion of standard course				true
16970	RA_3624		false				6,600 cGy to the LLL mass and 6,200 cGy to the supraclavicular area	30	121	Completion of standard course				true
16971	RA_3624	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	264	451	Progression and relapse			developed local progression as well as a new left adrenal nodule and upper abdominal lymph node	true
16972	RA_3624	Chemotherapy	true	Carboplatin			carboplatin (AUC 5) and pemetrexed 500 mg/m2	553	637	Completion of standard course				true
16973	RA_3624	Precision/Targeted Therapy	true	Ceritinib			LDK378 (Ceritinib)	653	2402	Progression and relapse				true
16974	RA_3624		false				L adrenal SBRT	2278	2285	Completion of standard course				true
16975	RA_3624	Precision/Targeted Therapy	true	Alectinib			Alectinib	2404	2667	Progression and relapse				true
16976	RA_3624	Precision/Targeted Therapy	true	Lorlatinib			Lorlatinib	2671	3030	Progression and relapse				true
16977	RA_3624	Precision/Targeted Therapy	true	Lorlatinib			Lorlatinib + Pemetrexed	3017	3030	Progression and relapse				true
16978	RA_3663	Chemotherapy	true	Cisplatin			cisplatin/taxotere q 3 wk x 4 cycles	48	110	Completion of standard course			Tolerated well	true
16979	RA_3663	Precision/Targeted Therapy	true	Erlotinib			Tarceva	1170	1189	Other			ALK Positive tumor revealed whilst on Tarceva	true
16980	RA_3663	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	1191	2304	Progression and relapse			Progression of multifocal lung lesions	true
16981	RA_3663	Precision/Targeted Therapy	true	Ceritinib			LDK378	2323	2784	Progression and relapse				true
16982	RA_3663	Chemotherapy	true	Carboplatin			carbo (AUC 5) and alimta (500mg/m2	2791	2884	Completion of standard course				true
16983	RA_3663	Chemotherapy	true	Pemetrexed			alimta (500 mg/m2)	2884	2954	Progression and relapse			Alimta given as maintenance	true
16984	RA_3663	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	3225	3295	Other				true
16985	RA_3663	Precision/Targeted Therapy	true	Lorlatinib			PF3922 (75mg) (Lorlatinib)	3316	5395	Progression and relapse			Patient switched to another clinical trial due to slow progression over the course of treatment	true
16986	RA_3663	Chemotherapy	true	Carboplatin			Carboplatin/Pemetrexed	5334	5383	Progression and relapse			Ongoing chemo with Lorlatinib	true
16987	RA_3663	ADC	true	datopotamab			DS-1062A, TROP2 ADC, 8 mg/kg	5402	5670	Progression and relapse				true
16988	RA_3663	Precision/Targeted Therapy	true	Binimetinib			lorlatinib/binimetinib	5681	5789	Toxicity			D/C binimetinib for grade 2 retinopathy	true
16989	RA_3663	Precision/Targeted Therapy	true	Lorlatinib			Lorlatinib	5789	5887	Progression and relapse			Continued Lorlatinib alone	true
16990	RA_3663	Precision/Targeted Therapy	true	Lorlatinib			lorlatinib 50 mg qd + TNO155 40 mg qd 2 weeks on/1 week off	5887	5946	Progression and relapse				true
16991	RA_3663	Precision/Targeted Therapy	true	zotizalkib			TPX-0131 1 mg qd	5950	5957	Toxicity			grade 3 ataxia, grade 2 cognitive disturbance.	true
16992	RA_4098		false				WBRT	9	22	Completion of standard course				true
16993	RA_4098	Chemotherapy	true	Carboplatin			Carboplatin/Pembro/Pemetrexed	24	136	Progression and relapse			Mixed response to therapy with slight progression	true
16994	RA_4098	Precision/Targeted Therapy	true	Selpercatinib			Loxo292	161	214	Toxicity			Drug held due to new PE in the setting of thrombocytopenia. Patient passed away on 03/07/2019 during hospital admission from 02/22/2019-03/07/2019	true
16995	RA_1405	Chemotherapy	true	Cisplatin			Cisplatin/Alimta x 4 cycles	14	124	Completion of standard course				true
16996	RA_1405		false					70	124	Completion of standard course			Concurrent RT treatment started at C3 Cisplatin/Alimta	true
16997	RA_1405	Precision/Targeted Therapy	true	Ponatinib			ponatinib 30mg daily	565	714	Progression and relapse			Best response 23% reduction systemically but CNS PD on first restaging	true
16998	RA_1405		false				whole-brain radiation therapy (WBRT)	631	653	Completion of standard course			hippocampus-sparing WBRT	true
16999	RA_1405	Precision/Targeted Therapy	true	Alectinib			alectinib	721	992	Progression and relapse			Progression in chest and brain	true
17000	RA_1405	Precision/Targeted Therapy	true	Alectinib			Carboplatin/Pemetrexed + Alectinib	994	1019	Progression and relapse				true
17001	RA_1405	Biological Therapy	true	Bevacizumab			taxol/bevacizumab	1043	1378	Progression and relapse			Progressed primarily in chest	true
17002	RA_1405	Precision/Targeted Therapy	true	Everolimus			Vandetanib 300 mg daily and everolimus 10 mg daily	1392	1504	Patient noncompliance			Poor tolerance by patient	true
17003	RA_1405	Chemotherapy	true	Vinorelbine Tartrate			Navelbine 30mg/m2	1511	1535	Patient noncompliance			Poor tolerance by patient	true
17004	RA_1405	Precision/Targeted Therapy	true	pralsetinib			BLU-667 200mg	1547	1662	Progression and relapse			CNS progression	true
17005	RA_1405	Precision/Targeted Therapy	true	Selpercatinib			LOXO-292	1666	2203	Progression and relapse			Growing CNS lesions	true
17006	RA_1405	Biological Therapy	true	Bevacizumab			LOXO-292 + bevacizumab	2203	2442	Progression and relapse			Continued treatment until death	true
17007	RA_1779	Precision/Targeted Therapy	true	Erlotinib			Erlotinib	22	596	Progression and relapse			Brain MRI with new brain metastases	true
17008	RA_1779	Precision/Targeted Therapy	true	osimertinib			Osimertinib	608	1969	Progression and relapse				true
17009	RA_1779		false				SRS to brain metastasis	1845	1849	Completion of standard course			SRS during ongoing Osimertinib treatment	true
17010	RA_5603	Precision/Targeted Therapy	true	Nazartinib			EGF816	20	588	Progression and relapse				true
17011	RA_5603	Precision/Targeted Therapy	true	osimertinib			Osimertinib 80mg + savolitinib (MET inhib) 600mg	601	886	Progression and relapse			Progressed after 6 cycles and further progression after 10 cycles	true
17012	RA_5603	Chemotherapy	true	Carboplatin			Carboplatin/pemetrexed/osimertinib x 3 cycles	887	949	Progression and relapse				true
17013	RA_5603	Chemotherapy	true	Docetaxel			Docetaxel/ramucirumab/osi	956	1006	Progression and relapse			ramucirumab dropped on 11/13/2019 due to blood clot	true
17014	RA_5603	Chemotherapy	true	Gemcitabine Hydrochloride			Gemcitabine	1029	1032	Progression and relapse			received one cycle before passing away on 12/11/2019	true
17015	RA_1694	Chemotherapy	true	Cisplatin			Cisplatin/Pemetrexed	33	418	Toxicity			Took a holiday from therapy in may 2017 for rising Cr and was able to stay of fall therapy with stable disease x 1 year	true
17016	RA_1694	Precision/Targeted Therapy	true	mobocertinib			TAK788	769	1013	Progression and relapse			Bx upon progression no clear mech of resistance	true
17017	RA_1694	Precision/Targeted Therapy	true	osimertinib			Osimertinib	1027	1152	Progression and relapse			Progression in lung and chest	true
17018	RA_1694	Chemotherapy	true	Pemetrexed			Osimertinib + Pemetrexed	1153	1860	Toxicity			chronic renal insuff in summer 2021 and decision made to stop pem permanently.	true
17019	RA_1694	Precision/Targeted Therapy	true	osimertinib			Osimertinib alone	1861	2027	Progression and relapse				true
17020	RA_1694	Precision/Targeted Therapy	true	amivantamab			Amivantamab	2028	2122	Progression and relapse			stable disease in chest and brain but progression in peritoneal carcinomatosis	true
17021	RA_1694	Chemotherapy	true	Gemcitabine Hydrochloride			Gemcitabine	2133	2161	Progression and relapse			progression after 2 cycles	true
17022	RA_1694	Chemotherapy	true	Docetaxel			Docetaxel + Osimertinib	2175	2301	Progression and relapse			progression after 4 months. Passed away on 08/20/2022	true
17023	RA_5180	Biological Therapy	true	Bevacizumab			Carbo/Taxol/Avastin	42	70	Completion of standard course				true
17024	RA_5180	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	106	1871	Progression and relapse				true
17025	RA_5180	Precision/Targeted Therapy	true	Lorlatinib			Lorlatinib	1901	3050	Progression and relapse				true
17026	RA_5180	Chemotherapy	true	Carboplatin			Carbo/Alimta	2943	3017	Completion of standard course				true
17027	RA_5180	Precision/Targeted Therapy	true	repotrectinib			TPX-005 (Repotrectinib)	3056	3315	Progression and relapse				true
17028	RA_5180	Chemotherapy	true	Pemetrexed			Alimta	3332	3357	Progression and relapse				true
17029	MGH013	Chemotherapy	true	Carboplatin			carboplatin, paclitaxel	10	73	Progression and relapse				true
17030	MGH013	Biological Therapy	true	Bevacizumab			Bevacizumab	10	73	Progression and relapse				true
17031	MGH013	Chemotherapy	true	Pemetrexed			Pemetrexed	94	521	Progression and relapse				true
17032	MGH013	Biological Therapy	true	Bevacizumab			Bevacizumab	94	521	Progression and relapse				true
17033	MGH013	Precision/Targeted Therapy	true	Erlotinib			Erlotinib	557	640	Progression and relapse				true
17036	MGH013	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	926	975	Progression and relapse				true
17037	MGH013	Chemotherapy	true	Vinorelbine Tartrate			Navelbine	976	1169	Progression and relapse				true
17038	MGH013	Precision/Targeted Therapy	true	Ceritinib			Ceritinib	1218	1557	Completion of standard course				true
17039	MGH013	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	1618	1684	Progression and relapse				true
17041	MGH020	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	163	559	Progression and relapse				true
17042	MGH020	Precision/Targeted Therapy	true	Ceritinib			Ceritinib	906	1398	Progression and relapse				true
17043	MGH020	Chemotherapy	true	Carboplatin			carboplatin, paclitaxel	10	30	Completion of standard course				true
17044	MGH037	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	54	925	Progression and relapse				true
17045	MGH037	Chemotherapy	true	Pemetrexed			Pemetrexed	926	947	Progression and relapse				true
17046	MGH048	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	26	362	Progression and relapse				true
17047	MGH048	Precision/Targeted Therapy	true	Alectinib			Alectinib	604	875	Progression and relapse				true
17048	MGH048	Precision/Targeted Therapy	true	Lorlatinib			Lorlatinib	888	962	Progression and relapse				true
17049	MGH048	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	963	991	Completion of standard course				true
17050	MGH048	Precision/Targeted Therapy	true	Entrectinib			Entrectinib	1015	1034	Progression and relapse				true
17051	MGH048	Chemotherapy	true	Docetaxel			Docetaxel	1036	1038	Progression and relapse				true
17052	MGH048	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	1039	1067	Progression and relapse				true
17053	MGH048	Immunotherapy	true	Pembrolizumab			Pembrolizumab	1047	1118	Progression and relapse				true
17054	MGH048	Precision/Targeted Therapy	true	Ceritinib			Ceritinib	1068	1112	Progression and relapse				true
17055	MGH051	Chemotherapy	true	Cisplatin			cisplatin, pemetrexed	13	33	Toxicity				true
17056	MGH051	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	34	47	Progression and relapse				true
17057	MGH051	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	48	132	Progression and relapse				true
17058	MGH051	Precision/Targeted Therapy	true	Ceritinib			Ceritinib	146	340	Progression and relapse				true
17059	MGH051	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	345	381	Progression and relapse				true
17060	MGH051	Chemotherapy	true	Pemetrexed			Pemetrexed	350	371	Progression and relapse				true
17061	MGH051	Chemotherapy	true	Docetaxel			Docetaxel	403	424	Progression and relapse				true
17062	MGH051	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	403	420	Progression and relapse				true
17063	MGH055	Chemotherapy	true	Cisplatin			cisplatin, pemetrexed	17	38	Toxicity				true
17064	MGH055	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	39	253	Progression and relapse				true
17065	MGH055	Precision/Targeted Therapy	true	Ceritinib			Ceritinib	262	395	Progression and relapse				true
17066	MGH058	Chemotherapy	true	Carboplatin			carboplatin, paclitaxel	30	75	Completion of standard course				true
17067	MGH058	Chemotherapy	true	Pemetrexed			Pemetrexed	486	912	Progression and relapse			no treatment between day 75 and day 486	true
17068	MGH058	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	1034	1872	Progression and relapse				true
17069	MGH058	Precision/Targeted Therapy	true	Ceritinib			Ceritinib	1873	2601	Progression and relapse				true
17070	MGH061	Chemotherapy	true	Cisplatin			cisplatin, pemetrexed	114	177	Completion of standard course				true
17071	MGH061	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	310	579	Progression and relapse				true
17072	MGH061	Precision/Targeted Therapy	true	Ceritinib			Ceritinib	580	861	Progression and relapse				true
17073	MGH062	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	81	110	Progression and relapse				true
17074	MGH062	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	111	668	Progression and relapse				true
17075	MGH062	Precision/Targeted Therapy	true	Ceritinib			Ceritinib	676	756	Progression and relapse				true
17076	MGH062	Precision/Targeted Therapy	true	luminespib			AUY992 (should it be luminespib/AUY922?)	767	781	Progression and relapse				true
17077	MGH062	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	790	910	Progression and relapse				true
17078	MGH062	Chemotherapy	true	Pemetrexed			Pemetrexed	931	971	Progression and relapse				true
17079	MGH062	Chemotherapy	true	Docetaxel			Docetaxel	995	1007	Toxicity				true
17080	MGH062	Precision/Targeted Therapy	true	Lorlatinib			Lorlatinib	1043	1331	Progression and relapse				true
17081	MGH062	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	1342	1559	Progression and relapse				true
17082	MGH062	Chemotherapy	true	Vinorelbine Tartrate			Navelbine	1351	1470	Toxicity				true
17083	MGH068	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	18	213	Progression and relapse				true
17084	MGH068	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	46	361	Progression and relapse				true
17085	MGH068	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	387	450	Progression and relapse				true
17086	MGH068	Chemotherapy	true	Pemetrexed			Pemetrexed	472	635	Progression and relapse				true
17087	MGH068	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	472	635	Progression and relapse				true
17088	MGH068	Precision/Targeted Therapy	true	Ceritinib			Ceritinib	639	1079	Progression and relapse				true
17089	MGH085	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	25	161	Progression and relapse				true
17090	MGH085	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	162	324	Completion of standard course				true
17091	MGH085	Chemotherapy	true	Docetaxel			Docetaxel	368	417	Toxicity				true
17092	MGH085	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	418	465	Progression and relapse				true
17093	MGH085	Precision/Targeted Therapy	true	Ceritinib			Ceritinib	466		NA			Ceritinib treatment still ongoing	true
17094	MGH086	Chemotherapy	true	Carboplatin			carboplatin, docetaxel	10	161	Completion of standard course				true
17095	MGH086	Precision/Targeted Therapy	true	Erlotinib			Erlotinib	710	1074	Progression and relapse				true
17096	MGH086	Chemotherapy	true	Pemetrexed			Pemetrexed	1106	1685	Progression and relapse				true
17097	MGH086	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	1786	2415	Progression and relapse				true
17098	MGH086	Precision/Targeted Therapy	true	Brigatinib			Brigatinib	2510	3935	Progression and relapse				true
17099	MGH086	Precision/Targeted Therapy	true	Lorlatinib			Lorlatinib	3936		Progression and relapse			Treatment stop date unknown (verified by MGH)	true
17100	MGH086	Immunotherapy	true	Avelumab			Avelumab	3936	4223	Other				true
17101	MGH090	Chemotherapy	true	Carboplatin			carboplatin, paclitaxel	11	73	Completion of standard course				true
17102	MGH090	Biological Therapy	true	Bevacizumab			bevacizumab	11	73	Completion of standard course				true
17103	MGH090	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	103	697	Progression and relapse				true
17104	MGH090	Precision/Targeted Therapy	true	Alectinib			Alectinib	698	782	Progression and relapse				true
17105	MGH10023	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	17	38	Progression and relapse				true
17106	MGH10023	Immunotherapy	true	Nivolumab			nivolumab	58	72	Progression and relapse				true
17107	MGH10023	Chemotherapy	true	Carboplatin			carboplatin, paclitaxel	80	183	Progression and relapse				true
17108	MGH10023	Chemotherapy	true	Gemcitabine Hydrochloride			Gemcitabine	234	338	Progression and relapse				true
17109	MGH10023	Chemotherapy	true	Vinorelbine Tartrate			Navelbine	345	387	Progression and relapse				true
17110	MGH508	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	15	333	Progression and relapse				true
17111	MGH508	Precision/Targeted Therapy	true	Lorlatinib			Lorlatinib	339	494	Progression and relapse				true
17112	MGH9051	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	33	345	Progression and relapse				true
17113	MGH9051	Precision/Targeted Therapy	true	Lorlatinib			Lorlatinib	345	513	Progression and relapse				true
17114	MGH9051	Precision/Targeted Therapy	true	repotrectinib			Repotrectinib	663	695	Progression and relapse				true
17115	MGH9051	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	695	800	Completion of standard course				true
17116	MGH952	Chemotherapy	true	Cisplatin			cisplatin, pemetrexed	22	50	Progression and relapse				true
17117	MGH952	Precision/Targeted Therapy	true	Brigatinib			Brigatinib	76	966	Progression and relapse				true
17118	MGH952	Precision/Targeted Therapy	true	Lorlatinib			Lorlatinib	974	1016	Progression and relapse				true
17119	MGH952	Chemotherapy	true	Carboplatin			carboplatin, gemcitabine	1023	1198	Progression and relapse				true
17120	MGH952	Precision/Targeted Therapy	true	Alectinib			Alectinib	1023	1255	Progression and relapse			Patient noncompliance on day 1035	true
17121	MGH952	Chemotherapy	true	Vinorelbine Tartrate			Navelbine	1199	1255	Progression and relapse				true
17122	MGH952	Precision/Targeted Therapy	true	repotrectinib			Repotrectinib	1267	1294	Progression and relapse				true
17123	MGH952	Chemotherapy	true	Vinorelbine Tartrate			Navelbine	1305	1317	Progression and relapse		unk		true
17125	MGH953	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	13	176	Progression and relapse				true
17126	MGH953	Precision/Targeted Therapy	true	Alectinib			Alectinib	179	414	Progression and relapse				true
17127	MGH953	Precision/Targeted Therapy	true	Lorlatinib			Lorlatinib	421	634	Progression and relapse				true
17128	MGH962	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	64	239	Progression and relapse				true
17129	MGH962	Precision/Targeted Therapy	true	Alectinib			Alectinib	252	333	Toxicity				true
17130	MGH962	Precision/Targeted Therapy	true	Lorlatinib			Lorlatinib	397	653	Progression and relapse				true
17131	MGH962	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	655	711	Completion of standard course				true
17132	MGH962	Chemotherapy	true	Pemetrexed			Pemetrexed	655	893	Completion of standard course				true
17133	MGH962	Precision/Targeted Therapy	true	Ceritinib			Ceritinib	804	925	Other				true
17134	MGH962	Precision/Targeted Therapy	true	repotrectinib			Repotrectinib	928	931	Progression and relapse				true
17135	MGH968	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	4	99	Completion of standard course				true
17136	MGH968	Precision/Targeted Therapy	true	Erlotinib			Erlotinib	4	13	Other				true
17137	MGH968	Biological Therapy	true	Bevacizumab			Bevacizumab	25	99	Completion of standard course				true
17138	MGH968	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	100	1827	Progression and relapse				true
17139	MGH968	Precision/Targeted Therapy	true	Taletrectinib			Taletrectinib	1842	1884	Toxicity				true
17140	MGH968	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	1899	1962	Progression and relapse				true
17141	MGH968	Biological Therapy	true	Bevacizumab			Bevacizumab	1920	1962	Progression and relapse				true
17142	MGH968	Precision/Targeted Therapy	true	Lorlatinib			Lorlatinib	1980	1990	Progression and relapse				true
17143	MGH968	Precision/Targeted Therapy	true	Cabozantinib			Cabozantinib	1991	2065	Progression and relapse				true
17144	MGH979	Precision/Targeted Therapy	true	Alectinib			Alectinib	19	105	Progression and relapse				true
17145	MGH979	Immunotherapy	true	Atezolizumab			Atezolizumab	19	105	Progression and relapse				true
17146	MGH979	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	179	291	Progression and relapse				true
17147	MGH979	Biological Therapy	true	Bevacizumab			bevacizumab	179	333	Progression and relapse				true
17148	MGH979	Chemotherapy	true	Pemetrexed			Pemetrexed	179	333	Progression and relapse				true
17149	MGH979	Chemotherapy	true	Cisplatin			cisplatin, gemcitabine	396	413	Progression and relapse				true
17150	MGH979	Precision/Targeted Therapy	true	Alectinib			Alectinib	414	435	Progression and relapse				true
17151	MGH979	Precision/Targeted Therapy	true	Ceritinib			Ceritinib	436	441	Progression and relapse				true
17152	MGH987	Precision/Targeted Therapy	true	Ceritinib			Ceritinib	494	655	Progression and relapse				true
17153	MGH987	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	656	718	Progression and relapse				true
17154	MGH987	Precision/Targeted Therapy	true	Alectinib			Alectinib	332	493	Progression and relapse				true
17155	MGH987	Precision/Targeted Therapy	true	Lorlatinib			Lorlatinib	719	810	Progression and relapse				true
17156	MGH987	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	48	331	Progression and relapse				true
17157	MGH987	Precision/Targeted Therapy	true	Entrectinib			Entrectinib	840	888	Progression and relapse				true
17158	MGH992	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	237	600	Progression and relapse				true
17159	MGH992	Precision/Targeted Therapy	true	Alectinib			Alectinib	601	882	Progression and relapse				true
17160	MGH992	Chemotherapy	true	Carboplatin			carboplatin, pemetrexed	883	933	Progression and relapse				true
17161	MGH992	Precision/Targeted Therapy	true	Alectinib			Alectinib	934	949	Progression and relapse				true
17162	MGH992	Precision/Targeted Therapy	true	repotrectinib			Repotrectinib	920		Progression and relapse			stop date unknown	true
17163	MGH700	Biological Therapy	true	Bevacizumab			2 cycles Carboplatin/Pemetrexed/Avastin	3	34	Completion of standard course				true
17164	MGH700	Precision/Targeted Therapy	true	Erlotinib			Erlotinib	34	979	Progression and relapse				true
17165	MGH700	Precision/Targeted Therapy	true	Rociletinib			11 cycles of Rociletinib (CO-1686)	979	1191	Progression and relapse				true
17166	MGH700	Chemotherapy	true	Docetaxel			Taxotere + Erlotinib	1191	1434	Progression and relapse				true
17167	MGH700	Immunotherapy	true	Nivolumab			Nivolumab	1434	1464	Progression and relapse				true
17168	MGH700	Precision/Targeted Therapy	true	Erlotinib			Navelbine + Erlotinib	1495	1583	Progression and relapse				true
17169	RA_T06710	Biological Therapy	true	Bevacizumab			1 cycle carboplatin, alimta, avastin	21	21	Other			Patient found to have EGFR mutation whilst on cycle 1	true
17170	RA_T06710	Precision/Targeted Therapy	true	Erlotinib			Erlotinib	43	477	Progression and relapse				true
17172	RA_T06711	Biological Therapy	true	Bevacizumab			1 cycle Carboplatin, Pemetrexed, Bevacizumab	27	42	Patient noncompliance			Developed hives, Allergy testing comfirmed allergy to Carboplatin	true
17173	RA_T06711	Precision/Targeted Therapy	true	Erlotinib			Erlotinib	84	539	Progression and relapse				true
17174	RA_T06711		false				3 Gy in a single fraction	538	538	Progression and relapse				true
17175	RA_1186	Precision/Targeted Therapy	true	Erlotinib			Erlotinib	26	656	Progression and relapse				true
17176	RA_1186	Chemotherapy	true	Carboplatin			2 cycles Carboplatin, Pemetrexed	672	691	Progression and relapse				true
17177	RA_1186	Precision/Targeted Therapy	true	Rociletinib			C0-1686	755	1230	Progression and relapse				true
17178	RA_1186	Chemotherapy	true	Docetaxel			2 cycles Taxotere	1230	1258	Toxicity				true
17179	RA_1186	Precision/Targeted Therapy	true	Afatinib Dimaleate			Afatinib	1230	1282	Toxicity				true
17180	RA_1192		false				total dose of 35 Gy in 14 fractions	14	31	Completion of standard course				true
17181	RA_1192	Precision/Targeted Therapy	true	Afatinib Dimaleate			Afatinib	32	735	Progression and relapse				true
17182	RA_1192		false				SRS to R singular met	359	359	Completion of standard course				true
17183	RA_1192	Precision/Targeted Therapy	true	osimertinib			Osimertinib	532	699	Progression and relapse				true
17184	RA_1192	Chemotherapy	true	Pemetrexed			pemetrexed	700	700	Progression and relapse				true
17185	RA_3999		false				Left VATS, left upper lobectomy and mediastinal lymph node dissection	0	0	NA				true
17186	RA_3999	Chemotherapy	true	Cisplatin			Cisplatin/pemetrexed	56	119	Toxicity			Switched to cisplatin to carboplatin for cycle 3	true
17187	RA_3999	Immunotherapy	true	Pembrolizumab			Pembrolizumab	294	569	Progression and relapse				true
17188	RA_3999		false				RT to mesenteric mass/node 45 Gy	345	380	Completion of standard course				true
17189	RA_3999		false				Hypofractionated RT to the AP window LN	427	448	Completion of standard course				true
17190	RA_3999	Chemotherapy	true	Docetaxel			Docetaxel	605	626	Completion of standard course				true
17191	RA_3493	Chemotherapy	true	Carboplatin			Carboplatin	315	379	Completion of standard course				true
17192	RA_3493	Chemotherapy	true	Pemetrexed			Pemetrexed/Pembrolizumab	315	595	Completion of standard course				true
17193	RA_3493	Immunotherapy	true	Pembrolizumab			Pemetrexed/Pembrolizumab	315	595	Completion of standard course				true
17194	RA_3901		false				60 Gy RT with no chemo	28	97	Completion of standard course				true
17195	RA_3901	Immunotherapy	true	Pembrolizumab			Pembrolizumab	213	213	NA			Death (no additional treatments after 213, but before their death date on 575)	true
17196	RA_2694	Chemotherapy	true	Cisplatin			cisplatin/taxotere	85	154	Completion of standard course				true
17197	RA_T06725	Chemotherapy	true	Carboplatin			1st cycle with Erlotinib	345	345	Patient noncompliance				true
17198	RA_T06725	Precision/Targeted Therapy	true	Afatinib Dimaleate			2nd cycle with Afatinib	369	369	Progression and relapse				true
17199	RA_T06727	Chemotherapy	true	Cisplatin			cisplatin/pemetrexed	444	444	Progression and relapse				true
17200	RA_T06725	Chemotherapy	true	Docetaxel			Taxotere	515	515	Progression and relapse				true
17202	RA_1141	Chemotherapy	true	Carboplatin			Carboplatin+pemetrexed x 4 cycles	766	890	Progression and relapse				true
17203	RA_1141	Chemotherapy	true	Etoposide			Etoposide 75 mg/m2 D1-D3 for SCLC transformation	1029	1068	Progression and relapse				true
17204	RA_1348	Chemotherapy	true	Carboplatin			chemotherapy	1666	2267	Progression and relapse				true
17205	RA_1348	Chemotherapy	true	Vinorelbine Tartrate			chemotherapy + targeted (navelbine/osimertinib)	2632	2646	Progression and relapse				true
17206	RA_2694	Precision/Targeted Therapy	true	Erlotinib			tarceva on clinical trial 07-259	164	894	Completion of standard course				true
17207	RA_T06726	Precision/Targeted Therapy	true	Erlotinib			Erlotinib with Hydroxychloroquine	53	316	Progression and relapse				true
17208	RA_T06725	Precision/Targeted Therapy	true	Afatinib Dimaleate			Afatinib	34	344	Progression and relapse				true
17209	RA_1141	Precision/Targeted Therapy	true	Erlotinib			Erlotinib	50	366	Progression and relapse				true
17210	RA_T06725	Precision/Targeted Therapy	true	Rociletinib			CO-1686	399	438	Progression and relapse				true
17211	RA_T06727	Precision/Targeted Therapy	true	Afatinib Dimaleate			Afatinib	52	444	Progression and relapse				true
17212	RA_T06725	Precision/Targeted Therapy	true	Afatinib Dimaleate			Restart Afatinib	442	487	Progression and relapse				true
17213	RA_T06725	Precision/Targeted Therapy	true	osimertinib			AZD9291	497	514	Progression and relapse				true
17216	RA_1141	Precision/Targeted Therapy	true	Nazartinib			EGF816	366	760	Progression and relapse				true
17217	RA_1141	Chemotherapy	true	Docetaxel			Docetaxel (D1,D8) + Osimertinib 80mg	921	1029	Progression and relapse				true
17218	RA_1348	Precision/Targeted Therapy	true	osimertinib			targeted (gemcitabinel/osimertinib)	2268	2513	Progression and relapse				true
17219	RA_2694	Precision/Targeted Therapy	true	Erlotinib			tarceva on clinical trial 09-097	1622	3001	Progression and relapse				true
17220	RA_2694	Precision/Targeted Therapy	true	osimertinib			Osimertinib	3004	3671	Progression and relapse				true
17221	RA_T06727		false				radiation to L5 vertebral lesion, 35Gy in 14 fractions	13	31	Completion of standard course				true
17222	RA_T06727		false				whole brain radiation for remaining lesions, 35Gy in 14 fractions	20	38	Completion of standard course				true
17223	RA_1141		false				WBXRT; 3500 cGY in 14 fractions	21	38	Completion of standard course				true
17224	RA_T06726		false				Radiation to Spine	38	38	Completion of standard course				true
17225	RA_T06727		false				SRS to residual lesion in brain	169	169	Completion of standard course				true
17226	RA_T06725		false				Palliative RT to L posterior chest wall/8th rib met	323	323	Completion of standard course				true
17228	RA_1141		false				SRS to a growing left parietal calvarial metastasis, treated with 18 Gy	634	634	Completion of standard course				true
17229	RA_1141		false				Cerebellar reirradiation for multiple small progressive CNS lesions	976	976	Completion of standard course				true
17230	RA_2694		false				RT to R superior skull met	2686	2709	Completion of standard course				true
17231	RA_2694		false				SRS to R mandibular met	2871	2871	Completion of standard course				true
17233	MGH175	Precision/Targeted Therapy	true	Erlotinib				26	143	Progression and relapse				true
17234	MGH175	Precision/Targeted Therapy	true	Afatinib Dimaleate				187	234	Progression and relapse				true
17235	MGH175	Precision/Targeted Therapy	true	Rociletinib				243	648	Progression and relapse				true
17236	MGH1118	Immunotherapy	true	Ipilimumab			Ipilimumab + nivolumab	26	26	NA				true
17237	MGH983	Chemotherapy	true	Gemcitabine Hydrochloride			carboplatin, gemcitabine	38	68	Progression and relapse				true
17238	MGH983	Chemotherapy	true	Paclitaxel			carboplatin, paclitaxel	130	173	Progression and relapse				true
17239	MGH983	Chemotherapy	true	Paclitaxel			carboplatin, paclitaxel	189	219	Progression and relapse				true
17240	MGH997	Chemotherapy	true	Etoposide			etoposide, cisplatin	21	79	Progression and relapse				true
17241	MGH9020	Chemotherapy	true	Pemetrexed			carboplatin, pemetrexed	61	180	Completion of standard course				true
17242	MGH9020	Chemotherapy	true	Pemetrexed			carboplatin, pemetrexed	596	637	Progression and relapse				true
17243	RA_2243	Chemotherapy	true	Pemetrexed			carboplatin, pemetrexed	296	414	Progression and relapse				true
17244	RA_3500	Chemotherapy	true	Pemetrexed			carboplatin, pemetrexed	214	348	Completion of standard course				true
17245	RA_3870	Chemotherapy	true	Pemetrexed			carboplatin/pemetrexed	272	421	Progression and relapse				true
17246	RA_2218	Chemotherapy	true	Pemetrexed			chemotherapy	3484	3547	Completion of standard course				true
17247	RA_1348	Precision/Targeted Therapy	true	osimertinib			chemotherapy + targeted (docetaxel/osimertinib)	2527	2583	Progression and relapse				true
17248	RA_6070	Precision/Targeted Therapy	true	Erlotinib			erlotinib + crizotinib	53	374	Progression and relapse				true
17249	RA_6070	ADC	true	Telisotuzumab			14-438: erlotinib 75 mg qd w ABBV399 q21days	423	633	Progression and relapse				true
17250	RA_6070	Immunotherapy	true	Pembrolizumab			Carboplatin /pemetrexed /pembrolizumab	676	830	Progression and relapse			CNS progression	true
17251	RA_6070	Chemotherapy	true	Pemetrexed			Carboplatin /pemetrexed /pembrolizumab	676	830	Progression and relapse			CNS progression	true
17252	RA_6070	Precision/Targeted Therapy	true	Gefitinib			INC280 + gefitinib	843	2005	Progression and relapse				true
17253	RA_2244	Chemotherapy	true	Pemetrexed			carbo/pemetrexed	507	619	Progression and relapse			Brain MRI: Stable to improved; Chest CT mild progression	true
17254	RA_3624	Chemotherapy	true	Etoposide			4 cycles of cisplatin/etoposide	30	121	Completion of standard course				true
17255	RA_3624	Chemotherapy	true	Pemetrexed			carboplatin (AUC 5) and pemetrexed 500 mg/m2	553	637	Completion of standard course				true
17256	RA_3624	Chemotherapy	true	Pemetrexed			Lorlatinib + Pemetrexed	3017	3030	Progression and relapse				true
17257	RA_3663	Chemotherapy	true	Docetaxel			cisplatin/taxotere q 3 wk x 4 cycles	48	110	Completion of standard course			Tolerated well	true
17258	RA_3663	Chemotherapy	true	Pemetrexed			carbo (AUC 5) and alimta (500mg/m2	2791	2884	Completion of standard course				true
17259	RA_3663	Chemotherapy	true	Pemetrexed			Carboplatin/Pemetrexed	5334	5383	Progression and relapse			Ongoing chemo with Lorlatinib	true
17260	RA_3663	Precision/Targeted Therapy	true	Lorlatinib			lorlatinib/binimetinib	5681	5789	Toxicity			D/C binimetinib for grade 2 retinopathy	true
17261	RA_3663	Precision/Targeted Therapy	true	batoprotafib			lorlatinib 50 mg qd + TNO155 40 mg qd 2 weeks on/1 week off	5887	5946	Progression and relapse				true
17262	RA_4098	Immunotherapy	true	Pembrolizumab			Carboplatin/Pembro/Pemetrexed	24	136	Progression and relapse			Mixed response to therapy with slight progression	true
17263	RA_4098	Chemotherapy	true	Pemetrexed			Carboplatin/Pembro/Pemetrexed	24	136	Progression and relapse			Mixed response to therapy with slight progression	true
17264	RA_1405	Chemotherapy	true	Pemetrexed			Cisplatin/Alimta x 4 cycles	14	124	Completion of standard course				true
17265	RA_1405	Chemotherapy	true	Carboplatin			Carboplatin/Pemetrexed + Alectinib	994	1019	Progression and relapse				true
17266	RA_1405	Chemotherapy	true	Pemetrexed			Carboplatin/Pemetrexed + Alectinib	994	1019	Progression and relapse				true
17267	RA_1405	Chemotherapy	true	Paclitaxel			taxol/bevacizumab	1043	1378	Progression and relapse			Progressed primarily in chest	true
17268	RA_1405	Precision/Targeted Therapy	true	Vandetanib			Vandetanib 300 mg daily and everolimus 10 mg daily	1392	1504	Patient noncompliance			Poor tolerance by patient	true
17269	RA_1405	Precision/Targeted Therapy	true	Selpercatinib			LOXO-292 + bevacizumab	2203	2442	Progression and relapse			Continued treatment until death	true
17270	RA_5603	Precision/Targeted Therapy	true	savolitinib			Osimertinib 80mg + savolitinib (MET inhib) 600mg	601	886	Progression and relapse			Progressed after 6 cycles and further progression after 10 cycles	true
17271	RA_5603	Chemotherapy	true	Pemetrexed			Carboplatin/pemetrexed/osimertinib x 3 cycles	887	949	Progression and relapse				true
17272	RA_5603	Precision/Targeted Therapy	true	osimertinib			Carboplatin/pemetrexed/osimertinib x 3 cycles	887	949	Progression and relapse				true
17273	RA_5603	Biological Therapy	true	Ramucirumab			Docetaxel/ramucirumab/osi	956	1006	Progression and relapse			ramucirumab dropped on 11/13/2019 due to blood clot	true
17274	RA_5603	Precision/Targeted Therapy	true	osimertinib			Docetaxel/ramucirumab/osi	956	1006	Progression and relapse			ramucirumab dropped on 11/13/2019 due to blood clot	true
17275	RA_1694	Chemotherapy	true	Pemetrexed			Cisplatin/Pemetrexed	33	418	Toxicity			Took a holiday from therapy in may 2017 for rising Cr and was able to stay of fall therapy with stable disease x 1 year	true
17276	RA_1694	Precision/Targeted Therapy	true	osimertinib			Osimertinib + Pemetrexed	1153	1860	Toxicity			chronic renal insuff in summer 2021 and decision made to stop pem permanently.	true
17277	RA_1694	Precision/Targeted Therapy	true	osimertinib			Docetaxel + Osimertinib	2175	2301	Progression and relapse			progression after 4 months. Passed away on 08/20/2022	true
17278	RA_5180	Chemotherapy	true	Paclitaxel			Carbo/Taxol/Avastin	42	70	Completion of standard course				true
17279	RA_5180	Precision/Targeted Therapy	true	osimertinib			Carbo/Taxol/Avastin	42	70	Completion of standard course				true
17280	RA_5180	Chemotherapy	true	Pemetrexed			Carbo/Alimta	2943	3017	Completion of standard course				true
17281	MGH013	Chemotherapy	true	Paclitaxel			carboplatin, paclitaxel	10	73	Progression and relapse				true
17282	MGH020	Chemotherapy	true	Paclitaxel			carboplatin, paclitaxel	10	30	Completion of standard course				true
17283	MGH048	Chemotherapy	true	Pemetrexed			carboplatin, pemetrexed	963	991	Completion of standard course				true
17284	MGH051	Chemotherapy	true	Pemetrexed			cisplatin, pemetrexed	13	33	Toxicity				true
17285	MGH051	Chemotherapy	true	Pemetrexed			carboplatin, pemetrexed	34	47	Progression and relapse				true
17286	MGH055	Chemotherapy	true	Pemetrexed			cisplatin, pemetrexed	17	38	Toxicity				true
17287	MGH058	Chemotherapy	true	Paclitaxel			carboplatin, paclitaxel	30	75	Completion of standard course				true
17288	MGH061	Chemotherapy	true	Pemetrexed			cisplatin, pemetrexed	114	177	Completion of standard course				true
17289	MGH062	Chemotherapy	true	Pemetrexed			carboplatin, pemetrexed	81	110	Progression and relapse				true
17290	MGH062	Chemotherapy	true	Pemetrexed			carboplatin, pemetrexed	790	910	Progression and relapse				true
17291	MGH068	Chemotherapy	true	Pemetrexed			carboplatin, pemetrexed	18	213	Progression and relapse				true
17292	MGH068	Chemotherapy	true	Pemetrexed			carboplatin, pemetrexed	387	450	Progression and relapse				true
17293	MGH085	Chemotherapy	true	Pemetrexed			carboplatin, pemetrexed	162	324	Completion of standard course				true
17294	MGH086	Chemotherapy	true	Docetaxel			carboplatin, docetaxel	10	161	Completion of standard course				true
17295	MGH090	Chemotherapy	true	Paclitaxel			carboplatin, paclitaxel	11	73	Completion of standard course				true
17296	MGH9051	Chemotherapy	true	Pemetrexed			carboplatin, pemetrexed	695	800	Completion of standard course				true
17297	MGH952	Chemotherapy	true	Pemetrexed			cisplatin, pemetrexed	22	50	Progression and relapse				true
17298	MGH952	Chemotherapy	true	Gemcitabine Hydrochloride			carboplatin, gemcitabine	1023	1198	Progression and relapse				true
17300	MGH968	Chemotherapy	true	Pemetrexed			carboplatin, pemetrexed	4	99	Completion of standard course				true
17301	MGH968	Chemotherapy	true	Pemetrexed			carboplatin, pemetrexed	1899	1962	Progression and relapse				true
17303	MGH979	Chemotherapy	true	Gemcitabine Hydrochloride			cisplatin, gemcitabine	396	413	Progression and relapse				true
17304	MGH987	Chemotherapy	true	Pemetrexed			carboplatin, pemetrexed	656	718	Progression and relapse				true
17305	MGH992	Chemotherapy	true	Pemetrexed			carboplatin, pemetrexed	883	933	Progression and relapse				true
17306	MGH700	Chemotherapy	true	Carboplatin			2 cycles Carboplatin/Pemetrexed/Avastin	3	34	Completion of standard course				true
17307	MGH700	Chemotherapy	true	Pemetrexed			2 cycles Carboplatin/Pemetrexed/Avastin	3	34	Completion of standard course				true
17308	MGH700	Precision/Targeted Therapy	true	Erlotinib			Taxotere + Erlotinib	1191	1434	Progression and relapse				true
17309	MGH700	Chemotherapy	true	Vinorelbine Tartrate			Navelbine + Erlotinib	1495	1583	Progression and relapse				true
17310	RA_T06710	Chemotherapy	true	Carboplatin			1 cycle carboplatin, alimta, avastin	21	21	Other			Patient found to have EGFR mutation whilst on cycle 1	true
17311	RA_T06710	Chemotherapy	true	Pemetrexed			1 cycle carboplatin, alimta, avastin	21	21	Other			Patient found to have EGFR mutation whilst on cycle 1	true
17312	RA_T06710	Chemotherapy	true	Pemetrexed			7 cycles Alimta, Erlotinib	295	477	Progression and relapse				true
17313	RA_T06711	Chemotherapy	true	Carboplatin			1 cycle Carboplatin, Pemetrexed, Bevacizumab	27	42	Patient noncompliance			Developed hives, Allergy testing comfirmed allergy to Carboplatin	true
17314	RA_T06711	Chemotherapy	true	Pemetrexed			1 cycle Carboplatin, Pemetrexed, Bevacizumab	27	42	Patient noncompliance			Developed hives, Allergy testing comfirmed allergy to Carboplatin	true
17315	RA_1186	Chemotherapy	true	Pemetrexed			2 cycles Carboplatin, Pemetrexed	672	691	Progression and relapse				true
17316	RA_3999	Chemotherapy	true	Pemetrexed			Cisplatin/pemetrexed	56	119	Toxicity			Switched to cisplatin to carboplatin for cycle 3	true
17317	RA_2694	Chemotherapy	true	Docetaxel			cisplatin/taxotere	85	154	Completion of standard course				true
17318	RA_T06725	Precision/Targeted Therapy	true	Erlotinib			1st cycle with Erlotinib	345	345	Patient noncompliance				true
17319	RA_T06725	Chemotherapy	true	Pemetrexed			1st cycle with Erlotinib	345	345	Patient noncompliance				true
17320	RA_T06725	Chemotherapy	true	Carboplatin			2nd cycle with Afatinib	369	369	Progression and relapse				true
17321	RA_T06725	Chemotherapy	true	Pemetrexed			2nd cycle with Afatinib	369	369	Progression and relapse				true
17322	RA_T06727	Chemotherapy	true	Pemetrexed			cisplatin/pemetrexed	444	444	Progression and relapse				true
17323	RA_1141	Chemotherapy	true	Pemetrexed			Carboplatin+pemetrexed x 4 cycles	766	890	Progression and relapse				true
17324	RA_1348	Chemotherapy	true	Pemetrexed			chemotherapy	1666	2267	Progression and relapse				true
17325	RA_1141	Precision/Targeted Therapy	true	osimertinib			Docetaxel (D1,D8) + Osimertinib 80mg	921	1029	Progression and relapse				true
17326	MGH1118	Immunotherapy	true	Nivolumab			Ipilimumab + nivolumab	26	26	NA				true
17327	MGH023	Chemotherapy	true	Carboplatin			Carboplatin/Docetaxel	30	91	Progression and relapse				true
17328	MGH023		false				SRS	935	935	Completion of standard course			No treatment between day 30 and 935	true
17329	MGH023	Precision/Targeted Therapy	true	Erlotinib			Erlotinib	945	1036	Other				true
17330	MGH023	Chemotherapy	true	Pemetrexed			Pemetrexed	1067	1310	Progression and relapse				true
17331	MGH023	Precision/Targeted Therapy	true	Crizotinib			Crizotinib	1542	2039	Progression and relapse				true
17332	MGH023	Chemotherapy	true	Paclitaxel			Taxol	1909	1967	Progression and relapse				true
17333	MGH023	Precision/Targeted Therapy	true	Ceritinib			Ceritinib	2072	2332	Progression and relapse				true
17334	RA_3690	Chemotherapy	true	Carboplatin			Carboplatin/Pemetrexed/Pembro	9	163	Progression and relapse				true
17335	RA_3690	Immunotherapy	true	Pembrolizumab			Carboplatin/Pemetrexed/Pembro	9	163	Progression and relapse				true
17336	RA_3690		false				Fractionated proton beam RT to choroidal met, 20 Gy over 2 fractions.	28	29	Completion of standard course				true
17337	RA_3690	Chemotherapy	true	Docetaxel			MM-121 + docetaxel	212	317	Progression and relapse				true
17338	RA_3690		false				SRS to R frontal metastasis 18 GY x 1	357	357	Completion of standard course				true
17339	RA_3690	Chemotherapy	true	Vinorelbine Tartrate				345	394	Progression and relapse			Navelbine	true
17340	RA_3690	Chemotherapy	true	Gemcitabine Hydrochloride				394	422	Progression and relapse				true
17341	RA_3690		false				SRS to 9mm right middle frontal gyrus and 6 mm right precentral gyrus. 18 Gy x 1 to each	409	409	Completion of standard course				true
17342	RA_3690	Chemotherapy	true	Irinotecan Hydrochloride				436	443	Progression and relapse				true
17343	MGH903	Chemotherapy	true	Carboplatin				49	123	Completion of standard course				true
17344	MGH903	Chemotherapy	true	Pemetrexed				49	123	Completion of standard course				true
17345	MGH903	Immunotherapy	true	Pembrolizumab				213	321	Progression and relapse				true
17346	MGH903	Chemotherapy	true	Docetaxel				322	426	Progression and relapse				true
17347	MGH903	Chemotherapy	true	Vinorelbine Tartrate				427	472	Progression and relapse				true
17348	MGH903	Precision/Targeted Therapy	true	Entrectinib				480	1239	Progression and relapse				true
17349	MGH903	Precision/Targeted Therapy	true	Trametinib			Trametinib + Enterectinib	1090	1239	Other			stop because of death on 1248	true
17350	RA_T01119	Chemotherapy	true	Cisplatin			Cisplatin/Etoposide	141	184	Toxicity				true
17351	RA_T01119	Chemotherapy	true	Etoposide			Cisplatin/Etoposide	141	184	Toxicity				true
17352	RA_T01119	Immunotherapy	true	Durvalumab			Durva	214	240	Toxicity				true
17353	RA_6524		false				nephro ureterectomy	0	0	Completion of standard course				true
17354	RA_6524	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			adjuvant	45	112	Progression and relapse				true
17355	RA_6524	Immunotherapy	true	Pembrolizumab				112	193	Progression and relapse	TMB and PDL1 high		4 cycles - mixed response predominantly progressive disease | Old note: patient with mixed reponse but predominanly progressive disease, 2 impressive right renal bed nodes that have shown marked regression during Pembrolizumab therapy.	true
17356	RA_6524	Precision/Targeted Therapy	true	Rezatapopt			20-544 - PC14586 for patients with p53 Y220C	249	383	Progression and relapse			Transferred to home care after progression	true
17357	RA_3450	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride				23	379	NA			dose reduced to 20mg/m2 Cis secondary to neutropenia after C6	true
17358	RA_3450		true	Futibatinib			14-135 TAS 120	379	400	Progression and relapse				true
17359	RA_3450	Chemotherapy	true	Cisplatin, Gemcitabine Hydrochloride			Gem 750mg/m2, Cis 20mg/m2	414	1009	NA				true
17360	RA_3450	Precision/Targeted Therapy	true	RYL-4008			20-577 RYL-4008 50mg daily	1035	1099	Progression and relapse			C1D15 held drug due to grade 2 central serous retinopathy Resumed at 30mg po qd C1D25 Dropped to 20mg qd C2D15 C2D16 HELD drug due to OSH admission for grade 3 thromboembolic event (pulmonary embolism) in setting of holding AC for biopsy; scans with stable disease by RECIST v1.1 with mild progression  C2D22 resumed C3D1 stopped drug	true
17361	RA_3450		true	LOXO			20-487 LOXO, IDH1 inhibitor (400mg qd)	1182	1196	Toxicity			C1D7 admitted for work-up progressive SOB, drug held C1D11 resumed C1D15 stopped drug for ongoing SOB  TIMC/Recist show SD (18% from baseline), however, coming off trial for AE (dyspnea - remains on O2)	true
17362	RA_3450	Chemotherapy	true	Fluorouracil, Oxaliplatin				1229	1450	Other		death		true
17363	MGH023	Chemotherapy	true	Docetaxel			Carboplatin/Docetaxel	30	91	Progression and relapse				true
17364	MGH10008		false					2177	2177	NA			SRS to CNS at 2177 days	true
17365	MGH10023	Chemotherapy	true	Pemetrexed			carboplatin, pemetrexed	17	38	Progression and relapse				true
17366	MGH10023	Chemotherapy	true	Paclitaxel			carboplatin, paclitaxel	80	183	Progression and relapse				true
17367	RA_3690	Chemotherapy	true	Pemetrexed			Carboplatin/Pemetrexed/Pembro	9	163	Progression and relapse				true
17368	RA_3690		true	Seribantumab			MM-121 + docetaxel	212	317	Progression and relapse				true
17369	RA_5432	Chemotherapy	true	Pemetrexed			Carboplatin/pemetrexed	19	39	Other			Day 0: RLL mass biopsy - PDL1 5%, ALK and ROS negative, EGFR negative	true
17370	RA_5432	Chemotherapy	true	Pemetrexed			PEMETREXED/CARBOPLATIN/OSIMERTINIB	780	992	Progression and relapse		Brain MRI with increase in mets		true
17371	RA_T06726	Other	true	Hydroxychloroquine			Erlotinib with Hydroxychloroquine	53	316	Progression and relapse				true
17372	MGH770	Precision/Targeted Therapy	true	osimertinib			Osimertinib	2014		NA			Additional treatment is still ongoing	true
17373	MGH714	Precision/Targeted Therapy	true	Rociletinib			Rociletinib	812	1312	Progression and relapse				true
17374	MGH714	Precision/Targeted Therapy	true	osimertinib			Osimertinib	1331	4287	Progression and relapse				true
17375	MGH714	Chemotherapy	true	Carboplatin			Carboplatin/Pemetrexed + Osimertinib	2667	3028	Progression and relapse				true
17376	MGH714	Chemotherapy	true	Pemetrexed			Carboplatin/Pemetrexed + Osimertinib	2667	3028	Progression and relapse				true
17377	MGH714		false				RT to the R lung/hilum, 6000 cGy/24 fractions	3067	3099	Completion of standard course				true
17378	MGH714	Chemotherapy	true	Carboplatin			Carboplatin/Pemetrexed/Bevacizumab	3815	3944	Progression and relapse				true
17379	MGH714	Chemotherapy	true	Pemetrexed			Carboplatin/Pemetrexed/Bevacizumab	3815	3944	Progression and relapse				true
17380	MGH714	Biological Therapy	true	Bevacizumab			Carboplatin/Pemetrexed/Bevacizumab	3815	3944	Progression and relapse				true
17381	MGH714	Chemotherapy	true	Pemetrexed			Pemetrexed/Bevacizumab/Atezolizumab	3945	3953	Toxicity				true
17382	MGH714	Biological Therapy	true	Bevacizumab			Pemetrexed/Bevacizumab/Atezolizumab	3945	3953	Toxicity				true
17383	MGH714	Immunotherapy	true	Atezolizumab			Pemetrexed/Bevacizumab/Atezolizumab	3945	3953	Toxicity				true
17384	MGH714	Chemotherapy	true	Gemcitabine Hydrochloride				4073	4287	Progression and relapse				true
17385	MGH130	Precision/Targeted Therapy	true	osimertinib			Osimertinib	3468		NA			Osimertinib treatment still ongoing	true
17386	MGH130		false				BRT to RLL nodule, 45 Gy in 5 fractions	5208	5212	Completion of standard course				true
17387	MGH130		false				SRS to right posterior temporal metastasis, 18 Gy x 1	5841	5841	Completion of standard course				true
17388	MGH130		false				BRT to RUL NSCLC, 50 Gy in 5 fx	6279	6283	Completion of standard course				true
17389	MGH086	Chemotherapy	true	Carboplatin			Carboplatin + Pemetrexed + Pembrolizumab	4541	4541	Toxicity				true
17390	MGH086	Chemotherapy	true	Pemetrexed			Carboplatin + Pemetrexed + Pembrolizumab	4541	4541	Toxicity				true
17391	MGH086	Immunotherapy	true	Pembrolizumab			Carboplatin + Pemetrexed + Pembrolizumab	4541	4541	Toxicity				true
17392	MGH020	Chemotherapy	true	Carboplatin			Carboplatin/Pemetrexed	577	891	NA				true
17393	MGH020	Chemotherapy	true	Pemetrexed			Carboplatin/Pemetrexed	577	891	NA				true
17394	MGH801	Chemotherapy	true	Carboplatin			Carboplatin/Pemetrexed	62	62	Completion of standard course				true
17395	MGH801	Chemotherapy	true	Pemetrexed			Carboplatin/Pemetrexed	62	62	Completion of standard course				true
17396	MGH801	Precision/Targeted Therapy	true	Erlotinib			Erlotinib	91	1185	Progression and relapse				true
17397	MGH801	Precision/Targeted Therapy	true	Afatinib Dimaleate			Afatinib	1186	1320	Progression and relapse				true
17398	MGH806	Precision/Targeted Therapy	true	osimertinib			Osimertinib	854	1474	Other			Death	true
17399	RA_2243	Immunotherapy	true	Atezolizumab			atezolizumab	414	465	Progression and relapse				true
17400	RA_2243	Chemotherapy	true	Docetaxel			Docetaxol	483	715	Progression and relapse				true
17401	RA_2243		false				SRS to left frontal lobe	738	738	Completion of standard course				true
17402	RA_2243	Chemotherapy	true	Gemcitabine Hydrochloride			gemcitabine	759	806	Progression and relapse				true
17403	RA_2243		false				Radiation to the cerebellum	848	848	Completion of standard course				true
17404	MGH047	Chemotherapy	true	Carboplatin			Carboplatin/Pemetrexed	19	64	Completion of standard course				true
17405	MGH047	Chemotherapy	true	Pemetrexed			Carboplatin/Pemetrexed	19	64	Completion of standard course				true
17406	MGH047	Precision/Targeted Therapy	true	Crizotinib			N/A	90	180	Progression and relapse				true
17407	MGH034	Chemotherapy	true	Carboplatin			Carboplatin/Paclitaxel/Bevacizumab	29	181	Completion of standard course				true
17408	MGH034	Chemotherapy	true	Paclitaxel			Carboplatin/Paclitaxel/Bevacizumab	29	181	Completion of standard course				true
17409	MGH034	Biological Therapy	true	Bevacizumab			Carboplatin/Paclitaxel/Bevacizumab	29	181	Completion of standard course				true
17410	MGH034	Chemotherapy	true	Pemetrexed			Pemetrexed/Bevacizumab	182	485	Completion of standard course				true
17411	MGH034	Biological Therapy	true	Bevacizumab			Pemetrexed/Bevacizumab	182	485	Completion of standard course				true
17412	MGH034	Chemotherapy	true	Docetaxel			Docetaxel/Bevacizumab	486	911	Progression and relapse				true
17413	MGH034	Biological Therapy	true	Bevacizumab			Docetaxel/Bevacizumab	486	911	Progression and relapse				true
17414	MGH034	Precision/Targeted Therapy	true	Erlotinib			N/A	912	943	Progression and relapse				true
17415	MGH034	Chemotherapy	true	Gemcitabine Hydrochloride			N/A	1033	1061	Completion of standard course				true
17416	MGH034	Precision/Targeted Therapy	true	Crizotinib			N/A	1119	1372	Progression and relapse				true
17417	MGH034	Precision/Targeted Therapy	true	Ceritinib			N/A	1396	1698	Progression and relapse				true
17418	MGH034	Precision/Targeted Therapy	true	Alectinib			N/A	1699		NA			Stop date NA	true
17419	MGH021	Chemotherapy	true	Cisplatin			Cisplatin/Pemetrexed	40	160	Toxicity				true
17420	MGH021	Chemotherapy	true	Pemetrexed			Cisplatin/Pemetrexed	40	160	Toxicity				true
17421	MGH021	Chemotherapy	true	Pemetrexed			N/A	186	218	Progression and relapse				true
17422	MGH021	Precision/Targeted Therapy	true	Crizotinib			N/A	433	816	Progression and relapse				true
17423	MGH021	Precision/Targeted Therapy	true	Ganetespib			STA9090	843	890	Toxicity				true
17424	MGH021	Precision/Targeted Therapy	true	Ceritinib			N/A	922	1008	Progression and relapse				true
17425	MGH021	Chemotherapy	true	Carboplatin			Carboplatin/Gemcitabine	1009		NA			Stop date NA	true
17426	MGH021	Chemotherapy	true	Gemcitabine Hydrochloride			Carboplatin/Gemcitabine	1009		NA			Stop date NA	true
17427	MGH037	Precision/Targeted Therapy	true	Crizotinib			N/A	54		NA			Stop date NA	true
17428	MGH048	Precision/Targeted Therapy	true	Crizotinib			N/A	26	362	Progression and relapse				true
17429	MGH048	Precision/Targeted Therapy	true	Alectinib			N/A	406	875	Progression and relapse				true
17430	MGH048	Precision/Targeted Therapy	true	Lorlatinib			N/A	881	962	Progression and relapse				true
17431	MGH048	Chemotherapy	true	Carboplatin			Carboplatin/Pemetrexed	963	991	Progression and relapse				true
17432	MGH048	Chemotherapy	true	Pemetrexed			Carboplatin/Pemetrexed	963	991	Progression and relapse				true
17433	MGH048	Precision/Targeted Therapy	true	Entrectinib			N/A	1015	1034	Completion of standard course				true
17434	MGH048	Chemotherapy	true	Docetaxel			N/A	1036	1038	Completion of standard course				true
17435	MGH048	Precision/Targeted Therapy	true	Crizotinib			N/A	1039	1067	Completion of standard course				true
17436	MGH048	Immunotherapy	true	Pembrolizumab			N/A	1047		NA			Stop date NA	true
17437	MGH048	Precision/Targeted Therapy	true	Ceritinib			N/A	1068		NA			Stop date NA	true
17438	MGH071	Precision/Targeted Therapy	true	Erlotinib			Erlotinib/Bevacizumab	62	671	Progression and relapse				true
17439	MGH071	Biological Therapy	true	Bevacizumab			Erlotinib/Bevacizumab	62	201	Completion of standard course				true
17440	MGH071	Chemotherapy	true	Carboplatin			Carboplatin/Taxol	133	201	Completion of standard course				true
17441	MGH071	Chemotherapy	true	Paclitaxel			Carboplatin/Taxol	133	201	Completion of standard course				true
17442	MGH071	Chemotherapy	true	Pemetrexed			N/A	229	315	Completion of standard course				true
17443	MGH071	Chemotherapy	true	Gemcitabine Hydrochloride			N/A	755	783	Toxicity				true
17444	MGH071	Precision/Targeted Therapy	true	Crizotinib			N/A	860	2488	Progression and relapse				true
17445	MGH071	Precision/Targeted Therapy	true	Brigatinib			N/A	2492	2518	Progression and relapse				true
17446	MGH071	Precision/Targeted Therapy	true	Lorlatinib			N/A	3518		NA			Stop date NA	true
17447	MGH079	Precision/Targeted Therapy	true	Crizotinib			N/A	35	166	Progression and relapse				true
17448	MGH079	Precision/Targeted Therapy	true	Alectinib			N/A	167	564	Progression and relapse				true
17449	MGH079	Precision/Targeted Therapy	true	Lorlatinib			N/A	572	576	Completion of standard course				true
17450	MGH079	Chemotherapy	true	Carboplatin			Carboplatin/Pemetrexed/Bevacizumab	577	822	Toxicity				true
17451	MGH079	Chemotherapy	true	Pemetrexed			Carboplatin/Pemetrexed/Bevacizumab	577	1034	Completion of standard course				true
17452	MGH079	Biological Therapy	true	Bevacizumab			Carboplatin/Pemetrexed/Bevacizumab	577	914	Toxicity				true
17453	MGH079	Immunotherapy	true	Nivolumab			N/A	1222	1230	Progression and relapse				true
17454	MGH079	Precision/Targeted Therapy	true	Ceritinib			N/A	1231		NA			Stop date NA	true
17455	MGH085	Precision/Targeted Therapy	true	Crizotinib			N/A	24	160	Progression and relapse				true
17456	MGH085	Chemotherapy	true	Carboplatin			Carboplatin/Pemetrexed	161	314	Completion of standard course				true
17457	MGH085	Chemotherapy	true	Pemetrexed			Carboplatin/Pemetrexed	161	323	Completion of standard course				true
17458	MGH085	Chemotherapy	true	Docetaxel			N/A	367	416	Toxicity				true
17459	MGH085	Precision/Targeted Therapy	true	Crizotinib			N/A	417	464	Progression and relapse				true
17460	MGH085	Precision/Targeted Therapy	true	Ceritinib			N/A	465		NA			Stop date NA	true